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Foreword
This year’s annual report of the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) includes
data from the 25 Member States of the European Union
and from Norway. The wealth of information presented not
only helps us to understand better the extent to which drug
problems affect both the citizens of Europe and the
communities they live in, but also enables us to reflect on
the policies and actions that Member States have developed
to respond to the complex and multifaceted challenge that
the use of drugs presents. 
Those familiar with the previous EMCDDA reports on the
European drug situation may be struck by the considerable
differences that arise from this enlarged perspective. Many
of our assumptions on the nature and direction of trends in
the drug problem need to be reviewed and adapted to
reflect the reality of the more complex, dynamic and diverse
situation that faces Europe today. 
Not all countries can provide information in all areas, nor
are all the data available open to simple comparison. For
this reason, methodological notes are provided and we alert
the reader to the caveats that need to be considered when
drawing conclusions. Nonetheless, the information that is
now available on the European drug situation is substantial
and increasingly robust. We look forward to bringing you
an increasingly comprehensive data set in future years as
investments currently being made by Member States bear
fruit. The more technically aware reader, or those wanting
more specific details on any aspect of this report, can
inspect the full data tables that underpin the summary
information presented here, which are available in the
accompanying statistical bulletin and in the extended online
version of this publication. For those requiring only a
concise overview of developments, the ‘At a glance’ section
provides a summary of key developments, which are then
explored in more depth in the body of the report. 
We gratefully acknowledge the fact that the information in
this report is the product of a partnership and dependent
on the work of our partners in the Reitox network and the
scientific experts who have contributed to national and EU-
level working groups. The report is also informed by, and
benefits from, our ongoing work with the European
Commission in support of the evaluation of the European
action plan on drugs (2000–04). 
Some commentators focus on the difficulties that may arise
from greater European integration, particularly the ability
of organised crime to benefit from the opening of borders
and the free movement of goods and individuals. Such
challenges are not ignored in this report, but another
message can also be found. We increasingly share, as
Europeans, common problems resulting from the use of
drugs, but we also bring to the debate different historical
experiences and perspectives. The data found in this report
represent a common commitment of our Member States to
collect comparable information and use it to facilitate the
development of more effective and better-targeted policies
and responses. The enlargement of the European Union
offers us a new opportunity to share our experiences of
what works and to cooperate more closely to develop
better-coordinated activities. In this endeavour the EMCDDA
is committed to playing its part in working with Member
States to assemble the high-quality data sets that are
necessary to underpin an informed debate.
Marcel Reimen
Chairman, EMCDDA Management Board
Georges Estievenart
Executive Director, EMCDDA
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Introductor y note
This annual report is based on information provided to the EMCDDA by the EU Member States and Norway (participating
in the work of the EMCDDA since 2001) in the form of a national report. The statistical data reported here relate to the year
2002 (or the last year available). In the area of responses to drug use and for the selected issues more recent data may be
reported.
The national reports of the Reitox focal points are available on the EMCDDA website
(http://www.emcdda.eu.int/?nnodeid=435).
An online version of the annual report is available in 20 languages and may be found at
http://annualreport.emcdda.eu.int. Further material, referred to in footnotes with the reference OL, is presented only in the
online version. Available in English, this includes a wealth of graphics, tables and background information. 
The 2004 EMCDDA statistical bulletin provides the full set of source tables on which the statistical analysis is based
(http://statistics.emcdda.eu.int). It also provides further detail on the methodology used.
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In this overview section, some of the key developments
covered in the EMCDDA’s 2004 annual report on the state
of the drugs problem in Europe are highlighted. The reader
should refer to the body of the report for a full discussion. 
Policies and the legal framework
Among the major policy developments noted in the report is
the mid-term evaluation of the action plan that stemmed
from the 1998 United Nations special session on the world
drug problem (UNGASS). In addition, the EMCDDA is
contributing to the evaluation of the EU action plan on
drugs (2000–04), which will conclude in 2004.
In June 2003, the Council of Ministers adopted a
recommendation on the prevention and reduction of health-
related harm associated with drug dependence. Key areas
covered by the recommendation include health protection
and risk reduction, reducing the incidence of blood-borne
diseases among drug users (HIV, HCV and TB), reducing
drug-related deaths and establishing appropriate evaluation
mechanisms. In 2003, the Council of Ministers also reached
a political agreement on a framework decision on drug
trafficking. This agreement focused on achieving alignment
of penalties and widening the target of action to those
criminal and terrorist organisations that derive funds from
drug trafficking.
Work continued in 2003 on the control of new synthetic
drugs in the European Union, with the Council of Ministers
adopting a decision to apply control measures to 2C-I, 2C-
T-2, 2C-T-7 and TMA-2.
In 2003, there was an increase in the number of countries
whose drug policy operates within the framework of an
overall national strategy, with drug plans adopted in
Denmark, Germany, Lithuania and Slovenia. Once, as
planned, Estonia and France follow suit in 2004, over three
quarters of all EU Member States will have adopted this
approach. Common themes found in national strategies
include a commitment to a balanced approach in respect of
demand- and supply-side activities and an explicit
recognition of the importance of coordination.
Evaluations of drug policy can provide important lessons for
the future. Areas in which monitoring or evaluations were
reported by Member States in 2003 include the impact of
new drug legislation; the impact of changing legal
provision regarding drug possession for personal use, and
particularly possession of cannabis; measures to allow local
authorities to act against premises associated with drug
trafficking or public nuisance; schemes designed to refer
those with drug problems to bodies outside the criminal
justice system; and actions to counter drug trafficking and
money laundering activities. Approaches taken in the
Member States to measure national drugs strategies are set
out in a selected issue on evaluation.
Two countries (Belgium, United Kingdom) reported changes
in the legal classification of cannabis. In both of these
countries problematic cannabis use is explicitly addressed
by laws or guidelines, and the legal changes instituted have
a number of important dimensions that have sometimes
been ignored in the media’s reporting of these actions.
An increasingly important area for future activities and
international cooperation is that of putting in place powers
to allow the assets of drug traffickers and criminal gangs to
be confiscated. Spain, France, Ireland and the United
Kingdom all report new developments in this area.
The issue of driving under the influence of drugs and how
to deal with it remains of considerable concern in many
Member States. In 2003, three countries (France, Austria
and Finland) made significant changes to clarify or
reinforce legislation in this area.
Drug prevention
Drug prevention work in Europe can be categorised as
targeting the community as a whole (universal prevention)
or those most at risk, at either group (selective) or
individual level (indicated). The most highly developed
models of universal prevention are programmes targeting
the school population, for which a fairly robust evidence
base is available to guide programme content and delivery.
A number of countries report encouraging developments in
the coverage and delivery of school-based prevention
programmes. However, in many countries there remains
significant potential for improvement in both the coverage
and quality of universal prevention work. Universal
prevention effort outside school settings also has
At a glance — an over view of the European drug situation
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considerable potential, but currently this kind of approach
is pursued in only a few countries.
Although the importance of developing prevention work
among those most at risk is increasingly recognised, there
remains a substantial need to invest in this kind of focused
prevention.
Cannabis
Cannabis remains the most commonly used illegal
substance in the EU, with a high level of variation between
countries. Recent studies among 15-year-old school students
suggest that lifetime prevalence varies from under 10 % to
over 30 %, with the highest rates being reported by boys in
the United Kingdom (42.5 %). A small but consistent
proportion (about 15 %) of 15-year-old school students who
have used cannabis in the last year report doing so on 40
or more occasions. Such intensive use of cannabis is
concerning, particularly the possibility that this group might
be at risk of experiencing negative consequences. This issue
and the fact that reported demands for cannabis treatment
have risen in Europe are covered in more detail in a
selected issue. The prevalence of recent (in the last year)
cannabis use peaks among young adults (15–34 years),
ranging in most countries between 5 % and 20 %. It
appears that cannabis use increased substantially in most
countries during the 1990s, but, in some countries at least,
has now stabilised.
More than 30 countries are cited as sources of the cannabis
seized in Europe, illustrating the global nature of cannabis
production. Europe is the world’s largest market for
cannabis resin, the majority of which originates in
Morocco, which is now the main worldwide source of this
form of the drug. Cannabis is also now cultivated within
most European countries, although in all countries, with the
exception of the Netherlands, imported cannabis products
still predominate. The potency of cannabis imported into
Europe appears to have remained relatively stable for a
number of years. Cannabis grown within the EU using
intensive methods is typically of higher potency, but there is
considerable overlap between the two products.
Amphetamine-type stimulants (ATS), LSD 
and other synthetic drugs
Historically in Europe, amphetamine has been the drug
most commonly used after cannabis. This now appears to
be changing in a number of countries, notably Germany,
Spain, the Netherlands, Finland and the United Kingdom,
where recent survey evidence suggests that use of ecstasy
now equals, or even exceeds, amphetamine use. Despite
this rise in ecstasy use, in 2002 Europe continued to
account for the majority of global seizures of amphetamine
(86 % by volume). Lifetime prevalence rates for ecstasy use
generally range from 0.5 % to 7 % of the adult population,
although rates are higher in younger males. For example,
lifetime prevalence rates of between 11 % and 17 % are
reported among 15- to 24-year-old males in the Czech
Republic, Spain, the Netherlands and the United Kingdom.
Overall, the increase in the use of ecstasy that occurred
during the 1990s now appears to have stabilised, with only
a few countries still reporting an upward trend. Studies of
particular populations repeatedly show that ecstasy use is
more common among young people attending what have
become known as ‘dance events/parties’, although some
recent evidence suggests that this link may be weakening. 
Deaths involving ecstasy are rare in comparison with
opiate-related deaths, but they arouse considerable public
concern. Problems of definition and measurement make
analysis of this topic difficult. Fewer than 100 ecstasy
deaths were reported to the EMCDDA in the last year for
which data were available. However, this figure must be
treated with caution, as some countries reported no data
and, when toxicological information was available, often
other substances were also present. Around two thirds of all
reports of ecstasy-related deaths received by the EMCDDA
came from the United Kingdom, where the trend is
upwards. It is unclear how much this finding reflects a high
prevalence of ecstasy use and to what extent it reflects
differences in reporting practices.
Member States continue to target the recreational use of
stimulants with a range of prevention and harm reduction
programmes, with activities in this area most apparent in
some of the new Member States. The use of ATS as a
primary reason for seeking drug treatment is rare except in
Sweden and Finland, which have a long history of
problems due to the chronic use of amphetamines, and the
Czech Republic, where problems with the use of ‘pervitin’,
a locally produced methamphetamine, have existed for
some time.
Although the use of methamphetamine constitutes a
growing problem in a global context, in Europe significant
use of this drug has until now been restricted to the Czech
Republic. However, sporadic reports of methamphetamine
At a glance — an overview of the European drug situation
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attributed to cocaine alone rose from 2 in 1994 to 26 in
2001. Cocaine may also contribute to deaths due to
cardiovascular problems, but these cases may be poorly
represented in the statistical evidence. 
Treatment options for those with cocaine problems tend for
the most part to be generic approaches, usually without a
pharmacological component. Work is under way to
improve the efficacy of pharmacological interventions but,
apart from prescribing for symptomatic relief, no clear
consensus exists on what constitutes good practice in this
area. The management of crack cocaine users, in particular,
can present challenges for treatment centres.
Problem drug use, heroin use and drug injection
Heroin use and injecting drug use form the major
component of the EMCDDA problem drug use indicator.
This indicator is a composite measure designed to help
estimate the size of the largely hidden chronic drug
problem. Estimates of problem drug use range from 2 to
10 cases per 1 000 of the adult population. Estimates of the
size of the problem drug-using population vary
considerably between and within countries, with relatively
high figures reported in Denmark, Italy, Luxembourg,
Portugal and the United Kingdom.
Problem drug users in Europe appear to be becoming a
more heterogeneous group. In many countries, most
problem drug users were historically characterised by
heroin use, but polydrug use and stimulant use are
becoming more common. Although estimation is difficult, it
appears that heroin use is relatively stable in many
countries and levels of new recruitment into the behaviour
(incidence) have fallen compared with the situation in the
1990s. This analysis may not hold true for the new
countries of the EU.
Europe accounts for just over a quarter of all heroin seized
worldwide. No clear trend in the volume of heroin seized in
the EU can be observed, and overall this appears to be
relatively stable. In terms of both volume and number of
seizures, the United Kingdom, followed by Spain, report
more seizures than other countries.
A limited amount of opiate production takes place in
European countries, largely confined to the production of
locally consumed poppy straw products. No clear trends
are observable from recent data regarding either the purity
of heroin or the price of heroin at street level.
use are now being received from a number of other
European countries, raising the spectre of potential further
diffusion of this particularly damaging form of drug use. 
Cocaine
Recent surveys suggest that between 0.5 % and 6 % of
adults have used cocaine at some point (lifetime
prevalence). Among young adults (15–34 years) lifetime
prevalence rates generally range between 1 % and 10 %.
Typically, around half of those who have ever used cocaine
report having done so in the last year. Consumption figures
are higher in Spain and the United Kingdom — in both
countries recent use (last year) prevalence among adults is
over 2 %, compared with less than 1 % in most other
countries. This means that prevalence of recent use of
cocaine in Spain and the United Kingdom is now similar to
that in the United States, although lifetime prevalence rates
remain lower. Cocaine trends are difficult to track at the
national level, but the data that do exist suggest that recent
cocaine use among young people has risen to some extent
in Denmark, Germany, Spain, the Netherlands and the
United Kingdom, with Greece, Ireland, Italy and Austria
also reporting increased use based on local or qualitative
sources.
The number of cocaine seizures increased between 1997
and 2002 in all countries except Germany and Italy. Trends
from available data suggest that when a complete analysis
is possible it will reveal that the number of seizures at EU
level rose again in 2002. In most countries the price of
cocaine is also reported to have fallen during this period.
The smoking of crack cocaine (cocaine base) remains
restricted to some of the larger cities in Europe, where use
appears to be most common in marginalised groups. For
example, data from studies of the users of drug
consumption rooms show that rates of cocaine smoking are
particularly high among female sex workers. Although rare
in the general population, cocaine smoking is particularly
associated with an elevated risk of health and social
problems.
Toxicological analysis shows that in some countries cocaine
is commonly found in combination with opiates in drug-
related fatalities. Deaths attributable to cocaine in the
absence of opiates remain rare but may be increasing. In
the United Kingdom, the numbers of mentions of cocaine on
death certificates increased eightfold between 1993 and
2001, and in the Netherlands the number of deaths
Annual report 2004: the state of the drugs problem in the European Union and Norway
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Opiates remain the principal cause of death associated with
illicit substances in Europe. Each year there are between
8 000 and 9 000 recorded fatal overdoses, but this figure
is almost certainly an underestimate. Most victims are
young men in their mid to late 20s or early 30s, although
ages at death appear to be rising. Although considerable
inter-country variation is found, in general drug-related
deaths steadily increased in the EU as a whole over the
1980s and 1990s. Between 2000 and 2001, many
countries reported a decrease in the numbers of drug-
related deaths and, as a result, at EU level, there was a
small but statistically significant fall in reported deaths, from
8 838 to 8 306. However, the number of deaths remains
high from a historical perspective.
A worrying recent development has been reports of the
trafficking of fentanyl, a synthetic opiate that is up to
100 times more potent than heroin. Recent seizures have
been reported in a number of countries bordering the Baltic
Sea and in Russia. In Estonia, fentanyl appeared on the
drug market as a heroin substitute at the end of 2001, and
in Finland a major consignment of methylfentanyl was
seized in 2002.
Studies of heroin users in treatment suggest a marked
difference between countries in the extent to which users
inject or smoke the drug. Among new treatment demands
by those using heroin, less than half now report injecting
and, in some countries, injecting appears to be coming
increasingly uncommon. Elsewhere, and particularly, but
not exclusively, in the new Member States, drug injecting
remains the norm among heroin users. Overall estimates of
prevalence of injecting drug use range from two to six
cases per 1 000 of the adult population.
The HIV epidemic is spreading in some of the new members
of the EU and in bordering countries although prevalence
rates in the EU countries vary widely. In western Europe, the
apparent stabilisation or decline in HIV prevalence is
threatened by concerns about some new local outbreaks
that have occurred since the mid-1990s and the continuing
high rates of infection found in some populations.
Rates of hepatitis C (HCV) infection remain high among
drug injectors in Europe, with studies finding that from a
quarter up to almost all the injectors surveyed have
antibodies to the virus. In some cases, a direct correlation
between rates of HCV and HIV infection can be observed.
Hepatitis B infection also remains common among injecting
drug users (IDUs) in Europe, despite the availability of
vaccination. With the possible exception of some of the
Baltic countries, the prevalence of tuberculosis among IDUs
in EU countries remains low, but high rates of infection are
found in some countries bordering the EU.
In general, investment in needle and syringe exchange
programmes (NSPs) for drug injectors appears to have
increased across the EU. Estonia and Latvia have rapidly
expanded services in this area, and NSPs have also been
introduced in Northern Ireland and Flanders (Belgium).
However, in some countries with established programmes
the number of syringes distributed has fallen, possibly
reflecting lower levels of injecting. The main trends in the
development of low-threshold services are for greater
integration with other survival-oriented services, such as
shelters and primary healthcare facilities, and for greater
flexibility in opening hours. Drug consumption rooms are
provided by three Member States, and in 2004 the
EMCDDA published a detailed study on these facilities.
Drug treatment
Drug-related treatment in the majority of Member States
largely involves treatment for opiate use, or polydrug use
including opiates. Some form of substitution treatment
remains the predominant therapeutic option for this group,
although in the new Member States availability of
substitution treatment is limited and drug-free treatment
regimes remain common. It should also be noted that in the
Czech Republic, Finland and Sweden injecting
amphetamine users constitute a significant proportion of
those in drug treatment.
Available data on those seeking help for drug problems
suggest that the characteristics of those in need of help
have now diversified. As well as injecting and non-injecting
use of heroin, a range of polydrug, stimulant and cannabis
use problems are reported. In 2002, for the first time, the
EMCDDA’s treatment demand indicator showed that, in
the 11 countries for which data are available, cannabis
displaced opiates as the drug for which the highest number
of new clients were referred for treatment in specialist
outpatient facilities. The extent to which this represents
changes in reporting practice, expansion of service
provision or changes in the characteristics of those in need
is discussed in detail in the selected issue on cannabis
problems in context.
It is increasingly recognised that drugs services need to be
integrated with other healthcare provision, especially those
At a glance — an overview of the European drug situation
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use, prisons are a high-risk setting for the spread of
infectious diseases. Measures to combat this have included
introducing substitution treatment and needle and syringe
programmes (NSPs) in prisons. The health consequences of
drug use in prisons, compounded by restricted access to
services and the isolation of prison health services from the
regular health system, are increasingly being addressed in
the context of the national health and welfare systems.
Alternatives to prison, introduced by innovations in penal
policy, are diverting drug users to quasi-compulsory
treatment or community service on the assumption that their
needs are better served by such interventions.
services targeting marginalised and socially disadvantaged
groups. Responding effectively to those who have both a
drugs problem as well as a psychiatric health problem is
particularly challenging. This subject is examined in the
selected issue on psychiatric co-morbidity.
Prison issues
Drug users are over-represented in prisons compared with
the general population. Estimates of lifetime prevalence of
drug use among prisoners vary between 22 % and 86 %,
depending on the prison population, detention centre and
country. With a relatively high prevalence of injecting drug

(1) http://www.unodc.org/adhoc/gass/content.htm.
(2) For an overview of the role of harm-reduction policy see Table 1 OL: Role of harm reduction.
In this chapter, recent developments in drugs policies in the
EU as a whole, as well as in individual Member States, are
described. In most cases, the information supplied is based
on changes occurring in 2003, a year that marked the
beginning of the second half of the EU action plan on drugs
2000–04. In addition, 2003 heralded the deadline for
national governments to carry out a mid-term review of
their progress in developing and implementing a national
drug control strategy, in accordance with the Declaration on
the Guiding Principles of Drug-Demand Reduction, which
stemmed from the 1998 United Nations General Assembly
Special Session (UNGASS) (1) on the world drug problem.
As the EU action plan 2000–04 concludes this year, it is
opportune to consider the progress that has been made in
the evaluation of this action. The EMCDDA is playing a full
and active role in this process, which, it is to be hoped, will
facilitate sound policy-making in the field of drugs. It is
principally from this perspective that strategies and
legislative developments at both national and EU levels will
be examined.
EU developments
In 2003, two new legal instruments were adopted at
European level to tackle the drugs problem. One addresses
the issue of public health while the other deals with illicit
drug trafficking. Other issues dealt with at EU level during
2003 included measures to take account of new synthetic
drugs, the implementation of coordination activities and
instruments and the role of the EMCDDA.
Public health
On 23 September 2002, the European Parliament and the
Council adopted a new Community action programme for
public health (2003–08), which is based on three general
objectives: health information, rapid reaction to health threats
and health promotion through addressing health
determinants. Actions under health information and
promotion strands are particularly relevant in the drugs area.
In June 2003, the Council of Ministers adopted a
recommendation entitled ‘The prevention and reduction of
health-related harm associated with drug dependence’, a
document produced at the instigation of the European
Commission in May 2002. This text constitutes a major
achievement, being the first EC recommendation in the field
of public health concerning drugs. More specifically, it is
aimed at reducing the health-related harm associated with
drug dependence (2). Many Member States have already
incorporated the findings of this document in their national
drugs strategies.
This document recommends the following:
• Member States should, in order to provide for a high
level of health protection, set as a public health
objective the prevention of drug dependence and the
reduction of related risks, and develop and implement
comprehensive strategies accordingly.
• Member States should, in order to reduce substantially
the incidence of drug-related health damage (such as
HIV, hepatitis B and C and tuberculosis) and the number
of drug-related deaths, make available, as an integral
part of their overall drug prevention and treatment
policies, a range of different services and facilities,
particularly aiming at risk reduction.
• Member States should consider a specified list of
actions, in order to develop appropriate evaluation to
increase the effectiveness and efficiency of drug
prevention and the reduction of drug-related health
risks.
Member States should report to the Commission on the
implementation of this recommendation within two years of
its adoption, and subsequently on request by the
Commission. This will allow implementation of the
recommendation to be followed up at Community level and
enable subsequent appropriate action to be taken to meet
the objectives of the EU action plan on drugs.
Chapter 1
New developments in policies and laws
15
(3) OJ L 167, 25.6.1997, pp. 1–3.
(4) http://www.emcdda.eu.int/?nnodeid=1356.
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The framework decision will come into force from the date
of its publication in the Official Journal of the European
Union, and Member States will have 18 months to take the
necessary measures to comply with this instrument.
New synthetic drugs
Continuing its task of controlling new synthetic drugs, the
Council of Ministers, in November 2003, adopted a
decision regarding control measures and criminal sanctions
in respect of the new synthetic drugs 2C-I, 2C-T-2, 2C-T-7
and TMA-2. These substances, which are not listed in any
of the schedules to the 1971 United Nations Convention on
Psychotropic Substances, are now to be subject to control
measures and criminal penalties in the Member States.
In October 2003, the Commission brought forward a draft
for a Council decision to replace the 1997 joint action
concerning the information exchange, risk assessment and
the control of new synthetic drugs (3). This initiative is
directly related to the outcome of the external evaluation of
the joint action undertaken by the Commission as stipulated
by the European Union action plan on drugs 2000–04. The
proposed new legal instrument aims to clarify the
definitions and procedures and extends the scope to all new
synthetic drugs and all new narcotic drugs alike.
Coordination
Also in November 2003, the Commission adopted a
communication on coordination activities and instruments in
the field of drugs in the EU. The communication is based on
the findings of a study, organised by the EMCDDA in
cooperation with the Commission, of the existing
arrangements and mechanisms for coordination in the
Member States (4). The communication confirms that
coordination is essential if the EU is to respond effectively to
the complexity of the drugs phenomenon and its
consequences.
Role of the EMCDDA
Finally, in December 2003, the Commission proposed
recasting the regulations governing the EMCDDA. The
proposal, which will be discussed by the Council in 2004,
covers several areas, including amendments to the basic
regulations, changes designed to strengthen the role of the
EMCDDA in the context of new drug use patterns and EU
enlargement and amendments to take account of the role of
the EMCDDA as a contributor to the evaluation of the EU
action plan on drugs.
In addition, the recommendation invites the EMCDDA to
bring technical support to the European Commission to
prepare a report, in accordance with the European action
plan on drugs, with a view to the revision and updating of
that recommendation.
Drug trafficking
Following the conclusions of a special meeting of the
European Council in Tampere, Finland, in 1999, and in
response to the EU strategy and action plan on drugs, a
proposal for a framework decision laying down ‘minimum
provisions on the constituent elements of criminal acts and
penalties in the field of illicit drug trafficking’ was submitted
by the European Commission to the Council and European
Parliament. The Council of Ministers in November 2003
reached a political agreement on this first framework
decision in the field of drug trafficking. This framework
decision is considered to be a key instrument in tackling
drug trafficking as the alignment of penalties for drug-
trafficking offences among Member States in an enlarged
EU becomes increasingly important.
The basic principle of this framework decision is that
Member States should criminalise not only drug trafficking
but also attempting to do so or inciting, aiding or abetting
others to traffic drugs. Measures contained in this
framework decision target drug traffickers and the criminal
and terrorist organisations that derive funds from trafficking
in order to finance their illegal activities.
This framework decision envisages the imposition of
sanctions on those who participate at any stage in the
traffic of substances covered by United Nations conventions
and EC decisions: production, offering for sale, transport,
distribution and possession or purchase with intent to
traffic. It asks countries to ensure that ‘offences … are
punishable by criminal penalties of a maximum of at least
between 1 and 3 years of imprisonment’ or between 5 and
10 years of imprisonment when the offence involves large
quantities of drugs or those drugs that cause the most harm
to health. The crux of the framework decision is that it sets
out a common definition of what is considered drug
trafficking at EU level and lays down recommended
penalties for this offence within the EU. In achieving
agreement among Member States, national differences in
the definition of what constitutes personal consumption had
to be overcome. For this reason, offences related to
personal drug consumption, as defined by the national laws
of Member States, are excluded from the framework
decision.
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(5) Because the structure and content of national drugs strategies vary greatly among countries, no attempt is made in this report to harmonise definitions and
concepts. Thus, the expression ‘national drugs strategy’ (in quotation marks) means any official document approved by a government and which identifies
general principles and specific interventions/objectives to be achieved (in a stated time span) in the field of drugs, whether officially presented as a drugs
strategy or as a plan of action, political notes, etc. For further information, see EMCDDA National strategies and coordination mechanisms report
(http://www.emcdda.eu.int/?nnodeid=1354).
(6) See Box 1 OL: Recently adopted ‘national drugs strategies’.
(7) Norway, although not a member of the EU, is a member of the EMCDDA. Of the 25 EU Member States, only four countries do not (yet) report on a so-
called national drugs strategy: Cyprus, Latvia, Malta and Austria. In Cyprus and Latvia, a drugs strategy is in preparation. In Austria, each province has its
own plan although there is no federal drugs strategy.
(8) See Table 2 OL: Current ‘national drugs strategies’ in the field of drugs in the EU countries.
(9) Included in this timespan is the Netherlands, which documents its drug policy in a policy note Drug policy in the Netherlands: continuity and change
(1995) and various follow-up documents (XTC 2001, Cocaine 2002, Cannabis 2004).
(10) The principle of a balanced approach was endorsed in the political declaration of UNGASS in 1998: ‘there shall be a balanced approach between demand
reduction and supply reduction, each reinforcing the other, in an integrated approach to solving the drug problem’. In this chapter, no attempt is made to assess
the extent to which Member States have achieved a ‘balanced approach’; rather, it is simply observed that such an approach is receiving increasing attention.
(11) For details, see http://www.emcdda.eu.int/?nnodeid=1360.
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National policies
‘Drug strategies’ (5)
The trend for Member States to adopt a ‘national drugs
strategy’, a cornerstone of EU drug policy, was reported in
last year’s annual report and continued in 2003 (Figure 1).
In 2003, drugs plans and programmes were adopted in
Denmark, Germany, Lithuania and Slovenia. In 2004,
Estonia and France (6) are expected to follow suit, bringing
the total number of Member States that operate a drug
policy under the framework of an overall national drugs
strategy to 21 out of a total of 25 (22 out of 26 if Norway
is included) (7) (8).
The fact that ‘national drugs strategies’ have been
implemented so widely in a relatively short period of time
(1997–2004) (9), and within a well-defined geographical
area, affords the opportunity to make comparisons of the
phenomenon in different Member States and obtain an EU-
wide perspective.
As a first observation, it is becoming more and more
common to adopt a holistic approach to drug policy,
incorporating both demand- and supply-reduction activities,
the so-called ‘balanced approach’ (10). All documents
analysed exhibit this trait. Secondly, coordination is
assuming a more important role. Increasingly, national
drugs strategies are carried out in a centrally coordinated
manner (most EU countries have national coordination
agencies and national coordinators (11)), albeit in close
cooperation with regional and local agencies. Thirdly,
greater consideration is being given to the delivery of
interventions on the ground and to the monitoring and
assessment of implementation as tools to ensure
accountability to decision-makers (see selected issue on
evaluation, p. 75).
However, there are important differences in both the
structure and content of ‘national drugs strategies’. For
instance, the level of detail provided and the emphasis given
to actions and objectives vary considerably. Some
documents are structured in such a way as to allow stated
actions and overall implementation to be followed up; others
are less detailed, presenting general objectives but not tying
them to operational objectives, targets or performance
indicators. Drugs policy documents also vary in their use of
terminology: some countries have adopted action plans,
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Figure 1: Variety of ‘national drugs strategies’
NB: The theoretical distinction between a drug policy, a national drugs strategy
(which should identify general principles as well as a framework and direc-
tion) and an action plan (which puts the strategy into action, setting out
detailed specific actions) is not always maintained in different national doc-
uments. Because of the diversity among countries we describe the national
strategic documents as officially presented without making any attempt to con-
solidate definitions or draw comparisons.
Sources: Member States’ national strategies.
Cyprus
Malta
Drugs strategy
Drugs strategy and action plan
Drugs action plan
Drugs programme
Drugs policy note
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The differences in content may reflect different political
objectives or differences in the national characteristics of
the drug phenomenon. We report here on two of the most
relevant areas of divergence: the substances covered and
the main aim of the strategies.
Although national drugs strategies typically focus on
classified drugs, many documents extend to the so-called
legal drugs, mainly alcohol and tobacco, particularly
when considering the areas of education, prevention
and treatment (Table 2). In some countries, this
consideration takes the form of specific actions and
projects, while in other countries ‘legal drugs’ are only
mentioned. In many countries that include alcohol in
their ‘drugs’ strategies, a national action plan on alcohol
is also in place.
others have strategies and some have implemented
programmes. Indeed, the different political objectives and
agendas might determine a very wide picture in which
rather varying sceneries are portrayed under the expression
‘national drugs strategy’ (Figure 1). Nevertheless, while the
terms action plan, programme and strategy may be used
interchangeably (12), they do not necessarily reflect
differences in political objectives or agendas.
Another aspect that varies between Member States is the
timeframe of the national drugs strategy. Most countries
have adopted a timeframe of 3–5 years; however, in some
countries the strategy covers a period of 8–10 years,
whereas in others no timeframe at all is indicated (Table 1).
In this respect, the link between ‘national drugs strategies’
and the EU action plan on drugs should be considered.
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Table 1: Timeframe of ‘national drugs strategies’ 
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
European Union (1) (2)
Belgium (2001) No indication of timeframe
Czech Republic
Denmark (2003) No indication of timeframe
Germany (Plan to fight narcotics 1990) Up to 2008–13
Estonia 2004–12
Greece
Spain
France (1) (2)
Ireland
Italy
Lithuania (1) (2)
Luxembourg
Hungary (2000) No indication of timeframe
Netherlands (1995) No indication of timeframe
Poland (1) (2)
Portugal (1) (2)
Slovenia
Slovakia Until the year 2003 with a prospect to the year 2008
Finland (1) No indication of timeframe (2)
Sweden 
United Kingdom (1) (2)
Norway
Shading indicates period covered by a ‘national drugs strategy’: (1) and (2) indicate successive ‘strategies’.
(12) A drugs strategy may be defined as a ‘unifying theme, framework for determination, coherence and direction’ and an action plan as a ‘scheme or
programme for detailed specific actions’ (Strategies and coordination in the field of drugs in the European Union, a descriptive review, November 2002:
http://www.emcdda.eu.int/?nnodeid=1354).
(13) (1) To reduce significantly over five years the prevalence of drug use, as well as new recruitment to it, particularly among young users under 18 years of age;
(2) to reduce substantially over five years the incidence of drug-related health damage (HIV, hepatitis, TB, etc.) and the number of drug-related deaths; (3) to
increase substantially the number of successfully treated addicts; (4) to reduce substantially over five years the availability of illicit drugs; (5) to reduce substantially
over five years the number of drug-related crimes; (6) to reduce substantially over five years money laundering and the illicit trafficking of precursors.
(14) For an extended version of this section, see Box 2 OL: National policies: evaluation of laws.
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Although all countries share the same general objectives
(reduction in demand, reduction in supply, etc.) and the EU
action plan 2000–04 sets six common objectives (13), the
way in which it is envisaged that those objectives will be
achieved varies depending on the general aim of the drug
policy. The principal difference is that in some countries the
aim is to achieve a ‘drug-free society’ while in others the
main objective is to reduce the negative consequences of
drugs for both individuals and society. However, the
situation is not clear-cut: the majority of ‘national drugs
strategies’ mix these two aims (even adding others), giving
more weight to one or to the other. The chosen aim (and the
extent to which emphasis is placed on achieving it) shapes
the actions originating from the ‘national drugs strategies’.
While acknowledging that differences are necessary to
address specific political agendas as well as local
characteristics and cultures, considerable effort has been
expended on coordination at the European level. The
adoption of a coordinated EU approach to drugs (EU drugs
strategy and EU action plan 2000–04), which has been
consolidated and structured in recent years, is intended to
continue in the future.
The future direction of drug policy in the enlarged EU and
whether 25 different national drugs strategies (without
considering the regional and local strategies) will eventually
be linked under the umbrella of the EU strategy remains an
open question. However, issues such as the types of
instrument that could be considered by Member States
(strategy, programme, action plan), as well as their
duration, constitutive principles and criteria, and main
objectives and goals could be collegially discussed among
the Member States.
National policies: evaluation of laws (14)
There has been an increasing trend in the last few years to
evaluate, or to report the evaluation of, new laws (whether
of their implementation and/or of their impact). In the field
of drugs, there may be monitoring or evaluation of many
different aspects of drug control laws, including the basic
law prohibiting use or possession, the responses to drug
offences and the fight against trafficking and money
laundering. In some countries, pilot schemes are
implemented and evaluated before the scheme is rolled out
across the whole country.
For example, since 1999, Belgium, the Czech Republic,
Germany, Hungary, Sweden and the United Kingdom have
all reported some form of monitoring or evaluation of
various aspects of basic legal provisions addressing the
offence of drug use or possession. This has resulted in
major changes in the drug legislation in Belgium, Hungary
and the United Kingdom.
Assessment of the effect of criminalisation has been the focus
of debate and evaluation. Among the evaluation initiatives,
we highlight two apparently similar situations that have led
to different outcomes. Both Hungary and Sweden have
recently evaluated the effects of criminalising drug use. In
March 1999, the Hungarian Criminal Code was amended to
make the use of drugs a criminal offence, and the option of
requiring offenders to undergo therapy was restricted to
addicted users. However, subsequent scientific studies found
that the aim of reducing the abuse, consumption and
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Table 2: ‘Legal drugs’ in national drugs strategies
• action envisaged;  substance mentioned; n.a.: not available.
(1) WHO alcohol database (http://www.euro.who.int/alcoholdrugs).
Country Alcohol Tobacco Action plan 
on alcohol (1)
Belgium ● ● No
Czech Republic ● ● No
Denmark n.a. n.a. Yes
Germany ● ● Yes
Estonia   Yes
Greece ● n.a. n.a.
Spain ● ● No
France ● ● Yes
Ireland ●  Yes
Italy  n.a. Yes
Lithuania n.a. n.a. Yes
Luxembourg n.a. n.a. No
Hungary ●  Yes
Netherlands ● ● Yes
Poland   Yes
Portugal ●  Yes
Slovenia   No
Slovakia ● ● No
Finland n.a. n.a. Yes
Sweden n.a. n.a. Yes
United Kingdom   Yes
Norway ● ● Yes
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problem. Such evaluations of laws may assess their
implementation, effectiveness or efficiency. In general, the
evaluations reported have tended to support the value of
the policy response under consideration. Yet the willingness
to actually reverse a policy based on evaluation results, as
has occurred in Hungary, shows a new trust in evidence-
based research that has often been lacking. This welcome
trend in evaluation forms part of a more general trend for
public administration to be more accountable, and
increasingly to rely on traditionally private-sector concepts
such as performance targets and cost-effectiveness.
Developments in national legislation
Cannabis legislation
In the past year, cannabis has been reclassified in two
countries, in both cases attracting much media coverage,
not all of it accurate. In Belgium, a package of two laws, a
decree and a prosecutorial directive instigated several
changes to the legal framework, perhaps the most
fundamental of which was to place cannabis products in a
different legal category from other drugs. New offences
were created, so that an adult committing a first or second
offence of possession of cannabis intended for personal
use, in the absence of indications of nuisance or
problematic use, would only receive a fine and be required
to register with the police. The prosecutorial directive
interprets cannabis sufficient for personal use as a
maximum of 3 grams or one plant. However, nuisance may
be punished by three months to one year in prison and/or
a fine of EUR 5 000 to 500 000, and aggravating
circumstances, such as possession in the presence of
minors, will incur stiff sentences.
In the United Kingdom, cannabis and its derivatives were
reclassified from class B and A respectively to class C under
the British classification system. As a result, the maximum
penalty for possession for personal use is reduced from five
to two years’ imprisonment, but clearly any cannabis
possession remains a criminal offence. Two associated
factors, the maximum penalty for possession with intent to
supply and the status of cannabis possession as an
arrestable offence, effectively remained unchanged as a
result of a parallel legislative action. However, guidelines
produced by the Association of Chief Police Officers
recommended that police should make arrests for
possession only in certain circumstances that include
smoking in public or near minors. Under-18s should also
still be arrested so that they can be referred for treatment.
Both Belgium and the United Kingdom specifically address
problematic cannabis use in their laws or guidelines, an
aspect discussed later in this report.
circulation of narcotic drugs was not achieved; the number
of people trying drugs and the number of registered
offences and offenders continued to rise. In addition, the
change in the law made the legal classification of drugs
more difficult and legal proceedings more complicated, and
had a negative effect on the conduct of participants in the
drug market. The study’s authors concluded that the
punishments were too rigorous and failed to take account
of the fact that young people become drug users not
because they have a criminal nature but because of their
circumstances. As a result, a new amendment, effectively
reversing the changes and taking account of the study’s
findings, was implemented on 1 March 2003.
In Sweden, in 2000, the National Council for Crime
Prevention researched the effects of the 1988 regulation
(strengthened in 1993) that made simple drug use an
offence. The research revealed that the introduction of the
regulation resulted in a sharp increase in the number of
people arrested for minor drug offences. Although many of
those arrested were well-known drug abusers, some were
young, previously unknown users. An important reason for
adopting the regulation was to identify young people at an
early stage in their drug career, and the report concluded
that this was accomplished. The report also discusses the
regulation’s impact on the drug market (which has
escalated). It concluded that there were no clear indications
that the criminalisation of drug use had a deterrent effect
on young people.
With regards to other responses, evaluations of several
legal instruments to deal with drug offenders are being or
have been conducted in the United Kingdom, such as
testing following trigger offences, drug courts and arrest
referral schemes. Other methods of dealing with drug
offenders are also being evaluated in Germany (treatment
instead of punishment), Ireland (arrest referral) and the
Netherlands (compulsory treatment).
The Netherlands is also using evaluation techniques to
assess the effectiveness of recent laws aimed at countering
drug trafficking (detention of couriers) and money
laundering (public contracts). In Sweden, governmental
authorities’ directives include specific requests for the
government to evaluate the organisation and
implementation of the police in fighting drugs. Evaluation
techniques have also been used to improve responses to
local drug dealing and public nuisance, such as
coordination of local responses in Ireland, the power to
close premises in the Netherlands and the ability to order
driving re-tests in Germany.
Evaluation is clearly being recognised as an increasingly
important tool in dealing with all aspects of the drug
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Confiscation of assets
In the last year, a number of countries have made changes
to their legislation regarding confiscation of trafficker assets
or management of funds set up from such assets. In Ireland,
an initiative of the Criminal Assets Bureau (CAB) involves
working together with the Garda National Drugs Unit
(GNDU) to identify and target the assets of local drug
dealers. In the United Kingdom, the Proceeds of Crime Act
(2003) established an Assets Recovery Agency, and under
the new legislation police and customs officers are granted
the power to seize and search for money. The Act contains
measures that will assist investigators in tracing the
proceeds of crime and investigate money laundering. 
In Scotland, the powers of enforcement and prosecution
organisations have been strengthened to enable them to
increase recovery from both criminal and civil cases.
In Spain, a new law enacted in 2003 regulating the funds
seized from drug-trafficking abrogates the 1995 law on this
issue. The new law aims to speed up the transfer of
documents that are needed to identify and locate seized
goods and widens the range of beneficiaries of the funds to
include international and supranational entities and foreign
governments. In the Netherlands, a study of confiscation
legislation, 10 years after it came into force, investigated
the nature and size of the assets of 52 large criminal
organisations that had been brought to justice over the
period. It concluded that only 10 % of the estimated
unlawfully acquired money could be confiscated, but it
remains difficult to prove exactly how much money was
unlawfully acquired. The investigators recommend
improving expertise in the area of criminal financial
investigation. In France, a circular from the Department of
Criminal Affairs and Reprieves in 2002 sets out the precise
rules of operation and organises the follow-up of funds
seized from narcotics trafficking or money laundering,
based on the finding that the drugs policy fund set up in
1995 has received no substantial income.
Drugs and driving
Three countries in the EU made significant changes to their
laws addressing driving after taking drugs. In Austria, in
2003, the 21st amendment to the Road Traffic Act came
into force, allowing police to ask drivers to submit a blood
sample for testing if impaired ability to drive owing to drug
influence is suspected. The sanctions in the event of a
positive test, and the consequences if a driver refuses to be
tested, are the same as for driving under the influence of
alcohol. In addition, under the Act a positive test result does
not result in a police report for violation of the Narcotic
Substances Act, but only in a notification to the district
health authorities.
In France, a new law introduced in February 2003 makes it
a specific offence to drive after consumption of substances
or plants classified as narcotics and makes it obligatory to
test all drivers involved in a fatal road traffic accident.
Much stricter punishments are imposed if drugs are
combined with alcohol. In addition, drivers involved in a
road traffic accident resulting in personal injury should
routinely be tested if there is reason to suspect that they
have used narcotics. Furthermore, the gendarmerie and
police are permitted to test drivers at random.
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Combating money laundering
At present, it is not possible to make an accurate estimate of
the global proceeds of drug trafficking because of a lack of
reliable data. However, a ‘consensus’ figure of 2–5 % of the
world gross domestic product has been reported by Europol
(2002). Narcotics trafficking still seems to be the largest
single source of laundered funds. International money
laundering necessarily involves illicit or unusual cross-border
movement of capital or goods, such as gold, platinum or
diamonds (WCO, 2003c).
Amendments to the Council Directive 91/308/EEC on
money laundering give a much wider definition of money
laundering based on a broader range of predicate offences
and extend the obligation to report to independent legal
professionals.
Europol’s extended mandate from January 2002 gives the
organisation competencies for all money laundering
operations for which the predicate offence is listed in Annex
2 of the Europol Convention (Europol, 2002).
Interpol has put in place a network of expert contact points
in each member country so that information on money
laundering can be shared more quickly and efficiently
(Interpol, 2002). The customs enforcement network (CEN) is
an electronic information and communication system
developed by the World Customs Organization, started in
June 2000. As of June 2003, there were over 700 users
representing 130 countries and over 700 reported currency
seizures. During 2002–03 the FATF (Financial Action Task
Force) made significant progress in the fight against money
laundering. FATF successfully completed the revision of the
40 recommendations (FATF, 2003a). Special attention was
paid to combating the abuse of alternative remittance
systems (FATF, 2003b).
(15) http://eldd-cma.emcdda.eu.int/comparative_doc/Drugs_and_driving.pdf.
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In June 2003, the European legal database on drugs
(ELDD) published a comparative study (15) of the legal
situation regarding drugs and driving in 16 countries
and reported that, although driving under the influence
of drugs was an offence in all countries, there was wide
variation in police powers to test drivers, the substances
involved and the sanctions available. The EMCDDA
presented this study at the Council of Europe’s
Pompidou Group seminar on road traffic and
psychoactive substances in June 2003.
In Finland, the revised Chapter 23 of the Penal Code states
that any person found to be driving with an active narcotic
substance or its metabolic derivative in the blood shall be
charged with drunken driving unless the substance has been
prescribed by a doctor. However, if the ability to drive is
impaired, the driver will be charged with drunken driving
regardless of whether or not the substance has been
prescribed. If the ability to drive is impaired to the extent that
the safety of others is endangered, a charge of aggravated
drunken driving can lead to a minimum fine of 60 day-fine
units or imprisonment for a maximum of two years.
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(16) See Figure 1 OL: National plans specifying prevention contents and strategies.
(17) See Figure 2 OL: Delivery modes of school-based prevention.
(18) See Table 3 OL: Summary parameters of school-based prevention.
(19) See Figure 3 OL: Prevention for youth outside schools.
The aim of drug prevention measures is to reduce the
number of people who are initiated into substance use or,
more often, to postpone drug use to a later age, thus at
least reducing the scale of the drug problem (Rhodes et al.,
2003). Drug prevention involves, but is not restricted to,
education about drugs and warning about their dangers. In
fact, this drug-specific element constitutes only a small part
of drug prevention. Effective strategies combine information
on substances with selected behavioural and cognitive
(normative beliefs) techniques that have preventative effects
on drug use behaviour (Flay, 2000).
Prevention is classified according to target group. Universal
prevention targets general (usually young) populations, for
example in schools, without considering specific risk
groups, while selective prevention is aimed at vulnerable
groups and indicated prevention is aimed at vulnerable
individuals. However, although school-based prevention is
often a political priority, it is debatable whether in reality it
constitutes a main pillar of prevention. As funding for
prevention is limited, and in some countries has declined
(for example in France the drug prevention budget
(State subventions) fell from EUR 15 million in 2001 to
EUR 11 million in 2002), it becomes ever more important
that drug prevention is of high quality and supported by a
firm evidence base. Ideally, prevention policies planned and
implemented from a public health perspective with the aim
of delivering a basic and cost-effective dose of universal
prevention (prêt-a-porter) to a large target population
would be complemented by more intensive and tailor-made
interventions targeted particularly at vulnerable groups and
individuals (16).
Universal prevention
The principles and content of modern drug prevention
strategies, especially school-based universal prevention
programmes, are based on evidence. Measurable long-term
effects, even if small (Stothard and Ashton, 2000), are a
considerable gain if achieved over large populations. The
basic principles, what works and what does not, are now
well established. Effective elements are interactive teaching
(involving peers) (Tobler and Stratton, 1997), the correction
of normative beliefs (Flay, 2000), a strong focus on social
skills and a small amount of information about substances,
which must be balanced and relevant to young people’s
social reality (Hansen, 1992; Dusenbury and Falco, 1995;
Paglia and Room, 1999; Tobler et al., 2000; Tobler, 2001).
In practice, in several Member States, policy-makers and
professionals continue to prioritise approaches which have
been shown to be ineffective, such as affective education
(e.g. raising self-esteem), information provision (increasing
awareness) and reflection.
Similarly, the factors that contribute to successful delivery (17)
of school-based prevention are also known: strict adherence
to an established curriculum delivered by suitably trained
teachers; clearly defined content; and provision of manuals
and materials. In addition, drug prevention should form
part of a comprehensive school policy on drugs and on
health promotion (Paglia and Room, 1999; Chinman et al.,
2004). However, in reality, three separate strategies can be
discerned, and only rarely are these integrated. In the first
strategy, prevention is delivered through large national
programmes (Czech Republic, Ireland, Lithuania, the
Netherlands) or a set of approved programmes (Greece,
Spain, Hungary, Sweden). In another approach, the focus is
on teacher training (French-speaking Belgium, parts of
Germany, Austria, the United Kingdom), with the
assumption that teachers will integrate the prevention
message into daily school activities. Finally, some countries
(e.g. Portugal, Finland) opt for networks of health-
promoting schools. Only in Ireland and Spain are all three
approaches applied cohesively across the whole country (18).
Universal prevention outside the school environment (19)
generally aims to reach young people in three main ways:
by providing alternative leisure pursuits such as youth work,
adventure and creative activities (Greece, Spain, Latvia,
Luxembourg, the United Kingdom); through youth work in
sports and sport clubs, in order to engage youngsters in
protective group norms, behaviours and attitudes
Chapter 2
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(20) See Figure 1 OL: National plans specifying prevention contents and strategies.
Quality control systems and standards exist in the Czech
Republic, Lithuania, Slovenia and Sweden, while in
Germany and Portugal new monitoring systems for
prevention interventions are now operational or under
development. Increasingly, concrete components of
prevention interventions are defined and recommended in
national strategies, e.g. promoting social and decision-
making skills and increasing self-esteem in Lithuania and
Sweden.
Coverage of school-based prevention, expressed as the
proportion of pupils exposed to universal prevention, can
be measured only for programme-based prevention, and
extensive coverage is an objective of some strategies
(Germany, Italy, Finland); or using outreach techniques
(Denmark, Austria, Poland, Portugal, Norway). Prevention
work outside school has immense potential to identify
young people at risk and to target vulnerable groups, but
this potential is exploited in only some Member States
(Ireland, Hungary, the Netherlands, Austria, the United
Kingdom).
Selective prevention
In contrast to the large-scale/low-dose focus of universal
prevention, selective prevention policies concentrate on
vulnerable individuals or groups. Selective prevention
utilises existing (ideally local) research about risk factors,
vulnerable groups and problematic neighbourhoods to
target responses where the risk of sliding into drug
problems is greatest. Selective prevention is receiving
increasing attention in some countries, e.g. in Finland and
Sweden, because of the increase in recreational cannabis
and alcohol use (see Chapter 3), but is still limited to a few
Member States (Figure 2), predominantly those that already
have strategic policies for universal prevention. A sound
theoretical base and evaluation are essential, so that
selection of target groups or areas is supported by research
data and the goals of interventions can be defined and
interconnected. For example, in Hungary, several
interventions focus on Roma populations and use peer-
group approaches. Prevention in recreational settings as a
specific subset of selective prevention is described in
Chapter 4.
Recent progress in the enlarged 
European Union
In Greece, Portugal and Sweden, prevention policies have
progressed towards modern concepts and clearer structures,
e.g. school-based prevention is better defined than it was in
the past. Programmes for younger children in kindergarten
and primary school have expanded, especially in Greece
and Austria.
Among Member States, prevention policies that are subject
to quality control systems (Figure 3) typically also exhibit a
higher level of structure (e.g. delivery by means of
sophisticated programmes (20)) and more attention to
selective prevention (see Figure 2). Key factors in comparing
European prevention policies are quality (evidence base of
concepts), structure (how and by whom delivery is
organised) and coverage (population size reached).
Figure 2: Member States in which selective prevention
(i.e. targeting vulnerable populations or areas) is mentioned
in strategies and implemented
Sources: Reitox national reports and ‘Report on selective prevention in the EU’
(http://www.emcdda.eu.int/?nnodeid=1569).
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(21) See Table 4 OL: Synopsis of key prevention parameters.
(Spain, Ireland, United Kingdom). In all Spanish
Comunidades Autónomas, the proportion of school
populations exposed to approved and recommended
prevention programmes has increased further, and in other
Member States (the Czech Republic, Greece, Norway)
coverage has recently been assessed. As a result of these
developments, drug prevention effort in many Member
States, previously characterised by ‘low focalisation
(predominantly unspecific interventions and few adequate
prevention materials), low intentionality (low training level
of the professionals working in the area), low pro-activity
and evaluation (low level of research and lack of evaluation
procedures), low continuity (frequent ad hoc interventions)
and low coordination and participation (lack of
coordination concerning the implemented activities)’
(Portuguese national report), is slowly improving.
… and lack of progress
In some Member States, progress is slow and non-evidence-
based concepts still prevail. The reasons for this include
inertia, an overemphasis on medical and addiction-centred
approaches, a failure to appreciate the importance of
social influences and a focus on personal variables. In
addition, in some countries, a lack of standards means that
prevention is solely the remit of local health professionals or
teachers, whose knowledge about evidence-based
prevention is often low, with the result that prevention is on
the level of popular opinions and beliefs. And in some
Member States (e.g. Denmark, Estonia, France, Latvia, parts
of Belgium, Germany and Italy), school-based prevention is
still largely based on information provision through
booklets, sporadic seminars, action days and exhibitions,
meetings, lectures or expert visits.
There is evidence, albeit limited (Flay, 2000), that successful
school-based prevention needs to be embedded in a health
promotion curriculum and a school drug policy and that it
must address aspects of social life and the community
(Paglia and Room, 1999). However, the inflationary use of
phrases such as ‘promotion of healthy lifestyles’, ‘holistic
approaches’ and ‘integral prevention’ often conceals the
absence of a sound basis for prevention policies and a
limited commitment to evidence-based prevention. There
has been no visible progress in family-based prevention. As
a component of universal prevention, family-based
prevention remains limited to parents’ evenings or groups
(e.g. Germany, Greece, Sweden), while it forms a
constituent of selective prevention (i.e. concentrating on
families at risk) only in Spain, Ireland, Poland, Sweden and
the United Kingdom (21).
Figure 3: Member States in which quality control, monitoring and
evaluation of school-based prevention are considered a priority
and are carried out
Sources: Reitox national reports.
Cyprus
Malta
No important evaluations, but some quality 
control and monitoring systems in place
No important evaluations, no quality control, 
but monitoring systems in place
Important evaluations, quality control and 
monitoring systems in place and implemented
No policy measures to assure evidence-based 
prevention practice in schools
No information
Coverage of school population with 
prevention programmes is known
BE: Ginger database
on prevention activities:
65 workers, 5 000 entries
SE: Evaluations,
beginning 
quality
controls, no
monitoring 
system
DE: Important
evaluations, 
no quality 
controls,
monitoring 
system
starting
AT: Evaluations,
informal quality
controls, no
monitoring 
system

(22) See methodological notes on population surveys in the 2004 statistical bulletin.
(23) Note that the age range in the US survey (12 years and over) is wider than the age range reported by the EMCDDA for EU surveys (15–64).
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In all EU countries, cannabis is the illegal substance most
commonly used, although there is considerable variation
between countries. The use of cannabis by young people
first became prevalent in some European countries during
the 1970s, and spread to other EU countries during the
1970s and 1980s (Figure 4 — the example of Spain).
Widespread drug use is a more recent phenomenon in the
countries new to the EU.
Prevalence and patterns
Drug use in the general population is assessed through
surveys, which provide estimates of the proportion of the
population that has used drugs over defined periods of
time (22). Recent population surveys indicate that a
significant proportion of the European adult population
(aged 15–64 years) have tried the substance at least once,
ranging from 5–10 % in Belgium, Estonia, Hungary and
Portugal to 24–31 % in Denmark, Spain, France and the
United Kingdom. For comparison, in the 2002 United States
national household survey on drugs, 40 % of adults
(12 years and older) reported having tried cannabis or
marijuana at least once, and 11 % reported having used it
during the previous 12 months (SAMHSA, 2002) (23).
Surveys indicate that cannabis use is concentrated among
young adults (aged 15–34 years), and particularly among
people in their 20s. Rates of cannabis use are notably
higher among males than among females. National surveys
also suggest that use is more common in urban areas or
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Figure 4: Changing patterns of diffusion of cannabis initiation by selected birth cohorts — the example of Spain
NB: Data based on 1997 national drug survey (n = 12 515; 15- to 64-year-olds) and 1999 national drug survey (n = 12 488; 15- to 65-year-olds).
Birth cohorts selected only if there are no significant differences between surveys and samples pooled for one-year birth cohort.
Source: Kraus, L. and Augustin, R., ‘Analysis of age of first cannabis use in Germany, Greece and Spain’, in EMCDDA Report CT.00.EP.14, Technical implementation and update
of the EU databank on national population surveys on drug use and carrying out a joint analysis of data collected.
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(24) See Prevalence_Tbl 2 in the 2004 statistical bulletin.
(25) Ibid.
(26) See also Figure 4 OL: Relative frequency of cannabis use among 15-year-old school students who used during the past year.
(27) See Figure 5 OL: Evolution of cannabis use among young people in some EU countries measured by population surveys.
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areas with a high population density. Some of the national
differences noted might, in part, reflect differences in levels
of urbanisation.
The numbers of 15- and 16-year-old school students who
perceive cannabis to be easily or very easily available are
consistently much higher than the numbers who report
lifetime experience of cannabis use (24), but both measures
show the same geographical variations. Differences
between countries are considerable. Recent surveys of 
15-year-old school students indicate that lifetime prevalence
of cannabis use ranges from less than 10 % in Greece,
Malta, Sweden and Norway to over 30 % in the Czech
Republic, Spain, France and the United Kingdom (25). The
highest prevalence rates are found among boys in England
(42.5 %), with slightly lower rates (38 %) among girls in
England. The difference in cannabis use between boys and
girls also varies between countries and tends to be less
pronounced in northern Europe. For example, in Sweden,
lifetime prevalence rates are 7.7 % for boys and 6.6 % for
girls, while the corresponding figures for Greece are 8 %
and 2.7 %.
A large proportion of cannabis use tends to be occasional,
or to be discontinued after some time. In most EU countries,
only 20–40 % of all adults who have ever tried cannabis
report having used it during the previous 12 months,
and only 1–10 % admit to having used it during the last
30 days.
Use of cannabis during the last 12 months is higher among
young adults (15–34 years) than among the overall adult
population, ranging in most countries from 5 to 20 %
(Figure 5).
A small but important, and consistent, proportion (around
15 %) of 15-year-old school students in the EU who have
used cannabis during the past year report using it on 40 or
more occasions (considered to be ‘heavy’ use). Figure 6
shows that male students are more than twice as likely as
female students to be heavy users. Among males, the
proportion of ‘heavy’ users ranges from less than 1 % in
most of the States bordering the Baltic Sea (Estonia, Latvia,
Lithuania, Finland and Sweden) and Malta, to between 5 %
and 10 % in Belgium, Germany, Spain, France, Ireland,
Slovenia and the United Kingdom. This compares with a
range of 0 % to a maximum of 4.6 % for female students.
The extent to which ‘heavy’ patterns of cannabis use
contribute to health problems and the increased demand for
treatment is addressed in the selected issue ‘Cannabis
problems in context’ (p. 82) (26).
Trends
The lack of long-term series of consistent surveys in most EU
countries limits identification of drug trends. Nonetheless,
different types of surveys (national, local, conscript and
school surveys) have shown that cannabis use increased
markedly during the 1990s in almost all EU countries,
particularly among young people. In some cases these
increases followed a decline in use during the 1980s (27).
Although many countries report that cannabis use has
continued to increase in recent years, four other countries
(the Netherlands, Finland, Sweden and Norway) report that
use has levelled off among school students, conscripts or
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Figure 5: Recent use (past year) of cannabis among young adults
(15–34 years) as measured by national population surveys
NB: Data are from the most recent national surveys available in each country except
for France where small sample size precluded use of the 2002 survey so
data presented here are from 2000.
For details of the number of respondents by age group, see GPSurvey_Tbl 4
in the 2004 statistical bulletin.
Not all data correspond exactly to the EMCDDA standard age range (Denmark
and UK 16–34; Estonia, Hungary and Germany, 18–34). Variations in age
ranges may marginally influence some national difference. In some countries
the figures were recalculated at national level to reflect EMCDDA definitions.
Sources: Reitox national reports 2003, taken from survey reports or scientific arti-
cles. See also the population survey tables in the 2004 statistical bulletin.
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(28) See Box 3 OL: The European school survey project on alcohol and other drugs.
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most cited as a source of cannabis resin, followed by
Albania and India, but 31 other countries were also
reported as sources, confirming that trafficking is
widespread and the number of source countries large
(CND, 2004). In 2003, the United Nations Office on Drugs
and Crime (UNODC) and the Government of Morocco
teenagers in the last 2–4 years. Results from the
forthcoming 2003 ESPAD school survey report will provide
a more detailed description of trends among school
students in the EU (28).
In conclusion, recreational and occasional cannabis use
increased substantially during the 1990s in many European
countries but may now be beginning to plateau, at least in
some countries. Current use has probably also increased, in
particular among young people.
Seizures and market information
In 2002, cannabis continued to be the most widely
produced and trafficked illicit drug worldwide. However,
given the global spread of cannabis production and the
absence of monitoring systems, it remains difficult to
estimate how much is produced (UNODC, 2003a; CND,
2004).
Production and trafficking
In recent years, Morocco has been the main worldwide
source of cannabis resin, followed by Afghanistan and
Pakistan, with some also coming from other countries in
central Asia, Russia, Lebanon and Albania (UNODC,
2003a). In 2002, Morocco continued to be the country
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Interpreting seizures and market data
The number of drug seizures in a country is usually
considered to be an indirect indicator of the supply and
availability of drugs, although it also reflects law-
enforcement resources, priorities and strategies, as well as
vulnerability of traffickers to enforcement. Quantities seized
may fluctuate more widely from one year to the next, for
example if in one year a few of the seizures are very large.
For this reason, the number of seizures is considered by
several countries to be a better indicator of trends. In all
countries, the number of seizures includes a major
proportion of small seizures at the retail level. Where
known, origin and destination of drugs seized may indicate
trafficking routes and producing areas. The price and purity
of drugs at retail level are reported by most of the Member
States. However, data come from a range of different
sources which are not always comparable or reliable,
making accurate comparisons between countries difficult.
Figure 6: Prevalence of ‘heavy’ cannabis use among 15-year-old school students by gender in 2001/02
NB: ‘Heavy’ cannabis use is defined as use on 40 or more occasions during the past year. Germany: regional sample only. Portugal: limited comparability owing to 
sample size and age.
Source: Currie, C. et al. (2004), HBSC international report from the 2001/02 WHO survey.
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carried out the first survey of cannabis production in
Morocco. The survey revealed that 27 % of the arable land
in the Rif region was devoted to cannabis cultivation, which
corresponds to a potential production of 3 080 metric
tonnes of cannabis resin in 2003 (UNODC and
Government of Morocco, 2003). Most cannabis resin
consumed in the EU originates in Morocco; it is smuggled
mainly via the Iberian Peninsula, although the Netherlands
represents an important secondary distribution centre for
further transportation to EU countries (Bovenkerk and
Hogewind, 2002; national reports, 2003).
Source countries of herbal cannabis are spread across the
world. Overall, the most mentioned source countries at
global level in 2001 were Albania, Colombia, South Africa,
Russia, Jamaica and the Netherlands. Except in Europe,
most of the cannabis herb trafficking is intra-regional, i.e. it
is produced and consumed locally or in neighbouring
countries (UNODC, 2003a). Herbal cannabis seized in the
EU in 2002 is reported to have originated from a variety of
countries, mainly the Netherlands and Albania (CND,
2004; INCB, 2004a), but also from Asia (Thailand), Africa
(Malawi, South Africa, Nigeria, Angola) and the Americas
(Mexico, Jamaica, United States) (Reitox national reports,
2003).
Local cultivation and production of cannabis takes place in
most of the EU Member States. Although in some cases
plants seized may have been in transit from another
country, seizures of cannabis plants in the EU (see Table 3)
could be taken as an indicator of local cannabis cultivation.
In Belgium, cannabis cultivation has become widespread
throughout the country in recent years. In the Czech
Republic, the first examples of large-scale hydroponic
cultivation of cannabis — replacing domestic ‘self-supply’
outdoor growing — were discovered in 2002. In Estonia,
the number of cannabis plantations discovered increased in
2002, and some large plantations were detected. In
Hungary, it is reported that cannabis herb is grown in an
ever larger area. Throughout the EU, most cannabis plants
are seized in Italy, followed by the Netherlands, where the
number of plants seized has increased since 1998. The
latter is also a consequence of the successful integral multi-
agency approach on the local level (i.e. close cooperation
among local authorities, electricity companies, tax
departments, etc.) in the Netherlands. It is estimated that,
although about half to three-quarters of the cannabis
consumed in the Netherlands is home-grown (‘nederwiet’),
the Netherlands is becoming less important as a source of
cannabis for export to other countries than as a country of
transit for foreign cannabis, especially as cultivation
increases in other EU countries.
Seizures
Worldwide, a total of 1039 tonnes of cannabis resin and
3 800 tonnes of herbal cannabis were seized in 2002.
Europe and Asia continued to account for most cannabis
resin seized, 70 % and 23 % respectively, while herbal
cannabis seizures were concentrated in the Americas
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Table 3: Seizures of cannabis plants 
in the EU countries and Norway in 2001
n.a.: data not available.
Sources: Reitox national focal points; except:
(1) Interpol (2003), National statistics on illicit drug production traffic and
use in 2001, Interpol, Lyon.
(2) Corkery, J. M. and Airs, J. (2003), Seizures of drugs in the UK 2001,
Findings No 202, RDS-Home Office, London.
Country Number Quantities seized: number 
of seizures of plants (in kg when number 
of plants not available)
Belgium n.a. n.a.
Czech Republic (1) n.a. 343
Denmark (1) n.a. 230
Germany 785 68 696
Estonia 24 6 043
Greece n.a. 18 821
Spain n.a. (3 907 kg)
France 681 (41 kg)
Ireland 20 365
Italy n.a. 3 219 414
Cyprus (1) n.a. 274
Latvia (1) n.a. (72.7 kg)
Lithuania n.a. n.a.
Luxembourg 2 11
Hungary n.a. n.a.
Malta n.a. n.a.
Netherlands n.a. 884 609
Austria 120 (36 kg)
Poland (1) n.a. 2 550
Portugal 64 3 807
Slovenia 426 1 925
Slovakia (1) n.a. 535
Finland 612 (16 kg)
Sweden 51 (3 kg)
United Kingdom (2) 1 875 71 507
Norway n.a. (17 kg)
(29) Although this should be checked against missing 2002 data when available. Data on numbers of cannabis seizures in 2002 were not available for Italy,
Hungary, Poland and Slovenia; data on both the number of cannabis seizures and quantities of cannabis seized in 2002 were not available for Cyprus, Malta,
the Netherlands, Slovakia and the United Kingdom.
(30) See Markets_Tbl 1 in the 2004 statistical bulletin.
(31) See Markets_Tbl 2 in the 2004 statistical bulletin.
(32) See http://www.guardiacivil.es/prensa/actividades/sive03/intro.jsp.
(33) See Markets_Tbl 14 in the 2004 statistical bulletin.
(34) See Markets_Tbl 15 in the 2004 statistical bulletin.
(35) See Markets_Tbl 16 in the 2004 statistical bulletin.
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ranged from slightly under EUR 2 per gram in Estonia and
Spain to EUR 14 per gram in Latvia (33). During the period
1997–2002, average prices of cannabis resin remained
stable or fell slightly in most of the EU — except in
Luxembourg, where a slight increase during the period was
reported. In 2002, a similar trend was reported in all
countries except Germany, France, Latvia, Lithuania and the
Netherlands, where the street price of cannabis resin
increased. Over the same five-year period, the price of
herbal cannabis also remained stable or declined in most
countries, although Belgium, Czech Republic, Lithuania and
Luxembourg reported some increase. In 2002, the price of
herbal cannabis rose in Germany, Lithuania and Latvia,
while remaining stable or falling in the other Member
States.
The potency of cannabis products is determined by their
content of ∆9-tetrahydrocannabinol (THC), the primary
active constituent (EMCDDA, 2004c). In 2002, in countries
from which data are available, cannabis products —
resin (34) and herb (35) — at retail level were reported to
have an average THC content that varied from less than
1 % to 15 %.
(70 %) and Africa (19 %) (CND, 2004). In terms of both
number of seizures and total quantities seized, cannabis is
the most seized drug in all countries of the EU, except
Latvia, where the number of heroin seizures is higher. Most
cannabis seizures in the EU are made by the United
Kingdom, followed by Spain and France (29). However, over
the past five years, in terms of quantities, Spain has
accounted for more than half of the total amount seized in
the EU. At EU level, the number of cannabis seizures (30) has
been fluctuating within an upward trend since 1997, while
quantities (31) seized have been decreasing since 1999.
After a decline in 2001, both numbers and quantities seized
in the EU — based upon trends in countries from which data
are available — rose again in 2002.
Some countries have invested in new technological systems
to improve the efficiency of activities aimed at combating
cannabis trafficking. For example, Spain recently developed
the external surveillance integrated system (SIVE) —
currently operational in the Algeciras region and some of
the Canary Islands — intended to aid real-time detection of
both cannabis smuggling and illegal immigration (32).
Price and potency
In 2002, the average retail price of cannabis resin in the
EU varied from EUR 2.7 per gram in Spain to EUR 21.5
per gram in Norway, while the price of herbal cannabis
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(36) See Figure 6 OL: Evolution of recent use (past year) of amphetamines and ecstasy among young adults (15–34 years old) in the United Kingdom (British
crime survey).
Netherlands, Finland and the United Kingdom) it has been
found that ecstasy use has reached or surpassed
amphetamine use in recent years (36). In addition, in some
other countries (the Czech Republic, Ireland, Portugal),
recent surveys, although not part of a series, suggest that
ecstasy use is relatively high.
According to recent surveys, lifetime prevalence of
amphetamine use among the general adult population
(15–64 years) varies from 0.5 % to 6 % in EU Member
States, except in the United Kingdom, where it is as high as
12 %. Ecstasy has been tried by about 0.5–7 % of the
population.
Recent use (last 12 months prevalence) of amphetamines or
ecstasy among adults is generally less than 1 %, although
figures for both substances are somewhat higher in the
Czech Republic, Spain, Ireland (1998 survey) and the
United Kingdom; in addition, recent use of amphetamines is
higher than average in Denmark and recent use of ecstasy
in the Netherlands.
Among the population as a whole, amphetamine and
ecstasy use is principally a phenomenon of young people.
Lifetime prevalence among young adults (15–34 years)
varies from 2 % to 11 % and recent use prevalence from
0.5 % to 6 %. National surveys report lifetime prevalence of
ecstasy use among males aged 15–24 years of 11–17 % in
the Czech Republic, Spain, the Netherlands and the United
Kingdom, and recent use rates of 5–13 % in the Czech
Republic, Spain, Ireland (1998), Latvia, the Netherlands
and the United Kingdom. It is likely that these figures would
be even higher if only urban populations were considered
(Figure 8).
Ecstasy use generally increased during the 1990s. Although
its use may be still increasing among young people, its
escalation among the general population seems to be
limited, at least for the time being.
For comparison, in the 2001 United States national
household survey on drugs, lifetime experience of ecstasy
use among adults (defined as 12 years and older) was
4.3 %, with 9 % reporting ever having used stimulants
In this chapter, the use of a range of synthetically produced
drugs is reviewed. Some of these, such as the
amphetamines, have a long history of use in Europe.
Others, such as the ecstasy group, have only more recently
begun to be commonly used for their psychoactive
properties. Also covered in this chapter are efforts to
identify the emergence of any new synthetic drugs on the
European scene.
Amphetamines is the generic term for amphetamine,
methamphetamine and a number of other, less commonly
known substances, all of which stimulate the central nervous
system. Of these, amphetamine is by far the most commonly
available in Europe. Globally, levels of methamphetamine
use are growing and causing considerable concern, as the
drug is associated with a range of severe health problems.
To date, significant methamphetamine use in Europe
appears to be restricted to the Czech Republic, although
sporadic reports raise fears that this drug may be gaining
ground elsewhere.
The ecstasy group, which is sometimes referred to as
entactogens, comprises synthetic substances that are
chemically related to amphetamines but which differ to
some extent in their effect. The best-known member of the
ecstasy group is 3,4-methylenedioxy-methamphetamine
(MDMA), but other related analogues are also sometimes
found in ecstasy tablets.
The overall prevalence of use of ecstasy, amphetamine and
LSD in the general population is low, but closer examination
reveals that prevalence among younger age groups is much
higher, and the use of these drugs may be particularly high
in some social settings and/or among some subcultural
groups.
Prevalence and patterns of use
Traditionally, population surveys show that, after cannabis,
amphetamines are the illegal substance most commonly
used, albeit the overall prevalence is clearly lower
(Figure 7). However, in several countries in which repeated
surveys have been undertaken (e.g. Germany, Spain, the
Chapter 4
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(37) Results from the 2002 US national survey on drug use and health statistics (Substance Abuse and Mental Health Services Administration (SAMHSA) Office
of Applied Studies). Available from the SAMHSA website (http://www.oas.samhsa.gov/nhsda.htm). Note that the age range in the US survey (12 years and
over) is wider than the age range reported by the EMCDDA for EU surveys (15–64).
(38) See Prevalence_Tbl 1 in the 2004 statistical bulletin.
(39) Box 3 OL: The European school survey project on alcohol and other drugs.
(40) See Prevalence_Tbl 1 in the 2004 statistical bulletin.
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(including 5.3 % who reported having used
methamphetamine). Recent use (last 12 months) of ecstasy
was reported by 1.3 % and recent use of stimulants by
1.4 % (including 0.7 % reporting methamphetamine use) (37).
Surveys and studies of the young
Comparable data on young people are largely based on
school surveys focusing on 15- and 16-year-old school
students.
School survey data for 2001–02 show that lifetime
prevalence of ecstasy use among 15- and 16-year-old
school students is stable or declining in six Member States
(Belgium, the Czech Republic, Spain, Italy, Hungary and
Sweden). Lifetime ecstasy use in these countries ranged
between 1 % and 4.7 % (38).
A 1 % increase in lifetime prevalence of ecstasy use among
15- and 16-year-old school students was reported in
England (5 %). The forthcoming European School Survey
Project (ESPAD) report (39) will provide important trend data
for more EU Member States since 1995 and 1999.
With the exception of Hungary, lifetime prevalence of
amphetamine use among 15- to 16-year-old school
students remained stable or declined in all countries that
provided new data for 2001–02 (40).
Both lifetime prevalence and intensive use of amphetamine-
type stimulants are generally higher among males than
females except in the Czech Republic, where both ESPAD
and WHO school surveys have found lifetime prevalence of
methamphetamine use (mainly ‘pervitin’) to be higher
among girls. This agrees with findings among young people
35
Figure 7: Recent use (past year) of amphetamines, ecstasy and cocaine among young adults (aged 15–34) as measured by national
population surveys
NB: Data are from the most recent national surveys available in each country, except for France where the small sample size precluded use of the 2002 survey so data 
presented here are from 2000 (see GPSurvey_Tbl 4 in the 2004 statistical bulletin).
Sample sizes (n) refer to the number of respondents for the 15–34 age group. For sample sizes with the number of respondents for the whole surveys see 
GPSurvey_Tbl 4 in the 2004 statistical bulletin.
Not all data correspond exactly to the EMCDDA standard age range (Denmark and the UK, 16–34; Estonia, Hungary and Germany, 18–34). Variations in age ranges
may marginally influence some national differences. In some countries the figures were recalculated at national level to reflect EMCDDA definitions.
Sources: Reitox national reports 2003, taken from survey reports or scientific articles. See also population surveys tables in the 2004 statistical bulletin.
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information suggests that patterns of use are very variable.
For example, a 2001 survey among rave party visitors in
the Netherlands found that more than half (58 %) had used
ecstasy during the past month. Of these, 17 % — defined
as ‘current ecstasy users’ — admitted using ecstasy ‘a few
times a week’, and 22 % did so weekly. One in three
(32 %) consumed ecstasy ‘a few times a month’. As regards
future trends, Spain has reported that the association
between ecstasy use and specific types of music or events
may be weakening, and that the drug may be becoming
less important in identifying specific groups.
Despite widespread concern about stimulant drugs and
driving, a Spanish toxicology study of road traffic deaths
carried out in 2002 identified ecstasy in only 0.4 % of
1441 drivers investigated.
attending drug treatment centres in the Czech Republic:
over half of the teenage clients seeking treatment for
problems related to stimulant use (mainly ‘pervitin’) are
female, whereas in the 20 years and over age groups there
are twice as many male clients as female clients.
No explanation for this teenage phenomenon has so far
been put forward, but it signals the need to monitor
carefully the situation with regard to women and use of
amphetamine-type stimulants.
Recent studies in the Netherlands and the United Kingdom
show that ecstasy use remains much more common among
those who attend (dance) parties than among the general
population (Deehan and Saville, 2003; Ter Bogt and
Engels, 2004). Data regarding the frequency of ecstasy use
and quantities consumed are limited, but available
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Figure 8: Recent use (past year) of ecstasy among all adults (aged 15–64), young adults (aged 15–34) and younger males (aged 15–24)
as measured by national population surveys
NB: Data are from the most recent national surveys available in each country, except for France where the small sample size precluded use of the 2002 survey so data 
presented here are from 2000.
Not all data correspond exactly to the EMCDDA standard age range (Denmark and the UK, 16–34; Estonia, Hungary and Germany, 18–34). Variations in age ranges
may marginally influence some national differences. In some countries the figures were recalculated at national level to reflect EMCDDA definitions.
Sources: Reitox national reports, taken from population survey reports or scientific articles. See GPSurvey_Tbl 3 and Tbl 4 in the 2004 statistical bulletin.
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(41) In Spain, hospital emergencies due to acute reactions to psychoactive substances have, for several years, been monitored in a sample of hospitals across
the country, during a week selected randomly from each month. ‘Mentions’ of substances are recorded. For methodological details, see the Reitox national
report 2003 (pp. 34–36).
(42) See Figure 7 OL: Proportion of mentions in hospital emergency episodes due to acute reaction to drugs, Spain 1996–2001.
(43) See Figure 8 OL: Importance given in Member States to prevention responses in recreational settings.
(44) See Table 5 OL: Summary parameters of prevention on recreational settings.
(45) See also Figure 8 OL: Importance given in Member States to prevention responses in recreational settings.
(46) In EDDRA (http://eddra.emcdda.eu.int/eddra/plsql/showQuest?Prog_ID=2828).
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Deaths related to ecstasy
Deaths involving ecstasy are rare compared with opiate
deaths, but they arouse serious public concern, probably
because of the young age of the victims and the totally
unexpected outcome. The term ‘ecstasy-related death’ needs
to be more clearly defined. At present, it could mean that
the substance was mentioned on the death certificate or that
it was found in the toxicological analysis (often in
combination with opiates, alcohol, cocaine or other drugs).
Data in the 2003 Reitox reports suggest that ‘ecstasy-
related deaths’ are very rare in most EU countries, and
deaths in which ecstasy has apparently been directly
involved are even rarer (two in Austria; two in France,
one ecstasy alone; 19 in Germany, of which eight were
attributed to ecstasy alone; one in Greece; and two in
Amsterdam, one associated with alcohol), although
reporting procedures are not homogeneous. The United
Kingdom reported 55 deaths involving ecstasy in 2001,
up from 16 in 1998. A British study based on a series of
202 cases reported to the national programme on
substance abuse deaths between 1996 and 2002 also
found an increase in ecstasy-related deaths between
1996–97 (12 cases) and 2001–02 (72 cases), with ecstasy
being the only drug mentioned in 17 % of cases (Schifano
et al., 2003). The relatively high numbers of ecstasy-related
deaths in the United Kingdom might be due to a genuinely
higher prevalence of ecstasy use, but also to better
monitoring and analysis procedures.
Hospital emergencies can also be considered as an
indicator of acute health problems related to substance use.
A moderate increase in emergencies related to ecstasy
and amphetamines was reported in Spain from 1996
to 2001 (41) (42); other countries do not collect systematic
national data from emergency rooms, and similar increases
have not been reported so far.
A British study that estimated the risk of ecstasy death, taking
account of the number of users, found a very wide range
(0.2–5.3 per 10 000 users), and stressed the need for better
definitions of both ecstasy-related deaths and reference risk
populations (Gore, 1999; Schifano et al., 2003).
Some ecstasy deaths may be avoided by relatively simple
measures, such as improving ventilation, providing access
to water and by encouraging safer behaviour through
health education work. Other deaths appear to be due to
rare idiosyncratic reactions to the drug. Such unpredictable
reactions are difficult to prevent and the intervention
options, other than providing medical assistance, are
therefore limited.
Interventions in recreational settings
Prevention in recreational settings is probably the most
established specific form of selective prevention. In some
Member States (43), contents, guidelines and services offered
have been established for some time. There has been a
slight increase in prevention activities, especially in new
Member States (44).
Interventions range from abstinence-oriented measures,
such as the Swedish campaign ‘There are many reasons not
to try drugs’ in summer 2003 (the aims of which were to
strengthen the resolve of those already opposed to drugs
and to persuade waverers to choose the right way), to pill-
testing for users in some countries (see study below) (45).
Recently, however, structural approaches have gained
importance in an increasing number of Member States,
especially the Nordic ones (mainly on alcohol) and Italy.
These are based on developing joint cooperative strategies
involving restaurants, clubs and bars, police, drug
prevention services, restaurant workers’ unions and
administrations. The focus is generally on security issues,
first aid, drug surveillance and prevention of emergencies
and of violence. Staff are trained to identify risk situations
and to intervene in a professional manner.
In Denmark, a development project on ecstasy prevention in
two ‘model counties’ focused on prevention interventions at
the municipal level (formulating local action plans and
drugs policies), in schools and colleges and in the party
environment. Interventions included producing a ‘no
tolerance guide’ to drugs in nightlife venues and a website
containing background material. Management and staff in
restaurants received training on how to deal with drugs.
First reports indicate that uptake of some ecstasy-specific
services, e.g. a telephone helpline and counselling services,
was low. There were few admissions to emergency wards or
treatment institutions.
A recent Dutch–German–Austrian study (Benschop et al.,
2002) (46) analysed the impact of pill-testing services on
drug-taking behaviour and the risk awareness of ecstasy
users in three European cities (Amsterdam, Hannover and
37
(47) ‘Pervitin’ is the local name for a type of methamphetamine illegally manufactured in the Czech Republic. It has a long history of use and is administered
mainly by injection. Its manufacture may be linked to the legitimate ephedrine industry (UNODC, ‘Ecstasy and amphetamines: a global survey’, 2003).
(48) See Chapter 3, Interpreting seizures and market data (p. 30).
(49) Although not included in this list, several illicit amphetamine laboratories were exposed in the United Kingdom in recent years. In addition, a clandestine
amphetamine laboratory was detected for the first time in Luxembourg at the beginning of 2003.
(50) This situation should be checked against 2002 UK data when available. Data on numbers of amphetamine seizures in 2002 were not available for
Belgium, Italy, Hungary, the Netherlands and Poland; data on both number of amphetamine seizures and quantities of amphetamines seized in 2002 were not
available for Ireland, Cyprus, Hungary, Malta, Poland, Slovakia and the United Kingdom.
(51) See Markets_Tbl 7 in the 2004 statistical bulletin.
(52) See Markets_Tbl 8 in the 2004 statistical bulletin.
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greatest quantities are seized in East and South-East Asia
(Thailand, China), followed by North America (UNODC,
2003a). Methamphetamine production in Europe is on a
much smaller scale: over the period 2000–01, only 2 % of
clandestine methamphetamine laboratories dismantled
worldwide were in Europe — mainly in the Czech Republic,
Russia and Slovakia. Within the EU, minor
methamphetamine production has also been reported in
Belgium, Germany, Estonia, France, Latvia, Lithuania and
the United Kingdom (UNODC, 2003a,b). In the Czech
Republic, production of methamphetamine has been
reported since the early 1980s; most is destined for local
consumption, although some of it is smuggled to Germany
and Austria (UNODC, 2003a). Although, data on
methamphetamine seizures are not systematically collected
by the EMCDDA, the Czech Republic, Denmark, Estonia,
Lithuania, Norway and Sweden reported having made such
seizures in 2002.
In 2002, except for a period early in the year when the
price rose owing to a shortage of its precursor (ephedrine),
the average retail price of ‘pervitin’ in the Czech Republic
remained relatively stable at EUR 32 per gram. Average
purity at retail level is reported to be 40 %.
Amphetamine
Based upon the number of laboratories dismantled,
worldwide amphetamine production remains concentrated
in Europe. In 2002, amphetamine laboratories were
uncovered in Poland and the Netherlands, and some also in
Germany, Estonia, France and Lithuania (49) (Reitox national
reports, 2003; CND, 2004). The source countries of
amphetamine seized in the EU in 2002 were mainly the
Netherlands and Poland and to a lesser extent Belgium,
Estonia and Lithuania.
Likewise, most amphetamine seizures are made in western
Europe. This subregion accounted for 86 % of the total
volume of amphetamine seized worldwide in 2002, with
eastern Europe accounting for 10 % and countries in the
Near and Middle East for 3 % (CND, 2004). Over the last
five years, the main amphetamine-seizing country in the EU
has been the United Kingdom (50). At EU level, the
increasing trend in the number of amphetamine seizures (51)
peaked in 1998 and quantities (52) peaked in 1997. Based
upon trends in countries from which data are available,
Vienna). Respondents in the three cities were remarkably
similar: differences between those who use the pill-testing
service and those who do not were small. The most
common source of information on ecstasy is peers, with the
mass media and lifestyle magazines playing only a minor
role. Users inform their friends about the test results. This
informal route of dissemination is considered a hidden
advantage of pill testing: it widens the net of drug
prevention and lowers the threshold for contact with
preventative services. Users and non-users seem to have
separate social networks and do not mix, even when
attending the same events (e.g. parties). The study did not
find any indication that pill testing stimulates ecstasy use or
that it would widen the circle of ecstasy users.
Treatment
Use of amphetamine-type stimulants (ATS) is rarely the
primary reason for attending a drug treatment centre.
However, there are some notable exceptions: 52 % of clients
in the Czech Republic, 35.3 % in Finland and 29 % in
Sweden report ATS as a primary reason for seeking
treatment. In the Czech Republic, the greatest demand for
treatment comes from users of ‘pervitin’ (47), of whom
approximately one third are teenagers (under 20 years
old), with over half of teenage users being female. In both
Sweden and Finland, amphetamines have historically
played an important role in defining the national drug
problem, and to some extent this remains the case today.
Seizures and market information (48)
According to the United Nations Office on Drugs and
Crime (UNODC, 2003a), the production of ATS —
‘synthetic drugs including the chemically related
amphetamine, methamphetamine and ecstasy’ — is difficult
to quantify because ‘it starts with readily available
chemicals, in easily concealed laboratories’. However, the
annual global production of ATS is estimated at about
520 tonnes (UNODC, 2003b). Global seizures of ATS
peaked in 2000 at 46.2 tonnes and since then have
declined to 25.7 tonnes in 2002 (CND, 2004).
Methamphetamine
At global level, the most important ATS in terms of quantities
manufactured and trafficked is methamphetamine. The
38
(53) This should be checked against missing 2002 data when available.
(54) See Markets_Tbl 14 in the 2004 statistical bulletin.
(55) Among a total of 43 synthetic drugs production locations uncovered in the Netherlands in 2002, 18 could be specifically related to MDMA.
(56) This situation should be checked against 2002 UK data when available. Data on numbers of ecstasy seizures in 2002 were not available for Belgium,
Hungary, the Netherlands and Poland; data on both the number of ecstasy seizures and quantities of ecstasy seized in 2002 were not available for Italy,
Cyprus, Malta, Slovakia and the United Kingdom.
(57) See Markets_Tbl 9 in the 2004 statistical bulletin.
(58) See Markets_Tbl 10 in the 2004 statistical bulletin.
(59) See Markets_Tbl 14 in the 2004 statistical bulletin.
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both quantities seized and numbers of seizures seem to
have increased again since 2000 and 2001 respectively (53).
In 2002, average amphetamine prices at user level varied
from EUR 11 per gram in Hungary and Estonia to
EUR 37.5 per gram in Norway (54). Over the last five years,
prices have been stable or fallen in most of the countries
able to provide such data.
The average retail purity of amphetamine in 2002 ranged
from 10 % (Germany) to 52 % (Norway), with the highest
purities being found, following Norway, in countries
bordering the Baltic Sea — Estonia, Latvia, Lithuania and
Finland. A notable exception is Portugal, where average
purity in 2002 was less than 1 %. For the last five years,
amphetamine purity has been stable or decreasing in all
countries, although in 2002 increases were reported by
Belgium, Estonia and the United Kingdom.
Ecstasy
Globally, Europe remains the main centre of ecstasy
production, although its relative importance appears to be
declining as ecstasy manufacture spreads to other parts of
the world, notably to North America and East and South-
East Asia (UNODC, 2003a; CND, 2004). Within Europe,
most ecstasy production takes place in the Netherlands and
Belgium. For example, within Europe, over the period
1999–2001, over 63 % of seizures of ecstasy precursors
were made by the Netherlands and 21 % by Belgium while,
of ecstasy-producing laboratories dismantled in the EU,
75 % were in the Netherlands, 14 % in Belgium, 6 % in the
United Kingdom and 4 % in Germany. Dismantling of
ecstasy laboratories (and/or ATS laboratories) was also
reported by Estonia, Spain, Latvia, Lithuania, Hungary,
Poland and Norway over the 1991–2001 period (UNODC,
2003a). In 2002, 54 ecstasy laboratories were detected
worldwide, including 18 in the Netherlands (55), three in the
United Kingdom and one each in France and Estonia (CND,
2004). Ecstasy seized in the EU is reported to originate
mainly from Belgium and the Netherlands, although Estonia
and the United Kingdom are also mentioned as producing
countries in several reports (Reitox national reports, 2003).
Ecstasy trafficking is still strongly concentrated in western
Europe, although, like production, it has spread throughout
the world in recent years (UNODC, 2003a). In terms of
volume seized, in 2002 western Europe accounted for 73 %
and North America for 20 % (CND, 2004). Over the last
five years, among EU Member States, the United Kingdom
has consistently been the country to seize most ecstasy (56).
After a decline in 1997, the number of ecstasy seizures (57)
at EU level has increased rapidly since then. Based upon
trends in countries from which data are available, the
number of ecstasy seizures seems to have fallen in 2002.
However, this should be confirmed against missing 2002
data — in particular from the United Kingdom — once they
are available. As far as quantities of ecstasy seized (58) are
concerned, these increased rapidly between 1997 and
2000 and levelled off in 2001. In 2002, they increased
again in most of the countries reporting data.
In 2002, ecstasy tablets were reported to cost, on average,
between EUR 6 (Czech Republic) and EUR 20–25 (Italy,
Finland) each (59). However, very recently (DrugScope,
2004), the price of ecstasy tablets has been reported to be
as low as EUR 1.5 in some places in the United Kingdom.
Over the last five years, ecstasy tablets became
progressively cheaper in most EU countries. In 2002, this
trend continued in all countries except Estonia, where the
price of a tablet increased slightly.
Compared with five years ago, the amphetamine content of
tablets sold as ecstasy seems to have decreased while
ecstasy and ecstasy-like substances are increasingly found.
In all EU countries in 2002, the only psychoactive
substances found in most tablets sold as ecstasy and
analysed were ecstasy (MDMA) and ecstasy-like substances
(MDEA, MDA). In Belgium, Denmark, Germany, Lithuania,
the United Kingdom and Norway such tablets accounted for
more than 95 % of the total number of ecstasy tablets
analysed. The MDMA content of ecstasy tablets varies
greatly between batches (even between those with the same
logo) within and across countries. In most EU countries in
2002, the average content of active substance (MDMA) per
tablet was reported to be between 60 and 80 mg, although
in Hungary and Norway the range was wider.
LSD
LSD is manufactured and trafficked to a much smaller extent
than other synthetic drugs such as ATS. Worldwide LSD
seizures fell by 73 % between 2000 and 2001. In 2001,
the countries that seized the largest number of units were
the United States, Spain and the Netherlands (UNODC,
39
(60) This situation should be checked against 2002 UK data when available. Data on numbers of LSD seizures in 2002 were not available for Spain, Italy,
Lithuania, Hungary and the Netherlands; data on both the number of LSD seizures and quantities of LSD seized in 2002 were not available for Belgium,
Ireland, Cyprus, Malta, Slovakia and the United Kingdom.
(61) See Markets_Tbl 11 in the 2004 statistical bulletin.
(62) See Markets_Tbl 12 in the 2004 statistical bulletin.
(63) See Markets_Tbl 14 in the 2004 statistical bulletin.
(64) Sydrug, Interpol’s global project on synthetic drugs, Lyon, April 2003.
(65) http://www.emcdda.eu.int/?nnodeid=1346.
(66) The 1997 joint action concerning the information exchange, risk assessment and the control of new synthetic drugs (OJ L 167, 25.6.1997) defines new
synthetic drugs as: synthetic drugs which are not currently listed in any of the Schedules to the 1971 United Nations Convention on Psychotropic Substances,
which pose a comparable serious threat to public health as the substances listed in Schedules I or II thereto, and which have a limited therapeutic value. It
relates to end products as distinct from precursors.
(67) Most of the new substances listed are very new on the market and do not have popular (street) names.
Annual report 2004: the state of the drugs problem in the European Union and Norway
ecstasy is smuggled from western Europe to North America,
South-East Asia and Oceania (Interpol, 2002).
It is becoming increasingly apparent that there are links
between the networks that smuggle drugs and those that
smuggle precursors. January 2003 saw the start of
operational activities under the banner of Project Prism, an
international initiative designed to address diversion of the
main precursors required for the illicit manufacture of ATS.
Traffickers are increasingly turning to pharmaceutical
preparations as a source of precursors (INCB, 2004b).
Early-warning system information
The joint action (65), along with its early-warning system
(EWS), was established to identify new synthetic drugs (66),
assess their risks and adopt a decision-making process
through which they can be controlled. New synthetic drugs
still constitute only a very small fraction of the overall
market for synthetic drugs, which remains dominated
by MDMA (ecstasy), amphetamines and LSD. Despite
the success of the joint action in identifying new synthetic
drugs, it is important to note that most of the data on new
compounds come from those Member States that possess
high analytical and reporting capacities in terms of both
forensic and toxicological laboratories and operational
networks of data providers. Consequently, the resulting
description of the situation may reflect the operation
of the national early-warning systems on new synthetic
drugs, rather than the actual situation in the European
drug market.
Drugs monitored by EWS
In 2003, all nine substances which had been subjected to risk
assessment since 1998 were routinely monitored within the
framework of the EWS — MBDB, 4-MTA, PMMA, GHB and
ketamine — as well as the following phenethylamines: 2C-I,
2C-T-2 and 2C-T-7 and TMA-2. Furthermore, a number of
substances on which the EMCDDA has obtained information
were monitored — among them a group of tryptamines 
(5-MeO-DMT, 5-MeO-DiPT, AMT, 5-MeO-AMT and 
5-MeO-tryptamine) and piperazines (BZP and TFMPP) (67).
2003a). Until 2000, the EU country making the greatest
number of LSD seizures was the United Kingdom, but the
United Kingdom has now been overtaken by Germany (60).
In the last five years, at EU level, both the number of LSD
seizures (61) and the quantities (62) seized have — except for
a plateau in 2000 — steadily decreased. In the EU in
2002, the average cost to users of an LSD unit ranged from
EUR 5 in the United Kingdom to over EUR 20 in Italy (63).
International action against synthetic drugs trafficking
The Commission, in cooperation with Europol, prepared a
report in December 2003 illustrating the current status of
major multilateral projects on the mapping of distribution
networks and of experiences gained in this field at Union
level, in the Member States and candidate countries. Key
projects presented in the report include the comprehensive
action against Synthetic Drugs in Europe (CASE), which
combines amphetamine forensic profiling, carried out by
the Swedish National Laboratory of Forensic Science (SKL),
and the collation, at European Union level, of law
enforcement data in order to identify synthetic drug
production sites and criminal organisations engaged in
production and trafficking of synthetic drugs and to initiate
criminal investigations. The project is supported by Europol
analysis work file CASE. Another project, called Europol
illicit laboratory comparison system (EILCS), matches
photographic and technical information from synthetic drug
production sites across the European Union, opening the
possibility of investigating links between different sites, the
equipment seized and the facilitators behind the supply of
equipment.
Furthermore, the Europol ecstasy logo system (EELS)
produces an annual logo catalogue, which is disseminated
globally to relevant law enforcement agencies. The EELS
has worked in close cooperation with the central analysis
programme ecstasy (CAPE) run by the German Federal
Criminal Police Office.
Interpol has initiated a project focusing on the organised
crime groups that produce and market synthetic drugs. The
Sydrug project draws together and links operational data,
allowing multinational operations (64). Trends show that
40
(68) Strictly, neither is a new synthetic drug under the terms of the 1997 joint action, but both are being monitored following their risk assessment.
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In 2003, both Spain and the United Kingdom reported that
police seized small amounts of MBDB. 4-MTA, which in
1999 was made a subject of control in the framework of
the joint action, seems to have disappeared from the market
as no seizures have been reported in recent years. One
seizure of PMMA was made in Sweden, while a seizure in
Denmark involved tablets containing both PMMA and PMA.
In Belgium, one laboratory reported urine samples positive
for PMMA and, in addition, toxicological analysis of an
intoxicated person reported by an emergency ward
revealed PMA (in combination with MDA and MDMA). It
seems that all three substances — MBDB, 4-MTA and
PMMA — are no longer popular among users of synthetic
drugs.
As far as drugs of the tryptamine group are concerned,
most seizures occurred in Sweden and Finland. However,
both France and Denmark reported on the acquisition of
5MeO-DiPT samples. Many tryptamine compounds are not
controlled at international or national level, and therefore
may be produced by commercial laboratories and sold on
the Internet as ‘research chemicals’ (mainly by US
companies). Furthermore, recipes for the synthesis of almost
all new and ‘old’ synthetic drugs are widely available on
the Internet.
BZP, which is often found in association with TFMPP, has
increasingly been reported from Sweden and has also been
identified in Belgium, Spain, the Netherlands and Finland.
Of the phenethylamines that were risk-assessed in 2003,
2C-I, which is often sold as tablets carrying the ‘i’ logo,
seems to be gaining in popularity — a number of small
seizures were reported from Finland, Sweden and the
United Kingdom and the drug was detected in France,
Spain and the Netherlands. Furthermore, 2C-H (a
compound that is non-active in humans but which is a
precursor of 2C-I, 2C-C and 2C-B) was seized in relatively
large quantities in Finland and the Netherlands, and there
is evidence that in the latter the substance was intended as
a precursor for the production of 2C-I.
Synthetic drugs with potential for further spread
As anticipated by the European EWS and the risk
assessment carried out by the EMCDDA’s Scientific
Committee in the framework of the joint action, GHB and
ketamine are two synthetic drugs (68) with potential for
significant further spread in the context of recreational
settings.
GHB
The UN’s decision to put GHB under control in 
March 2001 has been implemented by most EU Member
States. In 2003, police or customs seizures of GHB
(usually in liquid form) were reported in Belgium,
Denmark, Estonia, Spain, France, Finland, Sweden and
Norway. The reported trends in GHB were mixed. Sweden
reported a decrease in GHB seizures in 2003, while
Norway reported a substantial increase and the United
Kingdom no change. The Netherlands also reported no
change in the number of GHB samples delivered to the
drug information monitoring system (DIMS), although the
Netherlands National Poisons Centre reported a slight
increase in the number of requests for information about
GHB. Estonia reported a significant increase in the
availability of GHB. The Netherlands and Belgium
reported receiving a small number of GHB samples in
powder form.
Norway and Sweden reported notable increases in the
seizures of precursor chemicals for GHB — GBL (gamma-
41
New synthetic drugs subjected to control under
the joint action
Between 1998 and 2002, five new synthetic drugs have
undergone risk assessment in the framework of the joint
action (MBDB, 4-MTA, GHB, ketamine and PMMA). In
2003, the EMCDDA Scientific Committee, supplemented
by experts nominated by the Member States and
representatives of the European Commission, Europol and
the European Agency for the Evaluation of Medicinal
Products (EMEA), carried out risk assessment on four new
synthetic drugs: 2C-I (2,5-dimethoxy-4-iodophenethylamine),
2C-T-2 (2,5-dimethoxy-4-ethylthiophenethylamine), 2C-T-7
(2,5-dimethoxy-4-(n)-propylthiophenethylamine) and TMA-2
(2,4,5-trimethoxyamphetamine) (1). As a result, on
27 November 2003, the Council adopted the decision (2) to
submit the four compounds to control measures and criminal
penalties in the 15 EU countries.
Specific scientific risk assessment of new synthetic drugs is
extremely difficult, owing to limited peer-reviewed scientific
data. However, information based on animal studies of toxic
effects (e.g. for TMA-2), analogy to partially related
compounds as well as evidence from other information
sources such as individual users’ reports, media and
unofficial publications, provide the basis for the
assessments.
(1) The risk assessment reports are available on the EMCDDA website
(http://www.emcdda.eu.int/?nnodeid=1584).
(2) Council Decision 2003/847/JHA of 27 November 2003 concern-
ing control measures and criminal sanctions in respect of the new 
synthetic drugs 2C-I, 2C-T-2, 2C-T-7 and TMA-2.
(69) Reitox early-warning system progress reports for 2003.
(70) Ibid.
(71) Antenna Amsterdam is a multimethod monitoring system aiming to identify and interpret new trends and developments in legal and illicit drugs use and
gambling among young people in Amsterdam, and to update and improve drug prevention.
Annual report 2004: the state of the drugs problem in the European Union and Norway
Amsterdam did not change from 2001 to 2002, i.e. just
over 60 cases each year.
Ketamine
Seizures and/or detections of ketamine in human samples
were reported from Belgium, Greece, Spain, France,
Finland, Sweden, the United Kingdom and Norway in
2003. In Austria, Benschop et al. (2002) found a lifetime
prevalence rate of ketamine use of 11.7 % among their
sample of 225 young people attending raves in Vienna. An
obstacle to the prevention of further spread of ketamine is
that it is licensed as a veterinary medicine and therefore
seems to be readily available through diversion of
legitimate production.
Health risks from new patterns of use
In 2003, the EWS enabled the EU Member States to
exchange valuable information on some controlled substances
that may pose serious health risks through new patterns of
use. For example, EU countries received early warnings about
high-dose MDMA tablets based on information received from
Belgium, France and Europol and about tablets sold as
ecstasy but containing other dangerous substances such as
DOB (2,5-dimethoxy-4-bromoamphetamine) following
information provided from Ireland.
butyrolactone) and BD (1,4-butanediol) (69) — which have
many uses in various industrial processes and are therefore
widely available (both are rapidly converted to GHB once
ingested). In Norway and Sweden, GHB precursors are
reported to be more readily available on the illegal market
in 2003 than in previous years.
Questions relating to the use of GHB are increasingly
included in drug surveys conducted in recreational nightlife
and dance club settings. In Germany, the Federal Office of
Criminal Investigation (BKA) reported growing consumption
of GHB (70), while in Amsterdam, according to the 2002
panel study of Antenna Amsterdam (71), ‘GHB was still
being used in almost all club networks; trendsetters however
appeared to be less keen on the drug than a year before
and the spread of GHB seems to have halted’. In Austria, in
the context of a pill-testing study, it was found that lifetime
prevalence of GHB use among a sample of 225 young
people attending raves in Vienna was 12.6 % (Benschop et
al., 2002).
During 2003, GHB was detected in human samples in
Belgium, Sweden and Norway and in samples taken from
intoxicated subjects and hospital emergency patients in
Spain (Barcelona) and the Netherlands. The number of
GHB-related requests for emergency assistance in
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(72) Results from the 2002 US national survey on drug use and health statistics (Substance Abuse and Mental Health Services Administration (SAMHSA) Office
of Applied Studies). Available from the SAMHSA website (http://www.oas.samhsa.gov/nhsda.htm). Note that the age range in the US survey (12 years and
over) is wider than the age range reported by the EMCDDA for EU surveys (15–64). It is likely that if US data were reported for the age range 15–64 years, as
in the EU, the figures would be higher.
(73) Although the results of the 2001/02 survey suggest that this increasing trend among all adults and young adults seems to be levelling off (see Figure 7).
According to the Home Office, increases in cocaine use between 1996 and 1998 and between 1998 and 2000 were significant at the 5 % level. However,
there was no significant increase between 2000 and 2001–02. 
Surveys have identified selected groups whose cocaine
consumption is higher than in the population overall. For
instance, recent surveys from five countries (Denmark,
Germany, Spain, the Netherlands and the United Kingdom)
have found that, among 15- to 24-year-old males, reported
lifetime experience is between 5 % and 13 %, while recent
use rates in Spain and the United Kingdom can be as high
as 5–7 %. It is likely that in urban areas levels of use are
substantially higher. In addition, focused (non-
representative) surveys among dance clubbers have
reported lifetime prevalence rates of cocaine use of
between 40 % and 60 % (EMCDDA, 2001).
As a reference from outside Europe, in the 2002 United
States national household survey on drugs, 14.4 % of adults
(defined as aged 12 years or older) reported lifetime
experience of cocaine use, higher than in any European
country. Recent use (last 12 months) of cocaine was
reported by 2.5 %, which is also higher than in all
European countries except Spain (2.6 %) (72). Among males
aged 18–25 years, lifetime prevalence of cocaine use in the
United States in 2002 was 18.1 % and recent use
prevalence was 8.4 %.
Trends in cocaine use
Cocaine trends are difficult to track at national level
because consistent national survey series are rare and, in
some cases, sample sizes are small. Consistent series will
facilitate better identification of trends, in particular by
focusing analysis and sampling on selected groups such as
young males in urban areas.
General population
Recent cocaine use among young people seems to have
increased consistently in the United Kingdom until 2002 (73)
and possibly, to a lesser extent, in Denmark, Germany, the
Netherlands and Spain (Figure 9). Other countries, in their
Introduction
Cocaine users are commonly perceived as being either
affluent, fashionable and socially integrated, or
marginalised, deprived and socially excluded, with the
smoking of cocaine being particularly associated with
problematic use. It is important to note that the
concentration of the use of the drug in specific sub-groups
and geographical areas means that national data sets may
poorly reflect trends that may be important in the
communities or populations in which they occur. However,
concern is now rising that cocaine use may be becoming
more widespread in Europe and that the users of the drug
are becoming more socially diverse.
Prevalence of cocaine use
General population surveys
According to recent national population surveys, between
0.5 % and 6 % of the adult population admit to having tried
cocaine at least once (i.e. lifetime prevalence), with Spain
and the United Kingdom being at the upper end of this
range. Recent cocaine use (last 12 months) is, in general,
reported by less than 1 % of adults, although in Spain and
the United Kingdom recent prevalence rates are higher than
2 %. These figures are clearly lower than comparable figures
for cannabis, although levels of use among younger adults
can be considerably higher than the population average.
Among young adults (15–34 years), lifetime prevalence
ranges from 1 % to 10 %. Generally, recent prevalence rates
are approximately half those for lifetime use, with Spain
and the United Kingdom reporting figures over 4 %.
Among the general population, cocaine use either is
discontinued after a period of experimentation during
young adulthood or is occasional, occurring mainly at
weekends and in recreational settings (bars and discos).
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(74) See Prevalence_Tbl 1 in the 2004 statistical bulletin.
(75) See Figure 20 and TDI_Tbl 10 in the 2004 statistical bulletin.
(76) UK Forensic Science Service Drug Intelligence Unit (2003), Drug abuse trends: Crack issue, 24, p. 13.
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recent Reitox national reports (2001–03), have reported
increases based on local or qualitative information (Greece,
Ireland, Italy and Austria).
School population
Spain is the only Member State to report new data showing
a recent increase in lifetime prevalence of cocaine use
among 15- to 16-year-old school students, rising from
4.1 % in 2000 to 5.9 % in 2002 (74). Although there was no
increase among 15- to 16-year-old school students in Italy,
an increase was reported among older Italian school
students.
Other indicators
Increases in indicators of cocaine use (treatment demand (75),
use of low-threshold drug services, number of hospital
emergency episodes, police seizures, toxicological findings
in fatalities) in some countries have aroused concern.
Throughout the EU, cocaine-related treatments appear to be
increasing, and in some countries the increase is
particularly pronounced. Cocaine is the second most
commonly reported drug in treatment reports in the
Netherlands and Spain (35 % and 26 % of all demands
respectively). In Europe, most treatment demands appear to
be associated with the use of cocaine powder (generally
cocaine hydrochloride).
Globally, smokeable cocaine preparations are particularly
associated with problematic use patterns. Use of crack
cocaine as an emerging or growing problem in specific
cities or regions was reported in Germany, Spain, France,
Ireland, the Netherlands, Austria and the United Kingdom.
Patterns of use
In general, among young recreational users, cocaine
consumption is light and continued use is very rare. And
reports from some countries (Germany, Spain, the
Netherlands, Austria and the United Kingdom) suggest that,
even among problem drug users attending drug treatment
and low-threshold services, patterns of cocaine and crack use
are very variable between clients and over time. However,
data about the frequency of cocaine and crack use and
about quantities consumed are very limited. Consumption
room studies show that use of smokeable cocaine is
particularly high among female sex workers attending these
services (Stöver, 2001; Zurhold et al., 2001).
Routes of administration
More and better information about routes of cocaine
administration is needed in order to provide a better
understanding of health risks and indicators of use.
Cocaine hydrochloride (powder cocaine) is usually inhaled
intranasally and less commonly injected, whereas crack is
smoked in heated pipes and freebase cocaine is ‘chased’
by breathing in the vapours that are produced when the
drug is heated, typically on tinfoil above a flame. There are
also reports of cocaine being smoked in a cigarette or joint.
However, drug treatment workers in the United Kingdom
report that, when associated with heroin use, crack cocaine
is sometimes injected. ‘Crack’, like brown heroin, is
insoluble and must be mixed with an acid before it is
converted to its active, soluble salt, form (76).
The frequency of smoking as a usual route of administration
of cocaine, in the form of either crack cocaine or freebase
cocaine (different preparations which can be considered
as pharmacologically equivalent), fell in 2002 compared
with 2000.
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Figure 9: Prevalence of cocaine use (past year) among young
adults in some EU countries as measured by population surveys
NB: Data taken from national surveys available in each country. Figures and
methodology for each survey can be consulted in GPSurvey_Tbl 4 in the
2004 statistical bulletin.
For young adults, the EMCDDA uses the range 15–34 years (Denmark and
the UK from 16; Germany from 18; France 1992: 25–34 and 1995: 18–39).
Sample sizes (respondents) for the 15–34 years group for each country and
year are presented in GPSurvey_Tbl 4 in the 2004 statistical bulletin.
For Denmark, 1994’s figure corresponds to ‘hard drugs’.
Sources: Reitox national reports 2003, taken from survey reports or scientific 
articles. See individual sources in epidemiological tables on population 
surveys in the 2004 statistical bulletin.
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(77) In Spain, hospital emergencies due to acute reactions to psychoactive substances have, for several years, been monitored in a sample of hospitals across
the country over a period of one week per year. ‘Mentions’ of substances are recorded. For methodological details, see the Reitox national report 2003
(pp. 34–36).
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Responses
Treatment of problem cocaine use
Problem cocaine use is typically treated in a non-drug-
specific setting, i.e. alongside clients being treated for the
use of other illicit (or licit) drugs. Treatment options are
broadly limited to non-pharmacological interventions that
aim to modify addictive behaviour regardless of the
particular drug(s) consumed. Such interventions include low-
intensity interventions such as counselling, hospital
admissions and high-intensity interventions, such as long-
term inpatient treatment. Alternative treatments, such as
acupuncture, may also be offered (Seivewright et al., 2000).
As far as medically assisted treatment is concerned, there is
no well-established pharmacological treatment for problem
cocaine use. Only a limited selection of pharmacological
treatments are available for cocaine users, and these have
little, if any, proven effect. Two systematic literature reviews
found that there was no evidence supporting the clinical use
Cocaine deaths
Deaths due to cocaine, amphetamine or ecstasy
intoxication, in the absence of evidence of opiates use,
appear to be infrequent in Europe.
However, it is likely that current statistics inadequately
record cocaine-related deaths, and information is reported
in different forms. In some countries, cocaine is found in
combination with opiates in a high proportion of drug-
related deaths (Portugal 22 %, Spain 46 %). This figure may
be just as high in other countries, but generally reporting
systems attribute deaths solely to opiates when these are
found to be present. In the United Kingdom, the number of
‘mentions’ of cocaine on death certificates increased
eightfold over the period 1993–2001. And in the
Netherlands the number of deaths attributed to cocaine
increased from two in 1994 to 26 in 2001. The proportion
of drug deaths that are attributable to cocaine alone,
without opiate involvement, ranges from 1 % to 10 %,
although absolute numbers are small.
Cocaine may be an important contributor to deaths due to
cardiovascular problems (arrhythmias, myocardial
infarction, cerebral haemorrhages), particularly in users
with predisposing conditions (e.g. cerebral aneurysm or
sub-clinical heart defects). Many of these cases might pass
unnoticed because of a lack of awareness and/or because
of differences in the social circumstances of victims
compared with opiate users.
An indication of the potential dangers associated with
cocaine use comes from Spain (77), where, during the
period 1999–2001, cocaine was mentioned in 44–49 % of
emergency hospital admissions resulting from acute
reactions to drugs; in a high proportion of these cases
cocaine had been smoked or injected. In Barcelona, the
collection of data on hospital emergencies at all the main
city hospitals throughout the year over a longer period
enables a comprehensive picture of hospital admissions due
to drug reactions to be built up (Figure 10).
In addition to the health concerns that are directly related to
cocaine, there is an increasing worry that some of the
cutting agents used may themselves pose a further health
risk. For example, phenacetine is reported as a common
adulterant in seized samples of cocaine powder. This drug
has been linked to liver, kidney and blood disorders,
including cancer.
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Figure 10: Number of drug mentions in hospital emergency
episodes, by drug type, Barcelona, 1992–2002
NB: One hospital emergency episode may include mention of several substances.
Source: Sistema d’Informació de Droges de Barcelona (2003), La Salut a Barcelona,
2002, Agència de Salut Pública, Consorci Sanitari de Barcelona, Barcelona.
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(78) See Chapter 3, Interpreting seizures and market data (p. 30).
(79) Although this should be checked against missing 2002 data when available. Data on numbers of cocaine seizures in 2002 were not available for Belgium,
Italy, the Netherlands and Slovenia; data on both number of cocaine seizures and quantities of cocaine seized in 2002 were not available for Ireland, Cyprus,
Hungary, Malta, Poland, Slovakia and the United Kingdom.
(80) See Markets_Tbl 5 in the 2004 statistical bulletin.
(81) See Markets_Tbl 6 in the 2004 statistical bulletin.
(82) This should be checked against missing 2002 data when available.
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of either the anticonvulsant carbamazepine or
antidepressants in the treatment of cocaine dependence
(Lima et al., 2004a,b).
The limited range of treatment interventions specifically
designed for problem cocaine users will be augmented by
some initiatives targeting this client group. In the
Netherlands, a website for cocaine abusers has recently
been launched, and in the United Kingdom services were
expanded in spring 2003 by the development of new
agencies, along with new guidance and improved training.
In Austria, treatment services are working on adapting
services to the needs of problem cocaine users.
Other cocaine service implications
Observations in supervised drug consumption facilities
show that cocaine-related emergencies are characterised by
extreme restlessness and frequent paranoia, with staff
finding it difficult to know how to respond (EMCDDA,
2004a). An increase in crack cocaine dealing has been
associated with a higher level of aggression between clients
and dealers (Stöver, 2001).
The extent to which problems are the direct consequence of
the use of the smokeable forms of cocaine per se or are
related to the frequency and amount of its use or to pre-
existing social, psychological and drug problems is not
clear. Responses include specifically developed information
materials about risks and safer use, supervised consumption
rooms, ‘chill-out rooms’ and ‘day-shelters’ where users can
retreat and calm down, but also outpatient treatment
(Stöver, 2001).
Concern has been expressed about the potential risk of
exposing young drug users attending treatment settings
primarily for cannabis-related problems to the behaviours
and problems of cocaine users (Neale and Robertson, 2004).
Seizures and market information (78)
Production and trafficking
Colombia is by far the largest source of illicit coca in the
world, followed by Peru and Bolivia (UNODC, 2003a).
Global production of cocaine in 2002 has been estimated
at 800 metric tonnes, to which Colombia contributed 72 %,
Peru 20 % and Bolivia 8 %. Most of the cocaine seized in
Europe comes directly from South America (especially
Colombia) or via Central America and the Caribbean.
However, in 2002, some of the cocaine trafficked in Europe
passed through Brazil (and from there to Portugal) or the
United States (and thence to Italy). The main points of entry
in the EU are Spain, Portugal and the Netherlands, and to
a lesser extent France and the United Kingdom (Reitox
national reports, 2003; UNODC, 2003a; INCB, 2004a).
Seizures
According to the Commission on Narcotic Drugs (CND,
2004), cocaine is the third most trafficked drug in the world
after cannabis herb and cannabis resin. In terms of volume
seized, in 2002 most trafficking in cocaine continued to be
in the Americas and Europe. The latter accounted for
13.5 % of cocaine quantities seized worldwide (CND,
2004). Within Europe, most cocaine seizures occur in
western States. Between 1997 and 2002 Spain was
consistently the EU country with the highest level of cocaine
seizures. In 2001 and 2002 (79), it accounted for more than
half of the EU total of both number of seizures and
quantities seized.
Over the period 1997–2002, the number of cocaine
seizures (80) increased in all countries except Germany and
Italy. Based upon trends in countries from which data are
available, an increase in cocaine seizures at EU level seems
likely to be confirmed in 2002.
Over the same five-year period, quantities of cocaine
seized (81) fluctuated but with an upward trend. After a
record volume of cocaine seizures in 2001, quantities of
cocaine seized at EU level decreased substantially in
2002 (82) — mainly because of a reduction in the amount
seized by Spain (and Portugal) in comparison with 2001,
although some countries (Germany, France, Italy, Norway)
reported large increases in the quantities of cocaine seized.
The decline in the quantities of cocaine seized in 2002 in
Spain, the Netherlands and Portugal, together with the
increase reported by France, Germany and Italy, might
indicate a change in the relative importance of the points of
entry traditionally used by traffickers for cocaine destined
for Europe (CND, 2004). In relation to this, it should be
noted that since early 2002 the Netherlands has taken
radical measures to reduce the increasing flow of cocaine
couriers travelling from the Caribbean to Schiphol Airport,
and as a result the number of arrested cocaine couriers has
decreased dramatically.
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(83) See Markets_Tbl 14 in the 2004 statistical bulletin.
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In 2002, WCO and Interpol launched a joint initiative,
Operation Andes, to enable national customs and police
authorities to exchange and analyse information that would
help to identify illegal consignments of precursor chemicals in
Chile, Bolivia, Colombia, Argentina and Peru (WCO, 2003).
Price and purity
The average price (83) of cocaine at retail level varied
widely across the EU in 2002, from EUR 38 per gram in
Portugal to EUR 175 per gram in Norway. Between 1997
and 2002, the average retail price of cocaine was stable or
fell in all EU countries. Similar findings were reported in
2002, except in the Czech Republic and Lithuania, where
prices increased in comparison with the previous year.
Compared with heroin, the average purity of cocaine at
user level is high, varying in 2002 from 28 % in Estonia to
68 % in the Czech Republic and Norway. Between 1997
and 2002, the average purity of cocaine decreased in most
of the EU countries reporting time trend data. In 2002,
cocaine purity continued to decrease in most countries,
except in those reporting the highest average purities, such
as Belgium, the Czech Republic, Luxembourg and Norway,
where a rise in cocaine average purity was recorded.
Although seizures of crack cocaine have been reported by
some EU countries, they are sometimes not distinguishable
from cocaine seizures. Thus, trends in cocaine seizures
reported above might include crack.
International action against cocaine trafficking
Cocaine trafficking continues to be controlled largely by
Colombian criminals. However, groups from Albania and
Africa are also involved in the distribution of this substance.
Interpol’s Operation Trampoline revealed cocaine smuggling
from Venezuela and Colombia to Curaçao. This operation
resulted in the identification of several major trafficking
organisations operating from the Caribbean to practically
every region in the world (Interpol, 2002). During 2003, a
number of very important maritime operations to combat
cocaine smuggling took place along the Atlantic coast of
Europe. Up to 29 tonnes were seized. Most of these
operations were carried out by the Spanish authorities.
Operation Purple, an international programme launched in
1999 to track potassium permanganate (used in the illegal
manufacture of cocaine), continued to achieve successes.
During 2003, nearly 900 tonnes of this chemical were
prevented from being diverted into illicit drug production.
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(84) For more detail see the methodological notes on problem drug use in the 2004 statistical bulletin.
(85) See Prevalence_Tbl 3 and Prevalence_Tbl 4 in the 2004 statistical bulletin.
Although there have been considerable improvements in
estimation techniques, lack of reliable and consistent
historical data complicates the assessment of trends in
problem drug use. Reports from some countries of changes
in estimates, supported by other indicator data, suggest that
there has been an increase in problem drug use since the
mid-1990s. Estimates are available from 19 countries, of
which nine report an increase in problem drug use since
the mid- or late 1990s: Belgium, Denmark, Germany, Italy,
Luxembourg, Finland, Sweden (between 1992 and 1998),
the United Kingdom and Norway. Increases in Belgium and
Norway are based on estimates of injecting use. Although
no time series of national estimates are available from the
new Member States, other evidence suggests that trends
vary. In the Czech Republic, several indicators suggest that
problem drug use has stabilised since the late 1990s,
whereas in Estonia strong increases in some indicators of
problem drug use have been observed. In view of the
potential vulnerability to drug problems of countries in
social and economic transition, there is an urgent need to
develop surveillance capacity in the new Member States.
Patterns and scale of use
Problem drug use can be subdivided into important
groupings. A general distinction can be made between
heroin use, which historically has accounted for most
problem drug use in the majority of EU countries, and
problem use of stimulants, which predominates in Finland
and Sweden, where the majority of problem drug users are
primary amphetamine users. Similarly, in the Czech
Republic, methamphetamine users have traditionally formed
a significant proportion of problem drug users.
Increasingly, problem drug use appears to be becoming
more diverse, and the EMCDDA is currently reviewing if the
European operational definition needs to be refined in the
light of the changing drug phenomenon. For example,
polydrug use problems have become progressively more
important in most countries, while some countries where
opiate problems have historically predominated now report
changes towards other drugs. In Spain, estimates of
Problem drug use
The regular and sustained use of heroin, drug injecting
and, in some countries, the intensive use of stimulants
account for a substantial proportion of drug-related health
and social problems in Europe. The number of individuals
exhibiting this kind of behaviour is low relative to the
population overall, but the impact of problem drug use is
considerable. To help understand the scale of this problem
and to allow trends to be monitored over time, the
EMCDDA is working with Member States to redefine the
concept of ‘problem drug use’ and to develop strategies to
measure both its scale and its impact.
Problem drug use is defined operationally as ‘injecting drug
use or long duration/regular use of opiates, cocaine
and/or amphetamines’ (84). Variations in definitions and
methodological uncertainties mean that obtaining reliable
estimates in this area is difficult, and caution should be
used when interpreting differences between countries or
over time.
Prevalence
Estimates of the prevalence of problem drug use range
between 2 and 10 cases per 1 000 of the population aged
15–64 (based on midpoints of estimates), or up to 1 % of
the adult population (85). Problem drug use
disproportionately affects some geographical areas, such as
deprived inner cities, and some specific groups, notably
young males, making problematic use appear to be
particularly intense in some communities. Higher estimates
are reported by Denmark, Italy, Luxembourg, Portugal and
the United Kingdom (6 to 10 cases per 1 000 inhabitants
aged 15–64), and lower rates are reported by Germany,
Greece, the Netherlands, Poland and Finland (less than four
cases per 1 000 inhabitants aged 15–64; see Figure 11).
Among the new countries of the EU, well-documented
estimates are available only from the Czech Republic,
Poland and Slovenia, where figures are in the low to mid-
range, at 4.9, 1.9 and 5.3 per 1 000 population aged
15–64 respectively.
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problem opiate users are declining and an increase is
observed in cocaine-related drug problems, although,
reliable time trends of problem drug use that include
problematic cocaine use are not available. Germany and
the Netherlands report an increasing proportion of crack
cocaine users among their problem drug populations,
although the overall estimate of problem drug users in the
Netherlands remains unchanged.
The weighted-average rate of problem drug use in
the EU is probably between four and seven cases per
1 000 population aged 15–64, which works out as
1.2–2.1 million problem drug users in the EU after
enlargement, of whom some 850 000 to 1.3 million are
active injectors. However, these estimates are far from
robust and will need to be refined as more data become
available from the new Member States.
Drug injecting
Drug injectors are at very high risk of experiencing adverse
consequences, and it is therefore important to consider
drug injection separately, as a core category of problem
drug use.
Estimates of injecting drug use are made using indirect
(technically, multiplier) methods from mortality data or data
on human immunodeficiency virus (HIV) or hepatitis C virus
(HCV) infection. Again, data quality and methodological
issues give rise to interpretational questions; for example, in
these estimates it is difficult to distinguish current injection
from lifetime injection, and comparisons between countries
should be made with caution. Available national-level
estimates of injecting drug use range between two and six
cases per 1 000 of the population aged 15–64 (Figure 12).
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Figure 11: Estimated rate of problem drug use (rate per 1 000 aged 15–64)
NB: CR = Capture–recapture; TM = Treatment multiplier; PM = Police multiplier; MI = Multivariate indicator; TP = Truncated Poisson; CM = Combined methods.
Target groups may vary slightly owing to different methods and data sources; therefore comparisons should be made with caution. For more details see Prevalence_Tbl 3
and Tbl 4 in the 2004 statistical bulletin. The Swedish estimate has been adjusted to fit the EMCDDA definition of problem drug use. The Spanish estimate does not
include problem cocaine use; a higher estimate is available in Prevalence_Tbl 3 and Tbl 4, which takes this group into account but which may not be as reliable.
Sources: National focal points. See also EMCDDA project (2003), National prevalence estimates of problem drug use in the European Union, 1995–2000, CT.00.RTX.23,
EMCDDA, Lisbon, coordinated by the Institut für Therapieforschung, Munich (http://www.emcdda.eu.int/? nnodeid=1372).
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(86) See Figure 9 OL: Trends in injecting drug use.
(87) See Chapter 3, Interpreting seizures and market data (p. 30).
Annual report 2004: the state of the drugs problem in the European Union and Norway
Seizures and market information (87)
Production, trafficking and seizures of opiates
Most of the world’s illicit opium and heroin comes from a
few countries (UNODC, 2003a). Global production of illicit
opium in 2002 was estimated to be about 4 500 metric
tonnes, to which Afghanistan contributed 76 %; most of the
rest came from South-East Asia, with about 18 % from
Myanmar and 3 % from Laos. Global opium production has
remained stable over the last five years, except in 2001,
when a ban on opium poppy cultivation enforced by the
Taliban regime in Afghanistan resulted in a dramatic but
short-lived decline.
Heroin consumed in the EU is predominantly produced in
Afghanistan or along trafficking routes for opium, notably
in Turkey (UNODC, 2003a), and enters Europe by two
major trafficking routes. The historically important Balkan
Analysis of injecting rates among heroin users in treatment
suggests marked differences between countries in the
prevalence of current injecting drug use as well as varying
trends over time (86). The data that are available show that
less than half (43 %) of those being treated for heroin use
for the first time report current injecting compared with two
out of three (62 %) of all those treated (weighted averages).
In some countries (Spain, the Netherlands, Portugal), a
relatively small proportion of heroin users appear to inject,
whereas in other countries (Czech Republic, Slovenia,
Finland) injection of heroin is still the norm. In several long-
standing EU countries from which data are available,
injecting drug use seems to have fallen during the 1990s.
However, it is worrying that in some other (Germany,
Ireland, Finland) countries injecting drug use seems not to
decrease and may even show signs of increasing, while in
the new Member States, at least where data exist, almost all
heroin users seem to inject.
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Figure 12: Estimated rate of injecting drug use (rate per 1 000 aged 15–64)
NB: MM = Mortality multiplier; HM = HIV multiplier; CM = Combined methods for IDU (injecting drug use) estimation.
Target groups may vary slightly owing to different methods and data sources; therefore comparisons should be made with caution. Mortality and HIV multipliers are
assumed to give estimates of (mainly current) injecting drug use, which is only part of problem drug use. The other methods are assumed to result in estimates of 
problem drug use. For more details see Prevalence_Tbl 3 and Tbl 4 in the 2004 statistical bulletin.
Sources: National focal points. See also EMCDDA project (2003), National prevalence estimates of problem drug use in the European Union, 1995–2000, CT.00.RTX.23,
EMCDDA, Lisbon, coordinated by the Institut für Therapieforschung, Munich (http://www.emcdda.eu.int/?nnodeid=1372).
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(88) Although this should be checked against missing 2002 data when available. Data on the number of heroin seizures in 2002 were not available for
Belgium, Italy, Hungary, the Netherlands and Poland; data on both number of heroin seizures and quantities of heroin seized in 2002 were not available for
Ireland, Cyprus, Malta, Slovakia and the United Kingdom.
(89) See Markets_Tbl 4 in the 2004 statistical bulletin.
(90) This should be checked against missing 2002 data when available.
(91) Ibid.
(92) If fentanyl were accidentally consumed, being mistaken for heroin, the risk of toxicity would be very high.
(93) North European heroin route.
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route continues to play a crucial role in heroin smuggling.
Following transit through Pakistan, Iran and Turkey, the
route then diverges into a southern branch through the
Former Yugoslav Republic of Macedonia (FYROM),
Albania, part of Italy, Serbia, Montenegro and Bosnia-
Herzegovina and a northern branch through Bulgaria,
Romania, Hungary and Austria. Since the mid-1990s,
heroin has been increasingly smuggled to Europe through
the ‘silk route’ via central Asia, the Caspian Sea and Russia
(Reitox national reports, 2003; UNODC, 2003a; CND,
2004; INCB, 2004a). Although these routes are the most
important, seizures have occasionally been made
elsewhere, including in some African countries and
Colombia.
In addition to imported heroin, some opiate drugs are
produced within the EU. This is mainly confined to the
limited production of home-made poppy products (e.g.
poppy concentrate from crushed poppy stalks or heads) in
a number of east EU countries such as the Czech Republic,
Estonia, Lithuania and Poland. There is some evidence that
these home-produced products are being displaced in the
illicit market by imported heroin.
In volume terms, in 2002, Asia (52.5 %) and Europe
(28.1 %) continued to account for the majority of heroin
seized worldwide (CND, 2004), with European heroin
seizures being concentrated in western countries. Since
1998, the EU country accounting for the greatest number
and quantity of heroin seizures has been the United
Kingdom, followed by Spain (88). In 2001, the United
Kingdom was responsible for one third of the total number
of heroin seizures and 40 % of the total amount of heroin
seized in the EU.
Quantities of heroin seized (89) in the EU were stable until
1998, and then increased in 1999 and 2000. Based upon
trends in countries from which data are available, the total
amount of heroin seized in the EU seems to have remained
stable since 2000 (90), although the number of heroin
seizures in 2002 decreased in all countries from which data
are available (91).
A worrying development is the recent reports of trafficking
in fentanyl, a synthetic opiate that is up to 100 times more
potent than heroin (92). Recently, seizures have been
reported in a few countries bordering the Baltic Sea and in
Russia. Sweden made two seizures of fentanyl in 2002 and
23 in 2003. In Estonia, fentanyl and methylfentanyl
appeared on drug markets as substitutes for heroin at the
end of 2001, leading to 68 seizures of fentanyl and 11 of
methylfentanyl in 2002. In Finland, a major wholesale
consignment of 3-methylfentanyl was seized in 2002. In
Lithuania, fentanyl was found in six seizures in 2002. The
INCB (2004a) reported a recent seizure of 41 kg of
fentanyl in the Ukraine and the dismantling of three
laboratories where it was being synthesised. A substantial
increase in fentanyl on the European drug market would be
very worrying as its potential to cause problems is high.
This is emphasised by reports from the Baltic countries in
the past two years of drug overdose deaths in which
fentanyl was found in the toxicology analysis, often together
with heroin. Vigilance is required as the drug may go
unreported, especially if it is being mixed with illicit heroin
to increase its overall potency. In addition, there are some
anecdotal reports of the use of diverted fentanyl products;
for example, in Greece there have been reports of drug
users extracting fentanyl from analgesic Durogesic®
patches.
Buprenorphine — a pharmaceutical opioid — seems to be
emerging on the black market in some EU countries, such
as the Czech Republic, where Subutex® appeared in 2002,
and the United Kingdom, where seizures have been
reported for the last three years. Finland reported
significant seizures of Subutex® in 2001 and 2002, and
Norway reported a large seizure of Temgesic® in 2002. To
some extent this is not surprising, as buprenorphine
prescribing has increased considerably in many countries.
However, the drug is formulated to have a low abuse
potential so these reports merit further investigation.
International action against heroin trafficking
Global cooperation has been increasing to help meet the
challenge of increased heroin production from Afghanistan
(Europol, 2003). Since 2002, the Interpol project NEHRO (93)
has focused on a new heroin trafficking route between
central Asia and western Europe (Interpol, 2002; Europol,
2003). The World Customs Organisation (WCO) has also
launched Operation Tamerlane, which aims to integrate
enforcement involving customs, police and border guards
from all nations through which the ‘silk route’ passes or
which it borders upon (WCO, 2003a).
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(94) See Markets_Tbl 14 in the 2004 statistical bulletin.
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and the Ukraine are among the countries with the fastest
growing HIV epidemics in the world. Prevalence rates vary
widely in the other new EU countries, and several are still
at risk for similar outbreaks. Among the ‘old’ EU countries,
some that have so far avoided large HIV epidemics among
injecting drug users (IDUs) are now showing signs of
increased risk.
Analysis of case reporting data for IDUs suggests that HIV
incidence peaked in Estonia and Latvia in 2001, at rates of
991 and 281 cases per million population respectively,
being followed by a decline in 2002 to what are still very
high rates of 525 and 170 per million per year (Figure 13)
(EuroHIV, 2004). Possible reasons for the observed decline
are reporting artefacts, saturation of the IDUs at highest risk
and/or behaviour change. Of the new EU countries,
Estonia (6.2–13 %), Latvia (6.6–14.6 %) and Poland
(6.8–9.1 %) reported the highest prevalence in different
national samples of IDUs tested in 2001–03, while in those
years local highs of 41 % (out of 964), 22 % (out of 205)
and 29.7 % (out of 165) were found in these three countries
respectively. In Estonia, HIV prevalence data from multiple
sources seem to confirm a recent decline in prevalence
among tested IDUs (6.2 % in 2002 among 1186 IDUs
During 2003, Operation Topaz, the international
programme to prevent the diversion of acetic anhydride, an
important chemical used in the manufacture of heroin,
identified trafficking networks and front companies
diverting this product in Europe. Afghanistan and other
Asian countries joined the operation. Operation Topaz is
one of a number of internationally coordinated activities
that represent a trend towards targeting the precursor
chemicals necessary for illicit drug production as well as the
substances themselves.
Price and purity of heroin
In Europe, heroin occurs in two forms: the commonly
available brown heroin (its chemical base form) and the
less common and more expensive white heroin (a salt
form), which typically originates from South-East Asia. In
2002, in the EU, the average street price of brown heroin
was reported to vary between EUR 29 per gram in
Hungary and EUR 161 per gram in Sweden, while the price
of white heroin ranged from EUR 32 (Hungary) to EUR 213
(Sweden) per gram (94). This price differential is likely to
reflect the purity of the drug being sold. In the last five
years, the average retail prices of both brown and white
heroin have been stable or decreasing in those countries
from which data were reported, except in the Czech
Republic, where prices are reported to have increased. In
2002, the average street price of brown heroin decreased
in six out of a total of nine EU countries that provided data,
while for white heroin a majority (four out of six) of
countries reported an increase in the average price.
In 2002, the average purity of brown heroin at street level
in the EU varied from 10 % in Luxembourg to 43 % in
Spain, while the average purity of white heroin ranged
from 7 % in Estonia and Finland to 75 % in Norway. Over
the last five years, heroin purity has fallen or remained the
same in most EU countries. In 2001, the purity of brown
heroin increased in most countries reporting such data
(7 out of 10), but this trend was reversed in 2002 when
substantial declines in average purity were reported by five
(out of seven) countries: Denmark, Luxembourg, Portugal,
the United Kingdom and Norway. The average purity of
white heroin at street level declined in both 2001 and
2002, but time trend data are available from only three
countries (Denmark, Estonia, Finland).
Drug-related infectious diseases
HIV
The HIV epidemic is spreading rapidly in some of the new
EU countries and their neighbours. Estonia, Latvia, Russia
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Figure 13: Reported newly diagnosed cases of HIV infection
among IDUs per million population in some new EU Member States
Source: European Centre for the Epidemiological Monitoring of AIDS (EuroHIV).
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(95) For more detail on these data and for original sources, see IDisease_Tbl 1 and IDisease_Tbl 8 in the 2004 statistical bulletin.
(96) Ibid.
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sampled at national level, down from 13 % of 2 078 in
2001). In Latvia, national data from drug treatment centres
also show declining prevalence in tested IDUs (13.7 % in
2001 to 6.6 % in 2003); however, data from other national
sources (hospitals and arrests data: 7.8 % in 2000 to
14.6 % in 2002) and local sources (multiple settings in the
Riga region and in Tukums: 18.3 % in 2000 to 22.0 % in
2003) suggest a continued increase in prevalence in other
samples of tested IDUs. In Lithuania, a large increase in
newly reported HIV cases occurred as recently as 2002,
due to a major outbreak in a prison; however, prevalence
among IDUs remains low (in 2002 and 2003: 1.0 % of
2 831 and 2.4 % of 1 112 IDUs from multiple settings at
national level, and 0.6 % of 641 IDUs and 0.4 % of 235
IDUs attending a needle exchange programme in Vilnius
respectively). The prison outbreak exemplifies both the
urgency of implementing prevention measures in this
country and other regions where prevalence among IDUs is
still low and the important role that prisons can play in the
spread of HIV among IDUs (Dolan, 1997–98; Dolan et al.,
2003).
In Poland, national prevalence data from public health
laboratories suggest a decline in prevalence among tested
IDUs, from 10.7 % (of 3 106) in 2000 to 6.8 % (of 2 626)
in 2002. This decline is consistent with the trend in newly
reported cases in IDUs, which declined from a high of 8.6
per million population in 2000 to rates of 5.1 and 6.9 in
2001 and 2002 respectively. Local prevalence data
however suggest high prevalence in the region of Pomorskie
in 2002 (30 % of 165 IDUs recruited in drug treatment and
on the street; 15 % of 69 in the street sample only),
although it should be noted that prevalence among IDUs in
drug treatment may overestimate prevalence in the IDU
population as a whole. In the other new EU countries HIV
prevalence among IDUs was still very low in 2000–01,
although more recent data are mostly lacking. HIV
prevalence was on average less than 1 % in the Czech
Republic, Slovenia and Slovakia, similar to the findings in
neighbouring EU candidate countries Romania and
Bulgaria (EMCDDA, 2003a). Although these countries have
so far avoided HIV epidemics among IDUs, increases in
injecting drug use may lead to increases in the prevalence
of HIV infection and hepatitis in the near future if
prevention measures are not sufficient (see section
‘Reducing drug-related infections’ in this chapter).
In the ‘old’ 15 EU Member States, the HIV epidemic among
IDUs seems mostly to have stabilised or to be in decline
according to HIV case reporting data, with rates in 2002
ranging from 1.3 new cases per million population in
Greece to 115.7 in Portugal (the latter declining to 88.4 in
2003) (EuroHIV, 2004). However, as national case
reporting is not established in the countries with the largest
IDU-related epidemics, time trends from case reporting can
be misleading at EU level and seroprevalence data from
IDUs are an important complement. Available national-level
prevalence data suggest great variation between, as well as
within, countries: from 0–1 % in Finland (data from needle
exchanges) to 9.7–35 % in drug users in different national
samples in Spain (2001–03) (Figure 14). Prevalence in
tested IDUs is in general stable or declining (95), although
stable prevalence does not mean that transmission is no
longer occurring, and in some countries increases in
prevalence since the mid-1990s have occurred at local or
regional level. In addition, in some areas where rises have
previously been reported more recent data are lacking. The
increases in prevalence suggest that prevention measures in
those areas may be insufficient, even in some areas with
long-established epidemics. Ongoing transmission among
IDUs in several areas is further evidenced by a high
prevalence in young (under 25) and new IDUs (who have
been injecting less than two years) (EMCDDA, 2003b) (96).
Where HIV prevalence has remained high among IDUs,
sustained prevention efforts are important to prevent
transmission to new IDUs, sexual partners of IDUs and from
mother to child.
Hepatitis B and C and other infections
The prevalence of hepatitis B virus (HBV) antibody (6–85 %)
and hepatitis C virus (HCV) antibody (17–95 %) among
IDUs in the EU is generally extremely high, indicating a
substantial need for treatment and prevention (Figure 15).
The prevalence of HCV is lower (25–33 %) in some of the
countries where HIV prevalence is also low (notably some
new EU countries: Hungary, Slovenia, Slovakia), suggesting
that high-risk behaviour is these countries is still not
widespread. This implies that preventing the spread of these
diseases through harm reduction interventions may still be
possible (see below).
Injecting drug use can be a route for the transmission of a
range of other infectious diseases; for example, in recent
years outbreaks of IDU-related tetanus and wound botulism
have occurred in the United Kingdom, possibly related to
contamination of heroin and/or specific injection practices
(Hope et al., 2004). The prevalence of tuberculosis (TB)
among IDUs in the EU seems to be generally low and is not
increasing, except perhaps in the Baltic countries (Migliori
and Centis, 2002). However, in the neighbouring countries
of eastern Europe it is increasingly becoming a problem
because of its increasing resistance to treatment and
because of its very high prevalence among prisoners, many
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(97) See Table 6 OL: Provision and types of needle and syringe programmes (NSPs), pharmacy involvement, numbers of syringes distributed/sold.
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drug users at any time they get in contact with health
services as well as ensuring sufficient resources for
prevention and treatment.
Reducing drug-related infections
Since 2001, there has been a further increase in the
number and geographical coverage of needle and syringe
programmes (NSPs) in several Member States (97). In
particular, in Estonia and Latvia, a rapid expansion of new
services is taking place, supported by local, national and
international grants in response to significant HIV
epidemics. In Scotland, the number of syringes exchanged
increased almost threefold between 1997 and 2002, and
further increases are expected after the maximum number
of syringes was raised to 60 per client visit, facilitating peer
exchange. Closing the remaining geographical gaps in
west European countries, NSPs have now also been
of whom are drug users. Sexually transmitted infections
(STIs) can be both an indicator of high-risk sexual
behaviour and a risk factor for HIV infection (Estebanez et
al., 2001). Currently, the prevalence of STIs is increasing
rapidly in several EU countries, mainly among homosexual
men. Among drug users, STIs are very common in some
countries, e.g. Ireland and Italy (Giuliani and Suligoi,
2004), but in others (e.g. Sweden and Norway) are rarely
reported; however, in most countries surveillance data
specific for drug users seem to be lacking. If STI
surveillance data are to be useful as an indicator of high-
risk sexual behaviour among IDUs, to gauge the potential
for sexual transmission of HIV (Wiessing and Kretzschmar,
2003), it is important that they distinguish IDUs and thus
enable trends, specifically among IDUs, to be followed.
Overall, the epidemiological situation of infectious diseases
among IDUs is serious. This calls for systematic screening of
56
Figure 14: HIV prevalence among injecting drug users — studies with national and local coverage 2001–03 
NB:  = samples with national coverage;  = samples with local/regional coverage.
Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.
Data for Portugal and Italy include non-IDUs and therefore may underestimate prevalence among IDUs (proportion of non-IDUs in the samples: Italy 5–10 %, Portugal
not known). For France, this is the case in some of the samples.
Data for Germany, Italy, Hungary, Portugal and Slovakia are limited to HIV prevalence among IDUs in treatment and may not be representative of HIV prevalence among
IDUs who are not in treatment.
Data for Germany and Luxembourg, and part of the data for Belgium and France, are based on self-reported test results, which are less reliable than clinically 
documented tests.
Sources: Reitox national focal points. For primary sources, study details and data before 2001, see IDisease_Tbl 8 in the 2004 statistical bulletin.
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(98) See Table 7 OL: Prices for commonly used syringe-types (with needle) in euros.
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established in Northern Ireland (pharmacy based) and in
Flanders (Belgium). However, in Sweden, discussions about
an expansion of NSPs are still in progress.
Where studies on syringe access have been conducted, the
results show that purchase from pharmacies is the most
common source of injecting equipment (e.g. 30–45 % of
NSP clients in Belgium, 32 % in Luxembourg and 30–40 %
in Hungary). In four countries pharmacies play a significant
role in syringe exchange or provision: in Spain, Portugal
and the United Kingdom, pharmacies replace syringes for
free, and in France, State-subsidised ‘stérikits’ are sold
mainly in pharmacies. As a result of the involvement of
pharmacies, these four countries have achieved a good
geographical coverage of needle exchange points. In the
other countries, drug users have to purchase syringes (and
other paraphernalia), and the high price in some countries
is a matter of concern (98).
France and Portugal report that the numbers of syringes
being obtained from pharmacies is decreasing. In France,
the sale of syringes decreased by 45 % between 1999 and
2002, falling from 16.5 million to 9 million. These
reductions were not offset by increased activity in NSPs.
Possible explanations include an increase in non-injecting
modes of consumption, increased access of injectors to
substitution treatment or even increased levels of needle
sharing (Emmanuelli, 2003).
NSPs may be implemented by a range of different methods:
through low-threshold drug agencies, pharmacies and
general health and social service facilities as well as via
mobile exchange points (an equipped bus or outreach
workers) and special machines. In several new Member
States (the Czech Republic, Poland, Slovenia and Bulgaria)
in particular, but also in Belgium, Ireland and the United
Kingdom, peer outreach workers play an increasingly
57
Figure 15: HCV prevalence among injecting drug users — studies with national and local coverage 2001–02
NB:  = samples with national coverage;  = samples with local/regional coverage.
Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.
Data for Portugal and Italy include non-IDUs and therefore may underestimate prevalence among IDUs (proportion of non-IDUs in the samples: Italy 5–10 %, Portugal
not known). For the Czech Republic this is the case in one of the samples.
Data for England and Wales and part of the data for Finland are based on saliva tests, which underestimate HCV prevalence.
Data for Belgium, Italy, Hungary, Portugal, Slovenia and Slovakia are limited to HCV prevalence among IDUs in treatment and may not be representative of HCV 
prevalence among IDUs who are not in treatment.
Sources: Reitox national focal points. For primary sources, study details and data before 2001 see IDisease_Tbl 11 in the 2004 statistical bulletin.
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(99) Box 4 OL: Hepatitis C key issues presents the findings of three recent EMCDDA publications on hepatitis C.
(100) Analysis of guidelines for the treatment of hepatitis C virus infection with regard to treatment accessibility for drug users.
(101) For an overview of drug-related death see ‘Drug-related deaths and mortality among drug users’ in last year’s annual report (EMCDDA, 2003b).
(102) See methodological notes ‘Drug-related deaths EMCDDA definition’ in the 2004 statistical bulletin. See the EMCDDA protocol for drug-related death
(http://www.emcdda.eu.int/?nnodeid=1419).
(103) See DRDeaths_Tbl 1 in the 2004 statistical bulletin.
(104) See DRDeaths_Tbl 2 and DRDeaths_Tbl 3 in the 2004 statistical bulletin.
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care — provides an outreaching and assertive health
service to a vulnerable group of people with multiple
problems who despite an alarming situation that seriously
threatens their quality of life do not make use of regular
healthcare facilities (Roeg et al., 2004).
Contact with drug users and those at risk is essential for the
transmission of health education messages and the
prevention of drug-related health damage. This has been
achieved to a high degree in the Czech Republic, where a
dense network of 93 services spread across the country
reached more than 22 000 individual problem drug users
in 2002 — more than half of the estimated population of
problem drug users (Czech Republic national report, 2003,
p. 35).
Several other countries acknowledge the role of low-
threshold drugs services as a platform for offering basic
medical care, such as wound and abscess treatments, for
example the Norwegian ‘field nursing stations’. In Finland,
low-threshold medical services, called ‘health counselling
centres’, successfully conduct testing and vaccination
campaigns. The opportunity to receive medical care is
attractive even to drug users who are otherwise difficult to
reach, and contact with medical staff provides a chance,
over and above the occasions afforded by needle and
syringe exchange, to obtain resources and referrals to
services such as HIV counselling and testing, medical care
and drug treatment (EMCDDA, 2004a).
The need for low-threshold services is greater in countries
with ‘older’ epidemics, where long-term injectors have
considerable health problems and are more marginalised
and socially excluded: the increasing range of services
offered might also reflect an increasing service dependency
of this group.
Drug-related deaths (101)
Opiates are present in most cases of ‘drug-related deaths’ (102)
due to illegal substances reported in the EU, although in
many cases other substances are also identified during the
toxicological examination (Figure 16) (103).
Between 1995 and 2001, there were 8 000–9 000
overdose deaths reported each year by the EU countries (104).
These figures can be considered as minimum estimates as it
is likely that, in most countries, there is some level of under-
reporting. The majority of overdose victims are young men
(70–93 %) in their late 20s or 30s, with a mean age
important role in supplying sterile equipment to drug users
(McVeigh et al., 2003).
Developments in the treatment of drug-related
infections
High rates of hepatitis C virus (HCV) infection among drug
users are causing increasing concern among healthcare
professionals. Between 60 % and 80 % of people who
contract the virus become chronically infected, leading to
end-stage liver disease in up to 20 % of cases, but access
of drug users to treatment for hepatitis C is low. A policy
briefing and a scientific monograph on hepatitis C
produced by the EMCDDA are available online (EMCDDA,
2003c; EMCDDA, 2004d) (99).
The situation of drug users with regard to access to liver
treatment remains in most countries to be improved. As
treatment guidelines are considered an important tool for
steering the provision of medical treatment, the EMCDDA
carried out an analysis of guidelines for the treatment of
HCV infection in drug users in the 15 ‘old’ EU countries
and Norway in 2003–04 (100). The study found that in many
countries a review of national guidance was under way,
taking improved treatment options and considerably
enhanced outcomes into account. Some new guidance
documents referred explicitly to research that had
documented the benefits for drug users if treatment was
provided by interdisciplinary teams of hepatologists and
drug use specialists.
Special funding is to be made available by the Global Fund
against AIDS, Tuberculosis and Malaria (GFATM) to provide
anti-retroviral treatment to patients in Estonia and the
candidate country Bulgaria: the projected number of
persons who will receive anti-retroviral treatment is 500 in
Estonia and 200 in Bulgaria (GFATM Secretariat, 2004).
New trends in service provision
The main trends in the provision of low-threshold service for
drug users, originally centred on needle and syringe
exchange, include increased integration with other survival-
orientated services, for example shelters, and healthcare
and medical services, and the extension of opening hours
into evenings, nights and weekends.
Faced with an increasing number of chaotic drug users with
little inclination of contacting services, Dutch drug services
revert to ‘friendly’ persuasion to get normally out-of-reach
drug users into care. This approach — called ‘interferential’
58
(105) See Figure 10 OL: Evolution of the proportion of people over 35 years among victims of acute drug-related deaths in the EU countries from 1990 until 2001–02.
(106) See Figure 11 OL: Long-term EU trend in acute deaths directly related to drug use (1985–2001).
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between 31 and 40 years. In most EU countries, victims
exhibit an ageing trend, suggesting an ‘ageing cohort
effect’ (105). In Finland and, to a lesser extent, Greece and
the United Kingdom, such a trend is not apparent, a finding
that deserves attention as it might indicate an increased
incidence of injection or opiate use in recent years
(Figure 17).
There are regular reports from various EU countries about
victims of drug-related death in whom methadone can be
identified. Like any opiate, methadone is a potentially toxic
substance, but research clearly shows that substitution
treatment reduces the risk of overdose mortality among
programme participants. Several studies have indicated that
deaths in which methadone are implicated are more likely to
be the result of illicit rather than prescribed use, and others
have found a higher risk during the initial phases of
methadone maintenance treatment. These findings suggest the
need to assure quality standards of substitution programmes.
Trends in acute drug-related deaths
Trends in drug-related deaths vary from country to country,
although some general trends can be outlined for the EU
countries. An overall marked increase in drug-related
deaths was observed during the 1980s and early 1990s (106).
During the period 1990–2000, and despite decreases in
some countries, the overall increasing trend continued,
although at a lower rate. In 2000, 8 838 deaths were
reported, compared with 6 284 in 1990 (a 40 % increase).
Between 2000 and 2001–02, many EU countries reported
a decrease in the numbers of drug-related deaths, which in
some cases (Germany, Greece, Ireland, Italy and Portugal)
reached statistical significance. In Norway, police also
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Figure 16: Proportion of drug-related deaths with or without the
presence of opiates in some EU countries in 2001–02 (1)
(1) Or latest year for which information is available.
(2) In the Netherlands, some cases ‘without opiates’ refer to ‘other and unspec-
ified narcotics’ or ‘other and unspecified psychodysleptics’, which might
include cases with opiates and cases due to cocaine.
(3) In the United Kingdom, the toxicological information is based on np-SAD
(St George’s Hospital Medical School) based on coroners’ reports. Cases
with at least one opioid mention are included; there may be some overlap
and the total proportion may be lower.
NB: In some countries, the ‘national definitions’ of drug-related death include a
limited number of cases of deaths indirectly related to drug use.
Sources: Reitox national reports 2003, taken from national mortality registries or spe-
cial registries (forensic or police). Based on national definitions as presented
in the methodological notes ‘Definition of acute drug-related deaths in the
Member States’. See also DRDeaths_Tbl 1 in the 2004 statistical bulletin.
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Figure 17: Mean age of drug-related death victims in some EU
countries, 1990–2002
NB: The figure presents countries that reported mean age of victims in most of
the years of the reported period.
See also Figure 10 OL: Evolution of the proportion of people over 35 years
among drug-related deaths in the EU countries from 1990 until 2001–02.
Information based on national definitions as presented in the methodologi-
cal notes on national definitions of acute drug-related deaths. In England and
Wales, the ‘drugs strategy definition’ is used (2004 statistical bulletin).
Sources: Reitox national reports 2003, taken from national mortality registries or 
special registries (forensic or police).
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some countries), and current figures remain high from a
longer-term perspective.
Overall mortality among opiate users
Mortality cohort studies have shown that mortality among
opiate users is up to 20 times higher than in the general
population of the same age. The EMCDDA is coordinating
a cooperative project of mortality cohorts in eight countries,
and preliminary results have been presented in previous
EMCDDA reports. Further analysis is being conducted, with
the addition of cohorts from France and Scotland. It is
expected that the results will be presented in future annual
reports.
Reduction in drug-related deaths
Knowledge of social and personal risk factors, risks
for drug-related deaths and the circumstances in which
they are likely to occur, especially fatal heroin overdose,
has grown since the mid-1990s (e.g. Best et al.,
2000, 2001; Origer and Delucci, 2002), and the
findings indicate a considerable potential for medical
and educational approaches to reduce the number of
deaths. The reductions in overdose deaths recently
observed in several countries (France, Spain) have been
attributed to increased availability of substitution
treatment (e.g. in France: national report, 2002, 2003)
as well as to changes in the mode of administration,
with a reduction in injecting (EMCDDA, 2004b).
Reducing the number of drug-related deaths is a target at
European level (EU drugs strategy 2000–04 Target 2) and
reiterated in a growing number of national drugs strategies
in the Member States (108).
The dissemination to drug users and their social networks of
information and educational materials on overdose risks
and management (leaflets, posters, brochures or videos) is
common practice in most of the old Member States, but is
not usual in the new ones. Other evidence-based responses,
such as peer intervention in the case of drug emergencies
and the encouragement of ambulance calls among drug
users who might witness overdoses, are reported from
several countries, but systematic knowledge about the level
of provision of such courses is still not available. The
distribution of an opiate antagonist (naloxone) to drug
reported a significant decrease in drug-related deaths in
2002. At EU level there was an overall decrease between
2000 (8 838 cases) and 2001 (8 306 cases), which
represents a modest, although statistically significant,
reduction (6 %) (Figure 18) (107).
An increasing trend in drug-related deaths might be
expected in the new Member States or in the candidate
countries. At present, the quality of information on drug-
related deaths in some of these countries is limited and
trends observed should be interpreted with caution. Estonia
and Slovenia show an increasing trend, whereas in
Bulgaria and the Czech Republic there is no discernible
trend.
Despite favourable factors such as a shift away from
injection among opiate users in a number of countries and
increased treatment provision, the decrease in drug-related
deaths observed in the last two years is low (non-existent in
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Figure 18: Changes in the number of acute drug-related deaths —
EU and Norway total 1990–2001 (indexed to 100 for the average
over the period 1990–2001)
NB: Due to insufficient data 2002 index not computed.
Individual country trends are available in Figure 11 OL. Data on the num-
ber of cases per country can be found in DRDeaths_Tbl 2 and Tbl 3 (2004
statistical bulletin).
In the United Kingdom, data from the Office of National Statistics (ONS)
have been selected because they are available for a longer time period.
Sources: Reitox national reports 2003, taken from general mortality registries or spe-
cial registries (forensic or police). Based on national definitions as presented
in the methodological notes on national definitions of acute drug-related
deaths (2004 statistical bulletin).
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(107) See also Figure 12 OL: Trends in acute drug-related deaths in the different EU countries and the EU as a whole 1985–2001. For the United Kingdom see
also in the ‘Methodological notes on national definitions of drug-related deaths’ (statistical bulletin): ‘drugs strategy definition’ and ‘ONS traditional definition’.
The drugs strategy definition produces estimates very closely related to EMCDDA standard European definition (‘Selection B’).
(108) See Table 8 OL: Strategies and selected measures to reduce drug-related deaths in the 25 EU Member States and Norway.
(109) Ibid.
(110) See the Austrian EDDRA project contact in the EDDRA database (http://eddra.emcdda.eu.int/eddra/plsql/ShowQuest?Prog_ID=2066).
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users is one measure taken, or being considered, in some
countries to reduce overdose deaths (109) (EMCDDA,
2003a).
In some countries, supervised drug consumption facilities
are available for drug users in open drug scenes who are
at high overdose risk: such services exist in Germany, Spain
and the Netherlands, and are being prepared in
Luxembourg, Slovenia and Norway. If coverage is
adequate, these rooms may help to reduce drug-related
deaths at city level.
A project based in emergency departments in Austria
addresses drug users who overdose frequently (110).
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Consumption rooms
‘Drug consumption rooms’, facilities where confirmed drug
users are allowed to consume their drugs in hygienic
conditions, under supervision by qualified staff and without
fear of arrest, operate in 39 European cities. The European
report on drug consumption rooms (EMCDDA, 2004a)
describes what consumption rooms are and why and how
they came about; it describes the specific target groups of
these facilities, their objectives and functioning; and it
summarises the available evidence.
As highly specialised services, integrated in a wider network
of services to drug users, drug consumption rooms are
based on consensus and active cooperation between health
workers, police, local authorities and local communities. The
report shows that they are successful in establishing contact
with a highly problematic group of drug users and in
promoting their access to much needed primary healthcare
as well as social and treatment services. In providing access
to clean injecting equipment and a supervised environment
for drug consumption, morbidity and mortality risks as well
as nuisance due to public drug use are reduced.

(111) See Figure 13 OL: Inpatient drug-free treatment modes.
(112) In Ireland, buprenorphine is used for treatment of withdrawal symptoms only.
(113) See Table 9 OL: Applied substitution substances in the EU Member States.
(114) See Figure 14 OL: Substitution treatment or drug-free treatment predominance for opiate use.
Many of those who have developed a problem with drug
use will benefit from contact with a treatment agency.
A range of different treatment options is available across
the European Community, reflecting both national and
historic contexts as well as the differing characteristics of
the population in need of help. These are summarised
below. The availability of treatment varies between
countries and is, in general, less developed in the new
Member States. However, overall there appears to be an
ongoing investment in increasing capacity in this sector with
evidence of an improvement in the opportunities available
for those with drug problems.
A new development in this area is the use of the
communication potential of new technology, like the
Internet, to enhance the services available to drug users.
Considerable attention has been given to the role of the
Internet in the promotion of illegal drug use. It is therefore a
positive finding that some countries, such as the
Netherlands and Finland, have taken initiatives to explore
the potential of this medium to improve the information and
care options available. Activities have included exploiting
the direct communication links provided by e-mail and
mobile phones, and also looking at how e-counselling
services and SMS (text) services can benefit drug users.
A general trend across the EU is that drug-related treatment
has moved away from hospitals and into treatment centres
in community settings. This development is less evident in
the new Member States, where psychiatric hospitals remain
the primary treatment providers (Estonia, Latvia, Lithuania,
Slovenia), although this may be changing in some
countries; for example, in the Czech Republic care is
provided in both settings.
Characteristics of treatment services
Drug-free treatment
Drug-free treatment involves the application of psychosocial
and educational techniques to achieve long-term abstinence
from drugs. Traditionally, drug-free treatment has been
residential and long-term, e.g. in therapeutic communities.
Today, it is often also community-based. Medication may be
used to alleviate withdrawal symptoms. This is usually
restricted to antidepressants and/or benzodiazepines,
although in some therapeutic communities no such drugs
are provided (111).
As medically assisted treatment is usually available only for
opioid users, some form of drug-free treatment is generally
the only therapeutic option available for those experiencing
problems with non-opioid drugs.
Medically assisted treatment
Medically assisted drug treatment includes both substitution
treatment with agonists and treatment with antagonists.
Typically this sort of pharmacological intervention makes
use of naltrexone (an antagonist) or one of the following
opioid agonists: methadone, buprenorphine,
dihydrocodeine, heroin, slow-release morphine.
Methadone continues to be the most commonly prescribed
substitution substance in the enlarged EU. However, in
recent years treatment options have widened. By 2002 all
of the ‘old’ 15 Member States except the Netherlands and
Ireland (where it is only used for detoxification) (112)
reported the use of buprenorphine. Other substitution
substances, such as dihydrocodeine (Belgium, Germany,
Luxembourg, Austria), slow-release morphine (Austria) and
heroin (Germany, the Netherlands, the United Kingdom),
are used less frequently or as part of a medical trial
(Springer, 2003a) (113).
In terms of absolute numbers, substitution treatment has
become the most commonly available form of specialised
drug treatment for opiate users in the EU, with over
400 000 individuals receiving treatment of this kind.
However, with the exception of Slovenia, this form of
intervention is far less available within the new Member
States of the EU, where drug-free treatment options
dominate (114).
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(115) See Figure 15 OL: Introduction of methadone treatment in the EU.
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every client of substitution treatment should be allocated a
social consultant, in practice there is not always sufficient
capacity to achieve this. One Danish study found that
methadone clients who do not receive any psychosocial
support use a secondary drug significantly more often than
those who do receive such support. Further research is
currently investigating whether expanded psychosocial
support can improve treatment outcomes (Pedersen, 2001).
The Irish College of General Practitioners has endorsed
evidence-based substitution treatment guidelines (2003)
stressing the need for a psychosocial component.
The usefulness of psychosocial support depends also,
however, on clients’ perceived value of this kind of
therapeutic option. In Greece, it is reported that patients
in methadone treatment programmes make frequent use
of psychosocial counselling, whereas in Latvia only a few
patients are willing to receive this kind of intervention.
Quality assurance
Quality assurance of treatment can be defined as a
‘systematic attempt to monitor, document and improve the
quality of services provided’. Five quality assurance
mechanisms are generally accepted in the EU: accreditation
of treatment services, standards for treatment, training of
staff, monitoring of clients and outcomes and, finally,
evaluation of retention rates, outcomes, satisfaction,
discharge, etc. (Figure 19).
New developments regarding quality assurance in drug
treatment services are its inclusion in national drugs
strategies (Greece, Spain, France, Ireland, Sweden) or the
setting-out of minimum requirements for such services
(Belgium, the Czech Republic, Germany, the Netherlands,
Poland, Slovenia and the United Kingdom). Accreditation of
treatment services is a quality assurance mechanism in a
number of countries (Germany, Spain, France, Ireland,
Luxembourg, the Netherlands, Poland, Portugal and the
United Kingdom), although some admit that further
implementation is still required (the Czech Republic, the
Netherlands). Many countries report increased training of
staff, although the actual extent and coverage is not always
systematically monitored. Systematic, large-scale evaluation
of drug treatment services is relatively rare, occurring only
in Denmark, Italy, Latvia, Luxembourg, Poland, the United
Kingdom and Norway.
Social reintegration
There are three ‘pillars’ of social reintegration: (1) housing;
(2) education; and (3) employment and vocational training.
Housing is a prerequisite for a stable life, and interventions
Accessibility and admission criteria 
to substitution treatment
The trend towards making admission criteria for substitution
treatment less restrictive continues. Historically, admission
criteria were often highly selective, limiting this kind of
treatment to those who were regarded as having
particularly chronic problems. Today, admission to
substitution treatment is generally restricted to those aged
18 years or over with a history of 1–2 years of problematic
drug use (e.g. Belgium, Ireland, the Netherlands). Most new
Member States report higher thresholds, e.g. a minimum
age of 20 years and a history of problematic use of at least
five years (e.g. Estonia and Latvia), although Slovenia
allows drug users to receive substitution treatment from the
age of 16. Relatively strict inclusion criteria are also found
in Greece, Finland, Sweden and Norway, with the minimum
age for treatment ranging from 20 to 25, and a
requirement of 4–5 years of problematic use.
Despite the increase in availability of substitution treatment,
a number of countries report that demand still exceeds
supply, and waiting lists are reported from Belgium, the
Czech Republic, Greece, Estonia, Hungary, Ireland, Sweden
and Norway. Access can also be limited by the way in
which drug services are organised; for example, in
Lithuania patients have to pay for their medication, and this
reduces service uptake.
Introduction of substitution treatment
There is considerable variation between Member States
regarding the timing of the implementation of substitution
treatment. Some Member States introduced methadone
substitution programmes as long ago as the late 1960s and
early 1970s, whereas some countries did not introduce this
form of treatment on a widespread basis until the 1990s
(Belgium, Greece, France, Norway). Substitution treatment
is a relatively recent development in most of the new
Member States, with most countries launching substitution
treatment during the 1990s and Estonia introducing its first
programme only in 2001. The exception is Slovenia, which
has had established programmes since 1990 (115).
Psychosocial support in substitution
treatment
Although it is widely acknowledged that substitution
treatment should be accompanied by psychosocial support,
this is far from being a routine component of treatment.
In the Czech Republic, Germany and the Netherlands, a
shortage of resources limits the delivery of adequate
psychosocial support. And in Norway, although, in theory,
64
(116) See Figure 16 OL: Overview of social reintegration provision.
(117) See Figure 17 OL: New clients in treatment by year in some EU countries.
(118) See TDI_Tbl 1 and TDI_Tbl 2 in the 2004 statistical bulletin.
(119) See TDI_Tbl 5 in the 2004 statistical bulletin.
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aim at providing drug users (former or current) with a place
to live and/or subsidising the rent. Most drug users have
received relatively little formal education and would benefit
from upgrading of their literacy, numeric or other skills.
Finally, employment and vocational training initiatives aim
to achieve social independence by integrating the client into
the labour market either by finding, or even subsidising, a
job or through specific skills training.
Social reintegration is a less well-established response to
problem drug use than is treatment and, consequently,
monitoring and reporting in this field are also more patchy.
Some Member States report that this area needs much more
attention and financial resource (Germany, Estonia,
Finland). However, in some countries social reintegration is
receiving increased political attention through its inclusion
in national drugs strategies as well as in the form of
financial support (Greece, Ireland, England and Wales) (116).
Treatment demand data
Information on the number of people seeking treatment for
a drug problem provides a useful insight into general trends
in problem drug use and also offers a perspective on the
organisation and uptake of treatment facilities in Europe.
The EMCDDA’s treatment demand indicator (TDI) provides a
uniform structure for reporting on the number and the
characteristics of clients referred to drug treatment facilities.
Although TDI data can be regarded as providing a
reasonably robust and useful representation of the
characteristics of clients referred to specialised drug
services, for a number of technical reasons caution should
be exercised in extrapolating findings to the clientele across
the overall provision of services.
The general picture revealed by the most recent TDI data
and national reports continues to reflect the trend reported
in recent years of an increase in the total number of
individuals entering treatment services. Despite the overall
increase in treatment numbers, the number of new treatment
demands, that is individuals entering treatment for the first
time, appears to be fairly stable (117). The increase in overall
demand can be explained by a combination of factors,
including, in particular, improvements in the coverage of
the reporting system itself and some expansion in the
availability of treatment (118).
Characteristics of clients demanding drug
treatment
Both drug services and their clients tend to be concentrated
in inner cities and urban areas, where drug problems occur
in combination with a range of other social and health
problems, all of which are more common within
marginalised and disadvantaged communities.
Most clients enter specialised drug treatment in their 20s or
early 30s, with the mean age of clients entering treatment
for the first time being 26 years. However, the age
distribution observed across the European data set is not
uniform and shows peaks among those aged over 39 and
under 20. The main reason for this is that the age
distribution reflects the fact that problem users of opiates or
cocaine tend to be older than average, while those
demanding treatment for the use of cannabis or stimulant
drugs other than cocaine are typically younger (119). Thus,
in the countries that have seen a marked increase in the
number of clients referred for cannabis problems, such as
Denmark, Germany and Finland, clients are typically
younger than in countries such as Greece, Spain and the
Netherlands, where heroin or cocaine problems
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Figure 19: Quality assurance of drug-related treatment
(1) A centrally situated register or database keeping track of clients and/or
treatment provision.
Sources: Reitox national reports.
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are living with children; evidence suggests that the children
of drug users may face a range of difficulties. Drug
problems also make parenting particularly challenging
(Murphy-Lawless, 2002).
Drug of use
In the TDI, both the primary drug for which treatment is
sought and the secondary substance of use, if any, are
recorded. The three substances most frequently recorded as
either the primary reason for treatment or a secondary
drug are opiates, cocaine and cannabis (Figure 20).
Producing a clear picture of the drugs that are responsible
for individuals seeking drug treatment is complicated by the
fact that drug users commonly consume a range of
psychoactive substances. It is often difficult to identify to
what extent an individual’s problems are related to any one
substance in particular. In all countries, polydrug use is
common among treatment clients, and between 40 % and
80 % of all clients report using at least one additional
predominate. The historical development of the drug
problem also plays a role in determining the age of the
treatment population; for example, in Finland clients are
relatively young, reflecting the fact that the drug problem is
a comparatively new one. Similar results could be expected
for many of the new Member States, where again drug
problems are often a relatively new historical phenomenon,
although for the most part heroin problems predominate
within those seeking drug treatment (120).
Although male drug users predominate in all European
countries, the male to female ratio varies considerably
between countries, ranging from 3:1 to 6:1. Differences
between countries again reflect the type of drug problem as
well as region (the highest proportions of female drug users
are found in northern European countries and the new
Member States) and client age.
It is interesting to note that most clients seeking treatment
for heroin, cocaine and hypnotics or sedatives consume
these drugs daily, whereas for other drugs frequency of use
shows a wider distribution. This issue is explored in more
detail in the selected issue on cannabis problems in context
(p. 82).
Most treatment clients report starting drug use during
adolescence — most commonly between the ages of 15
and 19. However, a marked difference is reported for first
heroin and cocaine use, with 20–30 % of clients beginning
at age 25 or older (121).
Social demographics
Demographic information suggests that treatment clients are
disproportionately likely to be socially and economically
disadvantaged. More than half of clients fail to complete
their secondary education (122). The proportion without
regular employment is high compared with the general
unemployment rate: in some countries more than half of
drug users in treatment are unemployed (123). Housing
conditions are often also precarious: around 15 % of
people in treatment live in social institutions or in unstable
accommodation (124). In addition, it should be remembered
that homelessness itself might limit the ability of individuals
to take advantage of treatment options — and that
homelessness may aggravate both drug problems and their
consequences (EMCDDA, 2003b, p. 65).
Among clients living in stable accommodation, one third
live alone, another one third with parents and the
remainder with a partner or other people. More than 10 %
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Figure 20: Proportion of new clients attending drug treatment
services who report primary drug to be heroin, cocaine and
cannabis, 1996–2002
NB: Countries providing data are: CZ, DK, DE, EL, ES, NL, SL, SK, FI and SE
(except FI data missing 1996/97, SE data missing 2000).
Figures are summed over contributing countries for each year.
Sources: Reitox national reports 2003.
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(120) See TDI_Tbl 4 in the 2004 statistical bulletin.
(121) See Figure 18 OL: Age at first use by main drug and TDI_Tbl 5 in the 2004 statistical bulletin.
(122) See Figure 19 OL: All clients by level of education and TDI_Tbl 6 in the 2004 statistical bulletin.
(123) See Figure 20 OL: All clients by labour status and TDI_Tbl 7 in the 2004 statistical bulletin.
(124) See Figure 21 OL: Living conditions (where) among all clients and living conditions (with whom) among all clients.
(125) See TDI_Tbl 10 and TDI_Tbl 11 in the 2004 statistical bulletin.
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secondary drug. For many individuals multiple drug use is
common, and coexisting alcohol problems often further
complicate treatment. A worrying trend is that in many
countries the number of those found to have problems with
multiple substances appears to be growing.
Opiates
In most countries, opiates (largely heroin) remain the main
drug for which clients seek treatment and typically account
for between 40 and 90 % of all demands for treatment.
However, EU countries can be broadly divided into three
groups depending on the extent to which the treatment
population is characterised by those with heroin problems:
• below 40 % — Czech Republic, Hungary, Finland,
Sweden;
• 40–70 % — Denmark, Germany, Spain, the
Netherlands, Slovakia;
• over 70 % — Greece, Italy, Lithuania, Luxembourg,
Slovenia, the United Kingdom.
Cannabis
Cannabis is in overall terms the second most frequently
cited drug in reports on those entering treatment. This is
especially true for new clients (Figure 21), of whom nearly
one third (29.5 %) are recorded as having a primary
cannabis problem. The proportion of people seeking
treatment for cannabis varies widely between countries (125).
Cannabis treatment demands are discussed in depth
elsewhere (p. 82) in this report.
Cocaine
Cocaine is the third most common drug reported by those
entering drug treatment, but with marked differences
between countries. For example, demands related to
cocaine use are extremely low or even completely absent in
the new Member States. In most other countries, cocaine as
the primary drug accounts for less than 10 % of all
treatment demands, although the percentage is higher,
around 25 %, among new clients.
Less than 8 % of clients seeking treatment for cocaine use
reported drug injection as a usual route of administration.
Other stimulants
Stimulants other than cocaine are infrequently reported as
the primary reason for attending drug treatment except in
the Czech Republic, Finland and Sweden, where they
account for between a quarter and more than half of all
primary treatment demands. In the Czech Republic, more
than 50 % of reported treatment demands relate to a
primary methamphetamine problem. Elsewhere, use of
stimulant drugs as a reason for treatment attendance is less
common but is reported by nearly 10 % of those entering
treatment in Slovakia, 7 % in Germany, 6 % in Denmark,
and 5 % in Hungary. In all other countries the proportion is
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Figure 21: New clients attending drug treatment in 2002:
distribution by different primary drugs
NB: Total number of cases: 42 568.
(1) Outpatient treatment only.
Sources: Reitox national reports 2003.
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even lower. Data from 2002 also revealed an increase in
the number of stimulant users who reported injecting, from
14 % in 2000 to 27 % in 2002, although this group
remains relatively small in terms of absolute numbers
(Figure 22).
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Figure 22: Distribution of route of administration for heroin,
cocaine and other stimulants among attendees at outpatient
treatment services: 2000–02
NB: Data available for DK, DE, EL, ES, IE, NL, FI, SE and UK (2002 data from
Ireland were not available).
Base numbers of total numbers reporting route of administration are shown.
Sources: Reitox national reports (2001, 2002, 2003); TDI data (2000, 2001, 2002)
from outpatient treatment centres.
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(126) The term ‘reports’ for drug law offences is given in quotation marks because it describes different concepts in different countries (police reports of
suspected drug law offenders, charges for drug law offences, etc.). For an exact definition for each country, refer to the methodological notes on definitions of
‘reports’ for drug law offences in the 2004 statistical bulletin. (The term ‘arrests’ was used in annual reports until 2001.)
(127) The decrease in ‘reports’ for drug law offences in Portugal is due to the decriminalisation, in July 2001, of drug use/possession for use.
(128) The decrease in ‘reports’ for drug law offences in Estonia is due to the decriminalisation, in September 2002, of repeated drug use and of possession of
small amounts of drugs for personal use.
(129) See DRCrime_Tbl 2 in the 2004 statistical bulletin.
(130) In Norway, no distinction is drawn between ‘drug dealing/trafficking’ alone and ‘drug use/dealing and trafficking’. The remaining drug law offences are
related to ‘drug use’ alone.
(131) See DRCrime_Tbl 4 in the 2004 statistical bulletin.
(132) The law to decriminalise drug use and possession for use was passed in November 2000 and came into effect in July 2001.
(133) In the Netherlands ‘hard drugs’ are defined as drugs which pose unacceptable public health risks, such as heroin, cocaine, ecstasy and LSD.
Republic, Estonia, Lithuania, Hungary, Poland, Slovenia and
Norway. However, ‘reports’ of drug law offences decreased
in 2001 and 2002 in Italy and Portugal (127) and in 2002 in
Estonia (128), Ireland, Latvia, Slovenia and Finland.
In most EU Member States the majority of reported drug
law offences are related to drug use or possession for
use (129), ranging from 52 % of all drug law offences in
Finland to 90 % in Austria. In the Czech Republic, 90 % of
reported drug law offences relate to dealing or trafficking,
while in Italy and Spain — where drug use and possession
for use are not criminal offences — all drug offences relate
to dealing or trafficking. Finally, in Luxembourg, Portugal
and Norway (130), a majority of offences relate to both drug
use/dealing and drug trafficking.
In all countries for which data were available, with the
exception of Portugal, the proportion of all drug law
offences accounted for by offences related to drug
use/possession for use increased over the five-year period
1997–2002 (131). The rate of increase was generally slow,
but more marked upward trends were evident in Belgium,
Luxembourg and Slovenia, and in Ireland until 2001. In
Portugal, the proportion of use-related offences started to
decrease in 2000, one year before drug use and
possession for use were decriminalised (in July 2001) (132).
In most of the Member States, cannabis is the illicit drug
most often involved in reported drug law offences (Table 4).
In the countries where this is the case, cannabis-related
offences account for 34 % (Sweden) to 87 % (France) of all
drug law offences. Heroin is the drug most frequently
involved in Lithuania and Luxembourg, where it accounts
for 15 % and 51 %, respectively, of all drug offences, while
in the Netherlands offences involving ‘hard drugs’ (133)
Drug-related crime
Drug-related crime can be considered to encompass the
following four categories:
• Psychopharmacological crimes: crimes committed under
the influence of a psychoactive substance;
• Economic compulsive crimes: crimes committed in order
to obtain money (or drugs) to support a drug habit;
• Systemic crimes: crimes committed within the functioning
of illicit drug markets, as part of the business of illicit
drug distribution and supply;
• Drug law offences: crimes committed against drug
(and other related) legislations.
Data on the first three categories of crime are rare in the
EU, and those that are available come from ad hoc local
studies that are generally not routinely conducted and
difficult to extrapolate from.
‘Reports’ (126) of drug law offences (use, possession,
dealing, trafficking, etc.) reflect differences in national
legislations, but also different ways in which the laws are
applied and enforced, and differences in the priorities and
resources allocated by criminal justice agencies to specific
crimes. In addition, information systems on drug law
offences vary considerably between countries, especially in
relation to reporting and recording practices, i.e. what is
recorded and when and how. These differences make
comparisons between EU countries rather difficult.
Over the period 1997–2002, the number of ‘reports’ of
drug law offences increased in most EU countries. Increases
were particularly marked (twofold or more) in the Czech
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predominate. The relative proportion of drug-law offences
related to any specific drug is influenced by a number of
factors including the operational priorities of law
enforcement officials and explicit or implicit strategic
decisions to differentially target different types of drug-law
offences.
Since 1997, the proportion of drug offences involving
cannabis has been increasing in Germany, Spain, France,
Luxembourg, Hungary and Portugal, while it has remained
stable in Belgium, Italy, Lithuania, the Netherlands, Slovenia
and Sweden. In Austria, the share of cannabis-related
offences among all drug offences increased until 1999 but
has been decreasing since then (134).
Over the same period, the proportion of heroin-related
offences decreased in all EU countries from which data
were available (135), except Hungary and the United
Kingdom, where it increased (136), and Lithuania, where it
has fluctuated since 2000 (137). The opposite trend can be
observed for cocaine-related offences, which as a
proportion of all drug offences have increased since 1997
in all countries providing data, except Germany, Lithuania,
Luxembourg and Hungary, which reported downward
trends (138).
Drug users and prison
Drug users in prison
National routine information on the type and pattern of
drug use among prisoners is rare. Much of the data
available in the EU come from ad hoc studies carried out at
local level using samples of prisoners that vary considerably
in size and in terms of selection processes. In addition,
prisons studied are sometimes not representative of the
prison system as a whole, and a lack of repeat surveys
prevents analysis of trends in most countries. These factors
make extrapolation of results very difficult.
Compared with the general population, among the prison
population drug users are over-represented. Lifetime
prevalence of drug use among prisoners varies widely, from
22 % to 86 %, between prison populations, detention
centres and countries (139). As in the general population,
cannabis is the most frequently reported illicit drug, with
lifetime prevalence rates among inmates of between 11 %
and 86 %. Prisoners’ lifetime prevalence of cocaine (and
crack) use is 5–57 % and that of heroin 5–66 %.
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Table 4: Drug mostly involved in ‘reports’ for
drug offences in the EU countries and Norway
NB: For an exact definition for each country, refer to the methodological
notes on definitions of ‘reports’ for drug law offences in the 2004 sta-
tistical bulletin.
n.a.: data not available.
(1) Among all drugs mentioned (alone or not).
(2) Among main drugs.
(3) Among all offences broken down by drug (for some offences, a break-
down by drug is not available).
(4) Among offences for drug dealing/trafficking (since offences for drug
use/possession for use are not criminalised).
(5) Data under ‘heroin’ refer to ‘hard drugs’ (defined as drugs which pose
unacceptable public health risks, such as heroin, cocaine, ecstasy, LSD).
Some offences involve both cannabis and ‘hard drugs’ and have not
been included here, which explains why the total is less than 100 %.
(6) This proportion is underestimated as it represents offences for each drug
alone, e.g. offences for cannabis only (it does not include offences for
‘cannabis + other drug(s)’).
(7) Among persons given a summary fine by the prosecutor or sentenced
by a court.
Sources: National focal points.
Country Notes Year Proportion (%)
Cannabis Heroin Cocaine
Belgium 2002 67 8 7
Czech Republic (2) 2002 37 8 1
Denmark n.a. n.a. n.a.
Germany (2) (3) 2002 56 17 9
Estonia n.a. n.a. n.a.
Greece n.a. n.a. n.a.
Spain (1) (4) 2002 52 7 33
France (2) 2002 87 5 3
Ireland (2) 2002 65 9 6
Italy (1) (4) 2002 42 27 28
Cyprus n.a. n.a. n.a.
Latvia n.a. n.a. n.a.
Lithuania (1) 2002 10 15 1
Luxembourg (1) 2002 28 51 21
Hungary (2) 2002 66 16 2
Malta n.a. n.a. n.a.
Netherlands (2) (5) 2002 37 58
Austria (1) 2002 58 11 11
Poland n.a. n.a. n.a.
Portugal (3) (4) (6) 2002 36 17 8
Slovenia (1) 2002 82 10 2
Slovakia n.a. n.a. n.a.
Finland n.a. n.a. n.a.
Sweden (1) (7) 2001 34 7 2
United 
Kingdom (1) 2000 69 12 5
Norway n.a. n.a. n.a.
(134) See DRCrime_Tbl 5 in the 2004 statistical bulletin.
(135) The following countries provided breakdowns by drug of drug offences over time: Belgium, Germany, Spain, France, Ireland, Italy, Lithuania, Luxembourg,
Hungary, the Netherlands (only cannabis and ‘hard drugs’), Austria, Portugal, Slovenia, Sweden and the United Kingdom (until 2000 only).
(136) Data for the United Kingdom were available until 2000 only.
(137) See DRCrime_Tbl 6 in the 2004 statistical bulletin.
(138) See DRCrime_Tbl 7 in the 2004 statistical bulletin.
(139) See Prison_Tbl 1 in the 2004 statistical bulletin.
(140) See Prison_Annex in the 2004 statistical bulletin.
(141) See Prison_Tbl 3 in the 2004 statistical bulletin.
(142) See Table 10 OL: More recent prison drugs strategies, ministerial directives and service standards in the EU and Norway.
(143) See Prison_Tbl 2 in the 2004 statistical bulletin.
(144) See Prison_Tbl 4 in the 2004 statistical bulletin.
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some studies have reported values as low as 1 % or as
high as 69 %.
Where comparable data are available, they show that
young offenders are less likely to inject than adults and that
among the prison population women are more likely to
inject than men (143). Based on several studies in the EU,
Bird and Rotily (2002) have shown that around one third of
adult male prisoners are drug injectors. According to
available data provided by the Reitox focal points, between
0.2 % and 34 % of inmates (144) have injected drugs while
in prison. This raises issues of access to sterile injection
equipment and hygienic sharing practices among the prison
population and the potential spread of infectious diseases if
these matters are not addressed.
Prisons are a high-risk setting for the spread of such
diseases. Among the practices that have proven to be able
to reduce infectious diseases are the treatment of sexually
transmitted diseases and the provision of condoms,
substitution treatment, vaccination programmes and needle
and syringe exchange programmes.
Substitution treatment is increasingly provided in prisons.
In Belgium, Denmark, Spain, Austria and Slovenia
substitution treatment is available in all prisons. Belgium,
Denmark, Luxembourg and Norway allow prisoners to start
substitution treatment while incarcerated. In Italy initiation
of substitution treatment usually targets remand prisoners.
Prescriptions for progressively reducing substitution
treatment until abstinence is achieved are available in most
German Länder, the Netherlands, Slovenia and in prisons
serving larger cities in Italy. In the United Kingdom
maintenance programmes are considered appropriate
mainly for prisoners on remand or serving short sentences.
A specific scheme for hepatitis B vaccination, adapted for
prisoners, was recommended in 2002 by the National
Immunisation Committee of Ireland. It comprises three
consecutive weekly injections with a booster after
12 months and results in 99 % protection at 13 months
(Zuckerman, 2003).
A review of 14 international studies examining the
effectiveness of needle and syringe exchange programmes
in prison settings concluded that such programmes are
feasible and result in a reduction in both high-risk
behaviours and transmission of blood-borne viruses without
any negative consequences such as accidental needlestick
injuries or deliberate use of needles as a weapon against
prison staff or other inmates (Dolan et al., 2003). During
In the EU, the prevalence of regular drug use or dependence
prior to imprisonment ranges from 8 % to 73 % (140).
Prisons: a challenge to public health
Although some prisoners may view incarceration as an
opportunity to address their drug problems, this may be
difficult to achieve in practice (Long et al., 2004). The
majority of drug users reduce or stop their drug use on
admission to prison. However, some prisoners continue their
pattern of drug use and others start using drugs in prison.
Studies available show that between 8 % and 60 % of
inmates report having used drugs while in prison, and
10–36 % report regular drug use (141).
Many prisoners have restricted access to health services.
Health professionals working in prisons have little contact
with the regular health system; in addition, they are often
unable to access further training, which aggravates the
isolation of prison health services. These problems are
difficult to overcome, as seen in Ireland, where, despite
efforts by prison authorities and healthcare staff to improve
access to treatment and healthcare services for drug users,
there is little evidence of improvement.
A trend is emerging for responsibility for prison health
services to be transferred from the penal service to the
national health system. In Spain, a recently enacted law,
‘Ley 16/2003, de 28 de mayo, de cohesión y calidad del
Sistema Nacional de Salud’ (Law concerning the cohesion
of the national health system), aims to address demands for
integration of prison and public health systems. In Estonia,
the Ministry of Justice in cooperation with the Ministry of
Social Affairs aims to integrate healthcare in prisons into
the general healthcare system before 2006. In France, this
responsibility was transferred to the Ministry of Health as
long ago as 1994. In Italy, local health services have been
responsible for the care and treatment of inmates since
2000. In England and Wales, healthcare in prisons is
within the remit of the Department of Health and the
National Assembly for Wales respectively (in private
sector prisons, it is within the remit of the Home Office
for both regions). Before 2006 healthcare in all non-private
prisons in England will become part of the National Health
Service (142).
Infectious diseases in prisons and their prevention
Lifetime prevalence of injecting drug use among prisoners is
generally reported to be between 15 % and 50 %; however,
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(145) See Table 11 OL: Socio-health services targeting drug users in EU prisons in 2002.
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2002, needle and syringe exchange programmes were
implemented in 27 penitentiary centres in Spain and
12 970 syringes were distributed with no incidents
reported.
Although in Spain an increasing number of prisons are
providing facilities for needle and syringe exchange, such
programmes have been discontinued in the German Länder
of Hamburg and Lower Saxony (Stöver and Nelles, 2003).
However, there is still a needle and syringe exchange
programme in one women’s prison in Germany (Berlin)
(Weilandt, personal communication, 2004). In Josefstadt
Prison, Vienna, a pilot project is in preparation, and in
Luxembourg it is intended to provide injection equipment
for drug addicts in prisons under the healthcare
programme (145).
Alternatives to prison targeting 
drug-using offenders
Alternatives to prison will be the subject of a selected issue
in next year’s annual report, when a thorough and detailed
overview of such measures in the EU will be provided. This
year’s annual report will therefore deal with a specific
aspect of alternative punishments for drug users.
Emerging initiatives: drug courts 
and mediation between victim and offender
Drug courts are part of new structures developed in some
countries to deal with drug users who have committed a
non-violent offence. They act by delaying the sentence and
involving persons traditionally not involved in drug
treatment (judge, prosecutor, other law enforcement staff) in
the process. The idea is to prevent the offender from
returning to the criminal justice system and to drug use by
virtue of treatment and the pressure exerted by the criminal
justice system. Drug courts have been established in Ireland
and Scotland, where penal systems are based on common
law. In other EU countries with a civil law code, drug
courts, strictly speaking, do not exist, but similar initiatives
have developed.
In the German Land Baden-Wurttemberg, a project to deal
with juvenile offenders (Way out), similar to drug courts,
was instituted in 2003 as a result of an alliance between
police, public attorneys, judges, probation and drug advice
services and key stakeholders of three court districts
(Baudis, 2004). Similarly, in Milan, ‘The cure is worth the
effort’ is a programme involving the central court in close
collaboration with the local addiction and health services.
Here, drug-addicted offenders are referred to treatment on
the same day that sentence is pronounced.
The evaluation of the Dublin drug court (Farrell, 2002)
concluded that that there were strong indications that the
drug court would result in cost savings to the criminal justice
system over time. The Ministry of Justice has extended the
area of Dublin over which the drug court has jurisdiction.
A review of international drug court developments and
their effectiveness carried out by the Pompidou Group in
2003 concluded that the introduction of a therapeutic
drug court should be based on demonstrated need and
requires political support, mechanisms for inter-agency
cooperation and appropriate structural/financial support
for a guaranteed minimum period of five years
(Moyle, 2003).
Restorative justice is increasingly used to accelerate penal
proceedings against non-violent offenders (among whom
drug users are highly represented). This is in alignment with
the public interest by reducing the costs associated with
dealing with petty crime cases in overburdened criminal
justice systems. One of the more significant developments is
out-of-court mediation. This system aims to resolve disputes
between victims and offenders and to settle conflicts in
connection with penal proceedings.
In the Netherlands, the police offer first-time offenders
between the ages of 12 and 18 the option of making
reparations for their crimes through mediation. In the Czech
Republic, a probation and mediation service was
established in 2000, with juveniles and drug users as key
targets. It recorded 29 291 cases in 2002, 765 of which
involved drug-related offences.
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Approaches to measuring national
drugs strategies
Many countries have recently adopted a ‘national drugs
strategy’ (146). This section focuses on plans for the
evaluation of these strategies, which for the first time
has been enabled on a European scale by work
undertaken this year by the national focal points.
This work has helped to clarify references to evaluation
in ‘national drugs strategies’, which are not always 
self-explanatory or clear-cut.
Measures to evaluate European ‘national drugs strategies’
can be divided into three main activities: (1) monitoring,
meaning the routine collection of data regarding the drug
phenomenon as well as responses and interventions;
(2) evaluation of implementation, i.e. assessment of the
value added by the implementation of initiatives and by the
allocation of resources envisaged in the drugs strategy; and
(3) evaluation of impact (generally called assessment of
effectiveness), a judgment on the outcomes (short-term
effects) and the impacts (147) (long-term effects) on the drugs
phenomenon brought about (at least in part) as a result of
the national drugs strategy (Figure 23) (148).
The main distinction between countries in terms of the
approach taken to evaluate national drugs strategies is
between countries that monitor the drugs strategy and those
that envisage an evaluation of the implementation and/or
impact.
The concepts of monitoring and evaluation are not always
clearly distinguished in national drugs strategies, so it is
important to be aware of the difference. Monitoring is a
continuous and systematic process that generates routine
quantitative and qualitative data on the drug phenomenon
and the interventions put in place to tackle it. It can provide
regular feedback on the implementation of activities (i.e. on
inputs: what resources have been spent; and on outputs:
what measures have been implemented, over what time
period and by whom). However, monitoring does not
usually provide information about the impacts of a strategy
or provide answers as to why an activity does or does not
achieve its objectives. Although a monitoring system is often
able to provide information on the evolution of the different
aspects of the drug phenomenon and on the measures
implemented to combat it, it is generally unable to
determine whether or not those changes are the direct
consequences of the implemented measures (causality
imputation).
The issue of causality and other complex scientific questions
are addressed through evaluation (Table 5), which means a
‘judgment on the value of a public intervention’ (in this case
a national drugs strategy) ‘with references to criteria’
(relevance, efficiency, impact) ‘and explicit standards’
(quality, quantity) (definition extracted from European
Commission, 1999), and which, generally, requires in-
depth studies to be carried out. The constitutive element of
evaluation is therefore twofold: (1) proof, based on good-
quality data, i.e. collected through scientific methodologies
(monitoring and in-depth studies), of the existence of
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Figure 23: Levels of evaluation in ‘national drugs strategies’
(1) The term ‘drugs strategy’ also includes any equivalent action plans arising
from the strategy.
‘National
drugs
strategy’ (1)
Interventions
Evaluation of impact 
Have the measures
produced an impact
on the drugs situation?
Evaluation of
implementation
Have the planned actions 
been implemented
and what is the value
of their results?
Contextual
factors
Drugs 
phenomenon
Monitoring
What are the inputs
and outputs?
(146) Defined in Chapter 1, p. 17.
(147) For simplicity, here we will use the expression ‘evaluation of the impact’ to mean evaluations of both outcomes and impacts, two quite different scientific
exercises that are generally distinguished in the relevant literature.
(148) A comprehensive evaluation would include also the assessment of efficiency, which broadly measures the cost at which the outcomes and impacts were
achieved. However, data on this aspect were available only for Spain (see below).
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national report, p. 67). In Hungary and Poland, the
national drugs strategies suggest a system for following up
on the fulfilment of tasks (Reitox national reports), while in
Slovenia, although the new national strategy ‘envisages the
regular evaluation of implementation’, no evaluation has so
far been carried out (Slovenian national report, p. 61). In
Lithuania, the implementation of the national drugs strategy
(2004–08) will be carried out ‘according to the financial
possibilities of the country’ (Lithuanian national report,
p. 35). And in Estonia, the new national drugs strategy
‘includes monitoring and evaluation components and
defines the performance indicators’ (Estonian national
report, p. 86).
In Finland and Sweden (Finnish national report, p. 113;
Swedish national report, pp. 75–76), the national drugs
strategies place greater emphasis on monitoring the
implementation of the strategy than on the evaluation of its
impact. In Sweden, the drugs coordinator, appointed in
2002, has the responsibility of ensuring that the national
action plan is followed up (in annual reports). In Finland,
too, research is planned to lay down some benchmarks by
which the drug administration will monitor and evaluate its
activities. Luxembourg’s national focal point reports that the
output of the 2000–04 plan will be evaluated in 2005 in
order to elaborate further and future strategies
(Luxembourg national report, p. 94). In Germany, the 2002
drug and addiction action plan for the first time includes an
attempt to set operational targets and criteria that can be
used to determine the success or failure of interventions
(German national report, p. 101), while in Italy, the three-
causality between the implementation of a policy and a
change in the phenomenon under study; and (2) a value
judgment of the impact achieved, which eventually has to
be linked to decision-making.
In practice, the concept of ‘evaluation’ is inextricably linked
with ‘monitoring’, but, although some documents treat the
two terms as synonymous, it should be borne in mind that
monitoring is not the same as evaluation (although
monitoring is certainly part of it).
In the United Kingdom, the updated national drugs strategy
was published in 2002 following a wide-ranging review
that took account of the evidence base, including
evaluations of its supply and demand components. The
national drugs strategy is ‘monitored’, ‘tracked’ and
‘performance managed’ but not ‘evaluated’ (United
Kingdom national report, p. 106). In Norway, an aim of
the new drugs and alcohol action plan is to develop a
system for measuring the extent to which the plan’s goals
and sub-goals are achieved (Norwegian national report,
p. 65). In the Czech Republic, the 2001–04 national drug
policy strategy defines goals, objectives, aims, targets,
indicators of success and tools for efficiency evaluation for
each pillar of the strategy. The fulfilment of tasks is
regularly monitored; however, the strategy has not yet been
systematically evaluated according to the determined
indicators of success and defined evaluation tools. One
reason for this may be the considerable cost of external
evaluations (Czech Republic national report, p. 114). The
new Danish action plan envisages that a number of specific
activities will be ‘evaluated’ on an ongoing basis (Danish
76
Table 5: Evaluation terms commonly used 
(evaluation methods for action of a structural nature)
Overall evaluation Evaluation of an intervention in its totality
Coherence The extent to which the intervention logic is non-contradictory/the intervention does not contradict other interventions with similar objectives
Relevance The extent to which an intervention’s objectives are pertinent to the needs, problems and issues to be addressed
Consistency The extent to which positive/negative spillovers onto other economic, social or environmental policy areas are being maximised/minimised
Utility The extent to which effects correspond with the needs, problems and issues to be addressed
Effectiveness The extent to which objectives set are achieved
Efficiency The extent to which the desired effects are achieved at a reasonable cost
Cost-effectiveness analysis Evaluation tool for making a judgment in terms of efficiency
Cost–benefit analysis Evaluation tool for judging the advantages of the intervention from the point of view of all the group concerned, and on the basis of a monetary value
attributed to all consequences of the intervention
Output That which is financed and accomplished (or concretised) with the money allocated to an intervention
Impact A consequence affecting direct addressees following the end of their participation in an intervention, or after completion of a public facility, or else an 
indirect consequence affecting other addressees who may be winners or losers
Source: European Commission, 1999.
(national drugs strategy 2001–08: ‘Building on experience’,
p. 111). However, it seems that the evaluation will comprise
an examination of the extent to which the drugs strategy
has been implemented and whether it has met its strategic
aims, rather than a complete assessment of the impact of
the strategy on drug use. In Portugal, the drugs strategy
foresees ‘an external independent evaluation of its global
and sectorial implementation’ (Portuguese national report,
p. 65). An internal process of evaluation is also reported.
In those Member States that do not have, sensu stricto, a
‘national drugs strategy’, overall evaluation has attracted
little interest in recent years, even in countries with a culture
of evaluation of specific drugs projects. For example, in the
Netherlands, where research, monitoring and evaluation
are traditionally part of drug policy, a new (2002)
‘governmental steering strategy’ aims to provide guidance
on performance for public administrative bodies (including
those involved with healthcare and drugs) (Dutch national
report, pp. 83–84). And in Austria, although drug-related
monitoring has improved substantially in recent years,
neither provincial plans (other than preliminary evaluations
in Vorarlberg) nor the overall drug policy have been the
subject of evaluation (Austrian national report, p. 63). In
the remaining countries (Cyprus, Latvia, Malta and
Slovakia, as well as Bulgaria, Romania and Turkey), there is
insufficient information to report on evaluation of national
drugs strategies (where they exist at all).
Evaluations: 
‘ex ante’, ‘mid-term’ and ‘ex post’
The guide to the evaluation of EU activities (European
Commission, 2003) identifies four main reasons for
carrying out evaluations: (1) to contribute to the design of
year programme 2002–04 promotes evaluation in the field
of prevention and social reintegration.
Among the countries that present an evaluation either of the
implementation of the national drugs strategy or of its
effectiveness are Greece, Spain, France, Ireland and
Portugal (Table 6). The Spanish and Greek strategies refer
to the ‘evaluation of effectiveness’. In Spain, the nine-year
national strategy calls for the evaluation of its overall and
sectorial implementation at mid-term, in 2003, and in
2008. The aim is ‘to improve the effectiveness and
efficiency of the public policies’ (Spanish national report,
p. 85), measuring the quantity and the quality of the
service provided. Similarly, in Greece, the new action plan
on drugs 2002 refers to external evaluation of the overall
effectiveness of the policies implemented, which might take
place in the future, having as its basis EU and international
indicators (Greek national report, p. 110).
In France, Ireland and Portugal the national drugs
strategies call for an overall (149) and sectorial evaluation, in
some cases of effectiveness (Irish national report). However,
data received show that, in fact, evaluations conducted so
far have been a judgment more of the level of
implementation than of the effectiveness of the strategy. In
France, the evaluation of the three-year action plan
1999–2002 (carried out by the Observatoire Français des
Drogues et des Toxicomanies (OFDT) from 2000 to 2003)
included both an ‘overall evaluation’ and the evaluation of
five priority programmes (150). The evaluation stopped short
of judging the impact of measures taken on the overall drug
situation. It was, therefore, essentially an assessment of
progress, against which the achievement of operational
objectives has been assessed. In Ireland, the national drugs
strategy calls for ‘an independent evaluation on the
effectiveness of the overall framework by end of 2004’
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Table 6: Characteristics of some national strategies’ evaluations
‘National drugs strategy’ Scope of the evaluation Aim of the evaluation Evaluation terms
Greece Action plan, 2002–06 Overall and specific Effectiveness None
Spain National drugs strategy, 2000–08 Overall and specific Effectiveness and efficiency 2003–08
France Three-year plan against drugs and Overall and specific Implementation
for the prevention of dependencies, 
1999–2001 2002
Ireland National drugs strategy, 2001–08: Overall and specific Implementation 2004–08
‘Building on experience’
Portugal The national strategy for the fight Overall and specific Implementation 2004
against drugs 1999; action plan, 
2000–04
(149) Overall evaluation: evaluation of an intervention in its totality (Table 5).
(150) (1) The regional agreements on objectives in health and justice, (2) the interministerial policy on professional training, (3) the regional policy programmes
for the prevention of addiction, (4) outreach experiments by specialised facilities to provide general care for people exhibiting addictive behaviour and (5) risk
reduction programmes in the 18th district of Paris.
Annual report 2004: the state of the drugs problem in the European Union and Norway
have ready access to data sources. However, they might
tend to justify failures to meet objectives and are less willing
to make observations or suggest changes that could be seen
as a threat to the organisation. External evaluators, in
contrast, should provide a more objective and reliable view
as they are not involved with the organisation, but they
might have more difficulties in accessing information
sources, and they run the risk of trying to satisfy the client
by providing results as good as can be expected. Moreover,
external evaluators are usually costly. There is, then, a
choice to make between, on the one hand, a better
understanding of the situation and the ability to obtain
information objectivity and, on the other hand, greater
objectivity and expertise in evaluation.
Most Member States seem to favour a mixed approach: in
Ireland, the mid-term evaluation of the national drugs
strategy will be carried out in 2005 by external consultants
under the guidance of a cross-sectorial steering group; in
Portugal, internal staff and external consultants will run the
evaluation of the 2000–04 action plan; and in France,
external evaluators and internal staff of the OFDT have
carried out different aspects of the evaluation on the three-
year action plan. In Spain, the mid-term evaluation (2004)
is currently being undertaken by the staff of the national
plan on drugs (PNSD), whereas the Greek plan demands
an external evaluation. In Sweden, the National Institute of
Public Health will evaluate public health policy through
measurement of several lifestyle variables. One objective of
the policy (No 11) aims to reduce tobacco and alcohol use,
achieve a society free from illicit drugs and doping and
reduce the harmful effects of excessive gambling.
In all countries in which an evaluation process is carried
out, the national coordination agency appears to be the
authority responsible for organising and delivering the
interventions; (2) to improve the quality of the intervention;
(3) to aid the efficient allocation of resources (i.e.
efficiency); and (4) to report on the achievements of the
intervention (i.e. accountability). The same guide describes
three stages of evaluation: ex ante, mid-term and ex post.
Ex ante evaluation is carried out before the implementation,
supposedly to assess the need for action or to establish a
baseline. Ex ante evaluation is reported in national drugs
strategies as revision processes, conducted by
parliamentary commissions, government commissions or by
government departments, which are stated to be the basis
of several national drugs strategies (Belgium, Germany,
Spain, Ireland, Portugal, Sweden).
Mid-term evaluation is reported in the Spanish, Irish and
Portuguese ‘national drugs strategies’ as a tool to adjust
interventions and objectives ‘along the way’. The approach
of adjusting ‘along the way’ is not confined to countries that
are engaged in a proper evaluation process. Its use is also
reported in those countries that set up monitoring systems,
where it is used to contribute reliable information to help
adjust and reshape future actions. This would imply an
assessment of value more typical of evaluative activities.
Again, monitoring and evaluation are used
interchangeably.
Ex post evaluation embraces the entire intervention period,
usually with particular focus on the final results of the
intervention, with the aim of providing input for future ones.
Such activity is reported in France, where the final
evaluation of the French action plan had the aim of revising
interventions and objectives for a new drugs plan, and is
proposed for 2008 in Spain, Ireland and Portugal.
In the field of drugs, the aim of the evaluation process is
always to improve the quality of existing interventions and
the design of new ones. However, it may be assumed that
when one drugs strategy succeeds another the ex ante and
ex post evaluations merge, resulting in a cyclical process in
which the final results of the past strategy provide input for
the future strategy (Figure 24).
Actors in the evaluation
Another key issue covered in ‘national drugs strategies’ is
whether those in charge of evaluation should be ‘internal’
to the organisation or ‘external’. Examples of both kinds
can be found, and each type has advantages and
disadvantages.
Internal evaluators can offer a broader knowledge of the
structures and the communication mechanisms, are familiar
with the organisation and with the subject under review and
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Figure 24: Evaluation as a cyclical process
(1) The term ‘drugs strategy’ also includes any equivalent action plans arising
from the strategy.
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evaluation process: the Inter-ministerial Mission (MILDT) in
France, the PNSD in Spain, the Institute for Drugs and Drug
Addiction (IDT) in Portugal, the Drugs Directorate in
Ireland, the Drug Coordinator Office in Sweden and, as
announced in the 2001 Belgian ‘strategy’, the General
Drug Cell in Belgium, when it comes into operation. Within
these agencies, the drugs monitoring centres, which are
usually the same as the Reitox national focal points, are
responsible for providing the information and data
necessary for the evaluation, and sometimes are also
technically responsible for the evaluation.
Targets and indicators
The question of the extent to which the effects of actions
implemented as the result of a ‘national drugs strategy’ can
be measured is often raised. Indeed, both ‘international’
and ‘national’ drugs strategies refer to very ‘general
objectives’, such as ‘reducing the risks for drug users’ or
‘aim of a drug-free society’, as well as to ‘operational
objectives’, such as ‘increasing the number of treatment
slots’ or ‘establishing a drug coordination agency’. Both
‘general’ and ‘operational’ objectives could benefit from the
setting out of specific aims. The former are important as a
basis of national drugs policy, identifying a direction but
are difficult to measure; the latter indicate the delivery of
qualitative and quantitative initiatives, implying that they
should be easier to measure.
Experts and professionals warn that, in order to evaluate a
strategy scientifically, the objectives must be spelled out in a
clear, unambiguous, measurable way, distinguishing, but
linking, ‘general’ and ‘operational objectives’. Indeed,
‘operational objectives’ must be seen as a way of firming
up ‘general objectives’. Performance indicators should then
be set to measure the achievement of the objectives.
Currently, only a few national drugs strategies can be
included in this category.
Efficiency
Few national strategies make much mention of cost–benefit
or cost-effectiveness analysis, with the exception of the
Spanish strategy, which states that the evaluation of the
national strategy will also try to measure the efficiency of
the public policy. Although budgets and costs are a concern
for public administrations, in the field of drugs (as identified
in the last annual report, EMCDDA, 2003b) there is a
general lack of knowledge of the global cost of public
interventions in this area. This kind of analysis is regarded
generally as marginal and is included in only a few
research activities.
Constraints on evaluation
Within the scientific community it is acknowledged that it is
very difficult to determine whether or not a drug policy is
effective. Experts and professionals warn of the difficulties
posed by impact evaluation of a public policy: ‘layers of
complexity’ and a ‘multitude of cause and effect linkages’
must be considered. Indeed, it can be difficult to detect a
causal link between a drugs policy and its outcome and
impact because of the variety of interventions and effects to
be measured and the possible external factors (confounding
factors) influencing the reality (for example socioeconomic
conditions, subcultures). Some research suggests that drugs
phenomena might depend more on behavioural and
societal factors than on policy interventions.
Moreover, the illicit nature of drug use can be a serious
obstacle to data collection, which is an essential tool to any
evaluation process, leaving many important aspects of the
drug phenomenon unidentified. Thus, evaluation in the field
of drug intervention must be carefully thought out and its
results must be interpreted with caution.
Conclusion
From the data reviewed, it appears that ‘national drugs
strategies’ generally take evaluation to mean measuring
implementation — progress, achievements, even failures —
and eventually making some judgment of it, rather than
evaluating the impact on the overall drug situation. This is
an important conclusion. Most countries that have faced the
drug problem for many decades are now able (or willing)
to put in place, through monitoring systems, a basis for
measuring the drugs phenomenon and the effects of their
efforts. Thus, drugs policies can be considered to be more
accountable than ever before, which itself is an important
achievement.
A few countries have gone further, announcing that, in
addition to the development of monitoring systems, they will
conduct an evaluation of the implementation of the
‘national drugs strategy’, by which they mean a scientific
study to assess the worthiness or otherwise of all or part of
the strategy. However, so far no signs of scientific
evaluation of impact associated with overall national drugs
strategies are apparent.
Generally, countries that take a more structured approach
to drug policy, i.e. which have a written, objective-driven,
overall ‘national drugs strategy’, a central coordination
mechanism with, ultimately, a national coordinator and a
solid monitoring system, report the existence of a more
sophisticated evaluation process (Figure 25). It seems that
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the existence of a more structured approach, in itself a sign
of a financial and political commitment, is a prerequisite for
a more developed evaluation approach to a national drugs
strategy. This hypothesis should, of course, be confirmed by
further research.
The spread of a culture of monitoring and assessment has
added to the knowledge of the drugs problem in the EU,
and consequently the scene is set for more informed
decisions. Evaluation is now firmly recognised in current
drugs strategies as a critical element of accountability,
performance and financial prudence. Many projects and
specific interventions in the field of drugs already contain
an element of evaluation and, if extended to all major drug
policy interventions, this will gradually contribute to the
measurement of the effectiveness of European national
drugs strategies.
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Figure 25: Main characteristics of a structured drug policy approach
Financial 
and 
political 
commitment
Drugs 
strategy
written, 
objective driven,
 timed, overall
Monitoring 
system 
feasible indicators, 
 data systematised, 
quality controlled
Central
coordination
power of decision,
accountability,
leadership, access to
information, financial
autonomy
Routine 
evaluation
contribute to design
and improve
the quality
of interventions

(151) See European legal database on drugs (ELDD) website (http://eldd.emcdda.eu.int/trends/trends_cannabis.shtml).
(152) See: http://www.incb.org/e/conv/1961/index.htm.
context, the aim of which is to facilitate a more informed
debate on the potential public health impact of this most
common of all forms of illicit drug use.
The legislative context: 
legal status of cannabis in Europe
The legal penalties that should apply to those who use
cannabis remain an issue of some controversy in the EU (151),
and the Member States diverge considerably in their
approach to this question.
Cannabis extracts are classified as narcotic drugs under
Schedules I and IV of the 1961 United Nations Single
Convention on Narcotic Drugs (152). The convention requires
measures to be adopted to ensure that a wide range of
activities — including the possession of narcotic drugs —
are punishable. However, Member States have to interpret
and apply the convention taking into account their own
circumstances, and Article 36.1.b allows for the possibility
for options of ‘treatment, education, after-care,
rehabilitation and social reintegration’.
What this means in practice is that, across the EU, handling
of cannabis offences is heterogeneous. Some countries have
issued prosecutorial guidelines or legal codes that direct
how certain types of cannabis offence should be dealt with,
often recommending different legal pathways for what are
considered minor or more serious offences. And in some
countries a trend is emerging for therapeutic measures to
be implemented as an alternative to criminal prosecution
for cases of use and possession of small quantities of drugs
without aggravating circumstances. In addition, penal codes
may address problematic use by allowing (discretionary or
compulsory) suspension of prosecution provided the
offender undergoes counselling or treatment. Although
these alternatives usually apply to users of all drugs, as a
result of changes in the last year, the laws or guidelines in
Belgium and the United Kingdom now make specific
mention of problematic cannabis users with the aim of
directing them towards assistance.
Introduction
The term ‘cannabis’ is used to define various products that
are obtained from the cannabis or hemp plant (Cannabis
sativa L.), an annual species native to central Asia that now
grows in many temperate and tropical parts of the world.
The numerous varieties of Cannabis sativa exhibit a
correspondingly wide range of different biological and
chemical characteristics. Three forms of illicit cannabis are
found on the European drug market: ‘herbal cannabis’,
consisting of the dried flowering tops, stems and leaves of
the plant; ‘cannabis resin’, the dried brown or black
resinous secretions of the flowering tops, usually sold in the
form of compressed blocks but sometimes also found as a
powder; and, by far the least common, ‘cannabis oil’,
which is a sticky viscous liquid.
Cannabis has a long history of use by man, and at times
has been used by different societies as an important source
of fibre for cloth and rope, an aid to religious ritual, a
herbal medicine and an intoxicant. Worldwide, cannabis is
now the most commonly produced, trafficked and consumed
illicit drug (UNODC, 2003a). Despite both its long history
of use and its current popularity, our understanding of the
public health impact of cannabis use remains limited.
Recently, evidence of a potential association between
cannabis use, and especially intensive cannabis use, and a
range of health and social problems has been growing.
There is also increased concern about an apparent rise in
the number of cannabis users who are seeking help from
specialist drug services. However, the extent and nature of
problems found within populations of European cannabis
consumers remain unclear. Also unclear is the extent to
which statistical information on increasing demands for
treatment reflects changes in reporting and referral practice
as opposed to increases in the number of individuals
requiring help. To answer these questions we have to place
cannabis treatment demands in the broader perspective of
changing consumption patterns in Europe, the evolution and
development of reporting systems and even a consideration
of the changing nature of the drug itself. These matters are
addressed in this selected issue on cannabis problems in
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(153) A specific monograph on cannabis use and related problems will be published in the first half of 2005. Specific information on the health and physical
effects of cannabis use can be found on the EMCDDA website.
(154) See DRCrime_Tbl 5 in the 2004 statistical bulletin.
(155) For a definition of ‘dependence’ and ‘harmful use’, see International Classification of Diseases, 10th edition (ICD-10, World Health Organisation), Codes
F10 to F19: mental and behavioural disorders due to psychoactive substance use. Also frequently used is the Diagnostic and statistical manual of mental
disorders (IV edition) (DSM-IV, American Psychiatric Association), which uses the concepts ‘dependence’ and ‘abuse’.
(156) Greece, Spain, France, Ireland, Italy, Latvia, the Netherlands and Portugal. Data for Finland are not presented owing to the small number of last month’s
users in their survey (35). The number of cases and percentages for each country are presented in GPSurvey_Tbl 7 in the 2004 statistical bulletin.
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Physical, psychological and developmental
problems associated with cannabis use (153)
The national reports of the Member States point out that a
rise in the number of cannabis treatment demands probably
reflects an increased level of problems particularly
associated with intensive cannabis use. It should be noted,
however, that systematic and comparable data on the
problems experienced by cannabis users are largely
lacking. The scientific knowledge base in this area is still
developing but does provide increasingly convincing
evidence of an association between cannabis use and a
range of problems, although the nature of the causal
linkage is not always clear. An overview of the literature on
the problems associated with cannabis use is available
online (http://www.emcdda.eu.int/?nnodeid=4811).
It is important to distinguish between the acute (short-term)
effects of cannabis and the long-term or chronic impact of
the drug. A range of both positive and negative acute
effects have been reported. Negative effects include deficits
in attention and concentration difficulties, adverse effects on
motor function (reflexes, coordination), short-term memory
problems, anxiety and panic attacks and depression.
Positive effects include euphoria, relaxation and increased
sociability. The acute effects of the drug which arouse the
greatest concern are short-term drug-induced psychosis or
severe panic attacks, an increased risk of accidents,
particularly when driving or in hazardous work
environments, and, among young people, a negative
impact on school performance (Hall et al., 2001).
Understanding the chronic effects of cannabis is more
complex for a number of reasons, not least because it is
difficult to separate the effects of cannabis from the effects
of chronic use of other illicit drugs, tobacco and alcohol.
However, among the key concerns in this area are an
increased risk of lung cancer and other respiratory diseases
and an association with the development of long-term
psychiatric health problems, including depressive illness,
psychosis and schizophrenia. An additional concern with
chronic use is the possible development of dependent
behaviour. The extent to which the evidence suggests that
cannabis use is a risk factor, a causal factor or simply
associated through some more complex relationship with
these problems is explored in the review available online.
In most Member States, cannabis is the illicit drug most
often involved in reported drug law offences, which is
unsurprising given that it is also the drug most commonly
used (154). However, in contrast to other drugs, such as
heroin, there appears to be no strong association between
cannabis use and other types of offending.
Cannabis use and the measurement
of problems
Although the agreed international diagnostic criteria
provide useful guidance on the definitions of harmful drug
use, abuse and dependent use, problems arise when
cannabis is considered in the light of available European
evidence (155). In particular, there is considerable variation
in key measurement issues. For example, there is little
consensus regarding the definition of terms such as
‘intensive use’, ‘regular use’ and ‘problematic use’, and this
makes comparing the findings of different studies difficult.
Additionally, it is mostly in survey work that attempts have
been made to measure ‘dependence’ or ‘abuse’ according
to the ICD or DSM definitions at the population level; here
again standardised tools that would allow convincing
comparison of data from different studies or across
populations are currently lacking.
However, some work in this area is under way. For
example, a current French study aims to better define
problematic use and develop specific instruments to
measure frequency of use, perceived risk and psychological
and physical effects (Beck, 2003).
To date, the most commonly used measure of intensity of
use is the number of days on which the drug has been used
over a defined period. Daily or almost daily use of
cannabis is usually taken as an indicator of ‘intensive use’.
Although daily cannabis use does not necessarily imply
dependence, it is likely that a substantial proportion of
daily users would rate positive for dependence or abuse in
terms of the standard diagnostic criteria (ICD-10, DSM-IV).
As frequency of use is relatively easy to measure and to
harmonise in questionnaires, this measure is included in the
EMCDDA guidelines for the European model questionnaire.
Nine countries currently report frequency of cannabis use
data in this form (156).
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(157) Data on new clients are not available for the United Kingdom and information is reported in the national reports.
(158) In the United States, admissions to treatment, rather than individuals, are registered. In addition, in contrast to Europe, alcohol is included among the
substances of abuse. See the SAMHSA website (http://www.samhsa.gov); note that in the United States, Canada and Australia the term ‘marijuana’ is used
because the term ‘hashish’ (cannabis resin) is not common.
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influenced by data from Spain and Germany, countries that
have seen particularly large increases in reports of primary
cannabis problems; furthermore, in terms of overall
numbers, Spain accounts for around 50 % of all reported
treatment demands.
An increase in cannabis treatment demands is not restricted
to Europe. In the United States, where a different drug
treatment registration system is used (158), treatment
admissions for marijuana increased from around 20 000 in
1992 to nearly 90 000 in 2000 (SAMHSA, 2001;
EMCDDA, 2003d).
Trends in treatment demands for cannabis
problems
Cannabis is the illicit drug most used in Europe, but only a
small proportion of people who have used the drug seek
treatment. Despite this, in many countries cannabis is now
the second most frequently reported primary drug for which
people receive specialised drug treatment. According to TDI
(treatment demand indicator) data (see p. 65), collected
from all types of specialised treatment services, around
12 % of all clients and 30 % of those new to treatment are
now recorded as having a primary cannabis problem
(Figure 26).
The proportion of new clients (i.e. those with no previous
treatment history) seeking treatment for cannabis use varies
considerably between countries, from almost zero in
Lithuania to nearly half (48 %) in Germany, but in general
is in excess of one fifth (20 %) (Figure 27). However, not all
countries can provide data on new treatment demands and
within the larger data set of all treatment demands
cannabis problems are less evident.
Between 1996 and 2002, according to TDI data from
countries for which trend data are available, the number of
new clients demanding treatment for cannabis as the
primary drug increased from 3 713 to 12 493. In 2002,
averaged across the 11 countries for which data are
available, such clients represented 29 % of all new clients,
up from 9 % in 1996 (see Figure 20 for data sources).
Although all these countries, with the exceptions of Greece
and the United Kingdom (157), report an increase in new
cannabis clients as a proportion of all new clients, the
magnitude of the increase varied from 6 % in the
Netherlands to 31 % in Germany. Information provided in
the Reitox national reports suggests that the number of
people receiving treatment for primary cannabis use is also
increasing in some of the new Member States (Figure 28).
A recent review of cannabis treatment demands conducted
by the Dutch national alcohol and drugs information system
(LADIS) noted that 29 % of new clients entering treatment in
2002 were reported as having cannabis problems and that
cannabis clients represented a small yet annually increasing
number of individuals. The report also noted that, given the
scale of cannabis use in the Netherlands, the proportion of
those seeking treatment although growing remained
relatively small.
A note of caution must be sounded regarding the extent to
which generalisations can be drawn from the consolidated
European data set. Longitudinal data on new treatment
demands are available from only 11 countries. It is also
important to note here that the increase in cannabis
treatment demands reflected by TDI data is strongly
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Figure 26: Reported primary drug among new and all clients
attending drug treatment services in 2002
NB: n = 42 568 (new clients), 351 372 (all clients).
Countries providing data (new clients): CZ, DK, DE, EL, ES, LT, NL, SL, SK, FI, SE.
Countries providing data (all clients): CZ, DK, DE, EL, ES, IT, LT, LU, HU, NL,
SK, SL, FI, SE, UK.
Weighted on the number of clients by country.
Sources: Reitox national reports 2003.
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In considering the implications of increased treatment
demands for cannabis the following key questions arise:
• Does this finding represent an increase in the number of
people with physical and psychological problems
relating to their use of cannabis? If so,
— Does it result from an increase in the regular
intensive use of cannabis?
— Does it reflect other factors such as a possible
increase in cannabis potency?
• Can this increase be explained by factors independent
of an increased need for help, such as:
— improvements in the coverage of the treatment
reporting system;
— expansion of the types of treatment facilities
available, and in particular specific treatment
services targeting adolescents and young people
(Reitox national reports, 2003);
— changes to the way cannabis use is dealt with by the
criminal justice system, within schools or by agencies
working with young people, with an increase in
referrals to treatment of individuals who would not
otherwise have sought help spontaneously.
Understanding the extent to which each of these factors
affects treatment attendance is important. A first step is to
consider the characteristics of those entering treatment and
recorded as having a primary cannabis problem. This
analysis is based on those attending outpatient/ambulatory
treatment facilities.
Cannabis clients: characteristics and patterns of use
A number of standard options are available for recording
the source of referral for drug users entering treatment.
These distinguish drug users who have referred themselves
from those who have been referred through other agencies,
such as social or criminal justice agencies. Most cannabis
clients are referred to treatment by family and friends,
social services or the criminal justice system. In comparison
85
Figure 27: Cannabis as reported primary drug among new clients
attending treatment in 2002
NB: Total number of cases: 42 421.
Sources: Reitox national reports 2003.
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Figure 28: Trends in cannabis as reported primary drug among
new clients attending treatment: 1996–2002
NB: Treatment in overall numbers (% of all clients).
Average of trends (%) within countries.
Countries providing data: CZ, DK, DE, EL, ES, NL, SL, SK, FI, SE.
In Sweden, data for 1996–99 are from hospital treatment: the number of
cannabis cases is thus relatively low compared with other years.
Sources: Reitox national reports 2003.
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(159) See Figure 22 OL: Source of referral among all clients: for all drugs and for cannabis.
(160) See also TDI_Tbl 4 in the 2004 statistical bulletin.
(161) See Figure 23 OL: Labour status among cannabis clients and all clients.
(162) See Figure 24 OL: Living conditions among cannabis clients and all clients.
(163) See Figure 25 OL: Frequency of cannabis use by country.
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frequently than once a week (2–6 times per week); 15 %
used the drug once a week or less often and 28 % were
occasional users or had not used cannabis in the last
month. In contrast, 84 % of opiate users in treatment are
daily users.
The proportion of outpatient treatment clients who use
cannabis daily varies between countries. The highest
proportions of daily cannabis users are reported in the
Netherlands (80 %) and Denmark (76 %), while the highest
proportion of occasional users is reported in Germany
(41 %) (163).
The younger the age at which users first consume cannabis,
the higher is the risk of developing drug problems in the
future (Kraus et al., 2003). In Europe, 28 % of all cannabis
with users of other drugs, a smaller proportion of cannabis
clients are self-referred for treatment (159). A similar picture
is also seen in the United States and Canada, where
treatment demand for marijuana as primary substance is
largely found to be not self-initiated (EMCDDA, 2003d).
One important difference between referral routes is that those
referred by family members or social services (often schools)
are typically younger, less likely to be using any other drugs
in addition to cannabis and more socially integrated,
whereas clients referred by legal authorities or classified as
self-referrals tend to be older and often use other drugs as
well as cannabis (Reitox national reports, 2003). In Germany
and Finland, which have the highest percentages of primary
cannabis clients, legal authorities and schools play an
important role in referring cannabis clients.
Cannabis clients new to treatment are predominantly
young, males (83 %), with a mean age of 22–23 years,
whereas, in the case of other drugs, the proportion of
clients who are males is marginally lower and the mean
age higher. In the case of almost 80 % of new clients
classified as ‘very young’ (under 15 years of age) and
40 % of those aged 15–19, the primary drug for which
treatment is sought is cannabis (Figure 29) (160). These
groups are still predominantly male but include a higher
proportion of women than the client group overall.
Differences in age and gender distribution by country
broadly reflect the same patterns found among all clients.
The relatively young age of cannabis clients is reflected by
the large proportion, 45 %, who are still in education,
compared with only 8 % of clients being treated for
problems with other drugs. A further 24 % of those being
treated for cannabis problems are in regular employment,
equal to the number who are unemployed (161), which is in
stark contrast to clients using drugs such as heroin. In
addition, cannabis clients more often report living in stable
accommodation than those being treated for problems with
other drugs (162), reflecting the fact that many are young
people, students and living with their parents.
Patterns of use among clients receiving outpatient treatment
for primary cannabis use vary considerably and are quite
different from those found for other drug types, particularly
the opiates (Figure 30). Among clients in treatment for a
primary cannabis problem in 2002, only 36 % were daily
consumers of the drug and only 17 % used cannabis more
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Figure 29: Distribution of reported primary drug among
outpatient treatment attendees, by age group: 2002
NB: All clients. Countries providing data: DK, DE, EL, ES, LU, HU, SE, FI, UK.
Males from Denmark and the United Kingdom account for 56 % of all clients
in cannabis treatment under 20 years, with a further 17 % from Spain.
Sources: Reitox national reports 2003; TDI outpatient treatment centres.
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(164) See Figure 26 OL: Most used secondary drug among all cannabis clients by country and TDI_Tbl 9 in the 2004 statistical bulletin.
(165) See Figure 27 OL: Source of referrals among all clients, 2000–02.
(166) See Figure 28 OL: Frequency of use among all cannabis clients and TDI_Tbl 8 in the 2004 statistical bulletin.
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clients in treatment in 2002 started using the drug before
the age of 15, and the majority (80 %) before 20 years of
age. The corresponding figures for opiates are 9 % and
42.8 % and for cocaine 6 % and 26.5 %.
Most countries report that clients in treatment who have
primary cannabis problems often show a pattern of
polydrug use. This may indicate a reporting artefact, for
example if clients with polydrug problems were, for
convenience, to be recorded as primary cannabis users.
However, quantitative data on the proportion of polydrug
users among clients in general are not available. There are
differences between clients who use only cannabis and
those who use cannabis in combination with another drug
(Reitox national reports, 2003): the former are usually
younger and better socially integrated (more likely to be in
employment and have achieved a higher educational level
and less likely to drop out or have dropped out of school)
than the latter. The most commonly reported secondary
substances used by primary cannabis clients are alcohol
(32.9 %) and stimulants (25 %) (164), although the distribution
varies from country to country.
Some cannabis clients in treatment also admit to injecting
other drugs, and some report lifetime experience of
injecting despite currently using no drugs other than
cannabis. For example, in Greece in 2002, although
14.7 % of cannabis clients with recorded secondary drug
use had injected in the previous 30 days, 25.4 % of all
cannabis clients reported lifetime experience of injecting
another substance (Greek national report, 2003). Similarly,
information from the Czech Republic (national report)
suggests that in some treatment settings up to half of
cannabis clients are also injecting.
Trends in treatment demand: changing factors
The increase in demand for treatment for primary cannabis
problems should be viewed in the context of changes that
have occurred in the characteristics and patterns of use.
Between 2000 and 2002, in those countries reporting data,
the total number of referrals by legal authorities, family and
friends and social services increased exceptionally, by 103 %,
81 % and 136 % respectively (165). No relevant differences
were found between countries, except that in Germany the
proportion of referrals accounted for by the criminal justice
system also increased (from 21.7 % to 26.7 %).
No hard data on trends in the sociodemographic
characteristics of cannabis clients are available, although
some national reports (Czech Republic, France and
Luxembourg) describe an increase in the number of clients
with educational, social and psychological problems.
Between 2001 and 2002 the proportion of daily users
among cannabis clients increased from 31.7 % to
39.2 % (166); some countries report that the proportion
of daily users is higher among older clients (more than
20 years old).
Cannabis in the general population:
from experimental to daily use
As described above, although cannabis use increased
markedly in almost all countries during the 1990s and is
the most commonly used drug, most use still remains
occasional or of short duration. It is likely that those most at
risk of developing problems or becoming dependent are
those that use the drug intensively, but it is in this area that
information sources are weakest, although it is known that
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Figure 30: Distribution of frequency of use of reported primary
drug among all outpatient treatment attendees in 2002
NB: n = 109 699 (all clients). Countries providing data: CZ, DK, DE, EL, LU, HU,
SE, FI, UK (CZ — all types of treatment centres).
Sources: Reitox national reports 2003; TDI outpatient treatment centres.
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one exception (Latvia), approximately one quarter
(19–33 %) of those who had used cannabis in the last month
were doing so on a daily or almost daily basis (167) (168).
In these countries, daily users represented 0.5–2.3 % of
the total population (169) and 0.9–3.7 % of young adults
(15–34 years) (Figure 31). Most people (76–92 %) who
admitted having used cannabis in the previous month were
between 15 and 34 years old, and consequently daily users
were also concentrated in this age range. In addition, daily
users are predominantly male, although the proportion
varies from 62 % in the Netherlands to 92 % in Greece.
From these data, a crude estimate can be made of the
number of people using cannabis intensively in Europe.
Assuming that roughly 1 % of the population uses
cannabis on a daily basis, then, in a country with
25 million inhabitants (age 15–64 years), there would
be 250 000 daily cannabis users. In the EU as a whole,
recent users (use in the last 30 days) are typically young
males living in urban areas.
‘Use in the last 30 days’ is an indicator of current use and
includes those who are using the drug intensively. In recent
surveys, if Sweden (0.1 %) is excluded, 1–7 % of all adults
and 3–12 % of young adults report having used the drug in
the last 30 days. There are differences between countries,
however, and current use is most common in the Czech
Republic, Spain, France, Ireland and the United Kingdom.
In countries where it is possible to analyse trends in recent
use over time, an increase is found, although not a
dramatic one.
Data enabling frequency of cannabis use in the last
30 days to be examined in detail are available from nine
countries — Greece, Spain, France, Ireland, Italy, Latvia,
the Netherlands, Portugal and Finland (not presented). With
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Figure 31: Proportion of ‘daily users or almost daily users’ of cannabis among all adults and young adults in some EU countries, measured
by national population surveys
NB: Daily or almost daily users = use on 20 days or more during the month previous to the interview.
Data are from the most recent national surveys available in each country.
The age range for all adults is 15–64 years (Italy 44 years) and for young adults 15–34 years. Variations in age ranges may result in small disparities between 
countries.
Sources: Reitox national reports 2003, taken from population survey reports or scientific articles. See also standard epidemiological tables in the 2004 statistical bulletin.
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(167) In this section, the information will refer to ‘use on 20 days or more during the past 30 days’, expressed also as ‘daily or almost daily use’. The European
model questionnaire foresees collection of the exact number of days of use, but for reporting of national figures, the frequency of use was grouped into four
discrete categories, the highest one being ‘20 days or more’.
(168) See Figure 29 OL: Proportion of daily (or almost daily) users among adults (15–64 years old) who used cannabis in the previous month.
(169) Proportion of ‘last month’s users’ multiplied by proportion of ‘daily or almost daily users’, i.e. 6 % (last month prevalence)  25 % (proportion using ‘20
times or more’) = 1.5 %.
(170) Further information on this and other prevention programmes is available from the EMCDDA EDDRA database
(http://eddra.emcdda.eu.int/eddra/plsql/showQuest?Prog_ID=2091).
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with a total population of 302 million people aged 15–64
years, the prevalence would be around 3 million.
Even among young adults, intensive cannabis use varies
among age cohorts, and is generally higher among
younger groups. In the 2002 Spanish school survey, 3.6 %
of 14- to 18-year-old students reported daily or almost
daily use (i.e. at the top end of the range found in young
adults aged 15–34). And in the annual French survey of
17- to 19-year-olds (Escapad), daily use of cannabis in the
past 30 days was higher still, being reported by 9.2 % of
boys and 3.3 % of girls (Beck and Legleye, 2003).
The effects of cannabis dependence or abuse appear to be
less severe than those of other drugs. Most intensive
cannabis users seem to be relatively integrated young
people, who are at greater risk of other social problems
(driving accidents, failure to complete their education or
family disruption) than other criminal activities, and the
interventions should accordingly be appropriate and not
create further problems or exclusion.
Cannabis potency and dose issues
It has been speculated that an increase in the potency of
cannabis is in part responsible for increased problems and,
consequently, more treatment admissions. Understanding
the issues associated with cannabis potency, the dose that
individual users receive and its likely impact on acute and
chronic problems raises a number of complex issues. To
explore the scientific evidence available on cannabis
potency a special study was conducted by the EMCDDA,
the key results of which can be found on page 90.
Cannabis potency is only one factor in calculating the dose
an individual will receive over any given period (Hall et al.,
2001). Mode of administration, smoking technique, the
amount of cannabis used in any session and the number of
smoking sessions an individual engages in are all equally,
or even more, important in terms of calculating individual
exposure levels. High-potency cannabis has always been
available to some extent, and concern about this topic is
not new. It is also important to note that it is not understood
if cannabis users modify their behaviour to reach a desired
dose effect. Therefore, the extent to which high potency
cannabis necessarily results in high doses requires further
investigation.
Responding to the needs of those with
cannabis-related problems
Understanding the needs of those seeking help for cannabis
problems is fundamental to the development of effective
responses. Analysis of treatment demand and other
indicator data suggests that both cannabis users referred
for treatment and users as a whole constitute a
heterogeneous population with correspondingly
heterogeneous needs. This suggests that a continuum of
responses is necessary, ranging from prevention and risk
reduction activities through to formal treatment activity. One
possible concern is whether it is appropriate to refer young
people whose use of cannabis is only occasional to
specialised drug centres. The answer to this question very
much depends on how services are configured and the
extent to which clients mix with chronic users of other
substances. Nonetheless, the identification of appropriate
referral routes for those with differing patterns of cannabis
consumption remains an important topic for further
consideration.
On the prevention side, few initiatives have been designed
specifically to respond to the increase in cannabis
consumption among young people, as prevention is rarely
substance specific. However, some Member States report
new developments in this area, adopting two main
strategies: (1) stressing the danger that young people who
use cannabis will become involved in the criminal justice
system; and (2) attempting to reverse the social perception
of cannabis use as normative behaviour through mass or
targeted media campaigns.
In Germany, Greece, Ireland, Finland and the United
Kingdom, measures to reduce the psychosocial
consequences of first offences for cannabis consumption
among adolescents have been introduced. A recent
example of this (2000 onwards) is the FRED programme
in Germany, which is now operational in eight Länder
and offers young drug users early intervention of short
duration on a voluntary basis (170). In the United
Kingdom, youth offending teams work on a similar basis.
Following a change to the way in which some aspects of
cannabis use were dealt with by the criminal justice
system and reclassification of the drug (from class B to
class C), possession, not consumption, is the offence;
possession gets a warning. There is a specific process for
formally warning young persons (i.e. those under 18).
The United Kingdom also introduced a mass media
campaign to reaffirm the negative and illegal nature of
cannabis.
Another recent initiative is to take the prevention campaign
to ‘coffee shops’ where small amounts of cannabis are
available. This intervention takes the form of a course and
manual for coffee-shop owners in order to prevent drug-
related problems in these establishments. The handbook
provides information on cannabis, drug legislation,
psychiatric disorders, first aid, entrepreneurship and
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(171) http://eddra.emcdda.eu.int/eddra/plsql/showQuest?Prog_ID=385.
Annual report 2004: the state of the drugs problem in the European Union and Norway
problems and increasing concern regarding the negative
health impact of intensive cannabis use, interventions aimed
at reducing harm associated with cannabis use remain
poorly developed in comparison with those aimed at users
of other drugs.
Treatment options available to those with cannabis
problems are mostly to be found in treatment centres
offering care for clients addicted to licit or illicit drugs or
with other kinds of addictive behaviours. Services that are
educational skills. In the Netherlands, there is a tradition of
personalised and direct approaches towards cannabis
consumption, as illustrated by Hash and Weed Week (171),
when heavy cannabis users hold group meetings at which
the consequences of intense use and the potential for
behavioural change are discussed.
To some extent, these approaches take a harm-reduction as
well as a prevention-orientated approach. However, despite
the well-known link between smoking and respiratory
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Cannabis potency (source: EMCDDA, 2004c)
1. EU countries fall into two distinct groups depending on
whether herbal cannabis or cannabis resin is the most
commonly consumed product. Of the countries for which
information was available, cannabis resin was more
common in Germany, Ireland, Portugal and the United
Kingdom, whereas herbal cannabis was more common
in Belgium, the Czech Republic, Estonia, the Netherlands
and Austria.
2. There has been no long-term marked upward trend in
the potency of herbal cannabis or cannabis resin
imported into Europe. In all EU countries, with the
possible exception of the Netherlands, most cannabis
consumed is imported, although systematic data on the
availability of home-produced herbal cannabis are
currently lacking.
3. Indoor cultivation of cannabis occurs to some extent in
all European countries. In the Netherlands, it is
estimated that this product represents over half of the
cannabis consumed, but in most countries imported
products are more important.
4. Herbal cannabis grown indoors using intensive methods
(e.g. hydroponic systems with artificial lighting,
propagation by cuttings and control of day length)
usually has a higher THC content than the imported
drug. Although the potency range of home-grown
herbal cannabis may overlap with that of imported
cannabis, the average potency of home-grown cannabis
can be two or three times greater.
5. The overall increases in cannabis potency that have
been reported in some countries can be almost entirely
attributed to an increase in the proportion of home-
grown cannabis consumed.
6. Taking into account the market share of different
cannabis products, the effective potency has remained
relatively stable in nearly all countries for many years,
at around 6–8 %. The only exception is the Netherlands,
where, by 2001, it had reached 16 %.
7. In the Netherlands, locally produced cannabis resin has
a particularly high THC content, but this material is still
uncommon in that country and almost unknown
elsewhere.
8. Statements in the popular media that the potency of
cannabis has increased by 10 times or more in recent
decades are not supported by the limited data that are
available from either the United States or Europe. The
greatest long-term changes in potency appear to have
occurred in the United States, but it has to be borne in
mind that before 1980 cannabis potency in the United
States was low by European standards.
9. The overall conclusion of the study is that there have
been some modest changes in THC levels that are
largely confined to the relatively recent appearance on
the market of intensively cultivated domestically grown
cannabis in the EU. In addition, it is noted that the THC
content of cannabis products is extremely variable.
A clear information need exists to develop monitoring
systems that can assess the market share of different
cannabis products and track changes over time.
Currently, this information is to a great extent lacking.
10. The study identifies a number of important areas that
require attention if cannabis potency issues are to be
properly evaluated. These include: consensus on the
nomenclature of cannabis products; improved
monitoring of market information, improvement in
laboratory analytical standards, data collection and
presentation at European level; studies to explore the
relationship between potency, smoking behaviour and
blood THC/metabolite levels in Europe; and the need to
investigate the extent to which high-potency cannabis
results in increased dose exposure and any possible
relationship to health problems. It is noted that the costs
and benefits of responding differently to different
cannabis products merits consideration.
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designed for cannabis users are reported by some countries
(Denmark, Germany, Greece, France, the Netherlands,
Austria, Sweden and Norway), but, in general, specialist
care of this sort appears to be extremely limited. In many
countries, treatment services for problem cannabis users are
integrated with facilities for the treatment of generic drug
problems (Belgium, the Czech Republic, Denmark,
Germany, Spain, France, Ireland, Italy, Luxembourg, the
Netherlands, Austria, Portugal, Slovenia and Norway).
For the most part, those with a cannabis-related problem
are treated alongside clients being treated for problem use
of other illicit drugs, typically opioids. As many of these
specialised drug treatment centres are configured to meet
the needs of an often chaotic and marginalised population,
their suitability for those with less acute needs, such as most
cannabis users, is debatable. Treatment services in Member
States are aware of these issues, and a number of
countries, in their Reitox national reports, observed that it
could be counterproductive and disadvantageous to mix
problem cannabis users with problem heroin users or
polydrug users and cited this as one reason why cannabis
users should not receive inpatient care. It is easier to design
programmes specifically for cannabis users on an
outpatient basis. The Austrian national report suggests that
inpatient care, if required, should preferably take place
within a generic adolescent psychiatry department rather
than a specialist drug unit. Recent innovations reported by
Member States in responding to the needs of cannabis
users include a ‘cognitive treatment manual’ for chronic
cannabis users produced in Sweden, an Internet self-help
site for problem cannabis use established in the
Netherlands and the introduction of acupuncture treatment
in Finland.
Conclusions
The objective of this review is to place the observed
increase in reported cannabis treatment demands in a
broader analytical context. In doing so it is apparent that
many important questions that are fundamental to an
informed policy debate on this controversial topic remain
unanswered. What is also apparent is that the available
evidence does not justify an alarmist position but nor is it
cause for complacency.
People with cannabis-related problems constitute a non-
trivial proportion of treatment demands in specialised
facilities in some countries and form an important sub-
group within the larger treatment population. Most are
young males, typically around 20 years old, and most
started using the drug at 16 or 17 years of age.
Cannabis clients have different patterns of drug use than
those consuming other substances; moreover, there are
important differences among cannabis clients. The profiles
of different sub-groups of cannabis users in treatment is
likely to be directly relevant to understanding their needs
and thus to the provision of appropriate responses.
Important dimensions here are frequency of use, current
and past use of other drugs and referral source. In broad
terms, summarising national reports and TDI data, two
clear client profiles can be discerned:
• younger users, often students, referred to treatment
services by family or school and consuming cannabis
alone or sometimes together with alcohol or stimulants;
• polydrug users, who are typically older and less socially
integrated, referred to treatment more often by legal
authorities or health and social services, and
overlapping with the chronic drug-using population.
In addition, there is some evidence of a further group
referred to treatment by legal authorities who are not using
other drugs and appear to be only occasional users of
cannabis.
In reflecting on changes in the characteristics of primary
cannabis treatment demands over time, the available
information suggests:
• increased numbers referred from the criminal justice
system in some countries;
• increased referrals from family and other social support
networks (family, friend, social services, school);
• an increased proportion of intensive (daily) cannabis
use, although daily users remain in the minority;
• increasing levels of social and educational problems in
some countries, although data in this area are weak.
In considering the increase in treatment demands, it
appears that changes in referral practice have an impact,
and a substantial proportion of those referred appear not to
be intensive drug users. Nonetheless, in some countries at
least, a significant number of treatment demands come from
individuals whose use of cannabis is intensive. The
problems experienced by this group remain poorly
understood and research in this area is urgently needed.
The observation that a majority of treatment demands made
by the very young are for cannabis suggests that special
consideration of the needs, referral pathways and
responses of this group is required.
It is also important to recognise that treatment demand is
not a direct indicator of the scale and nature of cannabis
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most affected are young and may be using the drug
intensively during important developmental stages or when
they are particularly vulnerable. Among socially
disadvantaged families or communities, cannabis
dependence or abuse may compound individuals’ problems
by harming education or employment opportunities.
In summary, there remains a critical need for research to
provide an understanding of the relationship between
different patterns of cannabis use and the development of
problems. The extent to which cannabis users experience
problems and the nature of the problems that may be found
still remain poorly understood. Methodological tools are
required to assess problems at the population level. Such
information is a prerequisite to the development, targeting
and implementation of effective public health responses to
cannabis use in Europe.
problems. General population survey data suggest that,
compared with occasional use, intensive cannabis use is
relatively uncommon. However, the widespread use of
cannabis means that considerable numbers of people may
be using the drug intensively — at least for some part of
their life.
Estimates would suggest that intensive use may affect
between 0.5 % and 2 % of the adult population and between
1 % and 3 % of young adults. The prevalence among young
males is likely to be substantially higher. It is difficult to draw
from the survey evidence a clear picture of the number of
users experiencing problems with or becoming dependent
on cannabis. Although the effects of cannabis dependence
or abuse are less severe than those of other drugs, this may
nevertheless have a considerable public health impact
because of the scale of use and the fact that many of those
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Aetiology
Determining the aetiology of co-morbidity results in a
chicken and egg discussion: what came first? Existing
research about the causal relations between psychiatric and
substance disorders is inconclusive. The symptoms of mental
disorder and addiction problems interact and mutually
influence each other.
Research evidence indicates that psychiatric and personality
disorders usually occur before substance use disorders, i.e.
they increase individuals’ susceptibility to such problems
(e.g. Kessler et al., 2001; Bakken et al., 2003); however,
psychiatric disorders may also be aggravated by drug use
(e.g. for depression: McIntosh and Ritson, 2001) or occur
in parallel.
Drug use can also be perceived as a component or
symptom of a psychiatric or personality disorder and as an
attempt to self-medicate (e.g. Williams et al., 1990; Murray
et al., 2003). The fact that substance use alleviates
distressing symptoms encourages the development of
addiction. Once the drug use is discontinued, e.g. through
withdrawal or substitution treatment, the symptoms may
reappear. Acute drug-induced psychoses occur particularly
in users of cocaine, amphetamines and hallucinogens and
usually subside relatively quickly. It may, however, be very
difficult to differentiate between symptoms due to substance
intoxication and unrelated psychotic episodes.
Krausz (1996) suggests four categories of dual diagnosis:
• a primary diagnosis of a mental illness, with a
subsequent (dual) diagnosis of substance misuse that
adversely affects mental health;
• a primary diagnosis of drug dependence with
psychiatric complications leading to mental illness;
• concurrent diagnoses of substance misuse and
psychiatric disorders;
• a dual diagnosis of substance misuse and mood
disorder, both resulting from an underlying traumatic
experience, for example post-traumatic stress disorder.
Introduction
The co-occurrence of psychiatric illness and substance
disorders, commonly termed co-morbidity or dual
diagnosis, is not a new phenomenon. However, in recent
years the issue has gained momentum in the political and
professional discussion as it has become apparent that a
large and probably growing number of people are
affected. In this chapter the focus will be on the coexistence
of psychiatric and personality disorders and the use of illicit
drugs. In fact, it is often appropriate to speak about
multimorbidity, as affected individuals often also suffer from
somatic illnesses, e.g. human immunodeficiency virus (HIV)
or hepatitis C virus infection, as well as social disorders,
such as family problems, unemployment, incarceration or
homelessness. Care and treatment services are usually
inadequately equipped to deal with the diagnostic and
treatment needs of this client group, disregarding and/or
being incapable of coping with the totality of the client’s
problems. The result is frequently a ‘revolving door’
situation, with individuals in great need of treatment being
referred from one service to another while all the time their
situation deteriorates.
Note that the specific relationship between cannabis use
and psychiatric disorders is considered in more depth in the
selected issue on cannabis (p. 82).
Definition
Co-morbidity, or dual diagnosis, is defined by the World
Health Organization (WHO) as the ‘co-occurrence in the
same individual of a psychoactive substance use disorder
and another psychiatric disorder’ (WHO, 1995). According
to the United Nations Office on Drugs and Crime
(UNODC), a person with dual diagnosis is a ‘person
diagnosed as having an alcohol or drug abuse problem in
addition to some other diagnosis, usually psychiatric, e.g.
mood disorder, schizophrenia’ (UNODCCP, 2000). In other
words, co-morbidity in this context refers to the temporal
coexistence of two or more psychiatric or personality
disorders, one of which is problematic substance use.
Selected issue 3
Co-morbidity
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Similarly, the Swedish national report differentiates between
psychiatric patients suffering from co-morbidity and drug-
dependent clients with personality disorders that are
aggravated by drug use and which are not always
adequately diagnosed.
Morel (1999) distinguishes non-specific psychiatric
disorders found among drug addicts from complications
specifically connected with drug use. Disorders often found
among drug users include:
• anxiety–depressive disorders;
• sleep disorders, resulting from depression, anxiety
disorder or psychosis;
• aggressive and violent behaviour, indicating antisocial,
psychopathic, schizophrenic or paranoid personality
disorders.
Problems specifically linked to drug use include:
• pharmaco-psychoses induced by hallucinogenic drugs
or amphetamines;
• confusion syndromes.
Recent neuropsychological and neurobiological studies and
the advent of techniques that enable brain processes to be
visualised have made it possible to hypothesise about the
interactions between mental and physical trauma, brain
development, drug effects, stress and mental development.
The reward system is essential in the development of
addiction, and addiction is linked to structural changes
and adaptation of the brain at micro and macro levels
(Nestler, 2001).
Other theories link specific drugs to specific mental
disorders, e.g. it has been postulated that heroin could
reduce stress, alleviate pain and abolish menacing voices in
schizophrenic and borderline schizophrenic patients;
however, patients with severe mental illnesses do not use
heroin. Cocaine, it is suggested, could lighten depressive
states, allow behavioural disinhibition and permit
narcissistic personalities to act out grandiosity. Cannabis
could relieve tension and ecstasy ease social inhibitions
(Verheul, 2001; Berthel, 2003).
The 2002 Irish national report specifically examined
depression among drug users, based on the results of
several studies, and concluded that there is a strong
association between problem drug use, in particular use of
opiates and benzodiazepines, and high rates of depression.
German research into the relationship between substance
disorders, depression and suicide concluded that the risk of
suicide is greatly increased in those with a depressive
disorder (Bronisch and Wittchen, 1998). It is possible that
some individuals with depression may self-medicate with
opiates and benzodiazepines: clients in treatment
programmes have lower depression scores than clients in
low-threshold services (Rooney et al., 1999) or at initiation
of treatment (McIntosh and Ritson, 2001).
A survey in Norway (sample size = 2 359) found that a
high proportion of drug users have experienced severe
family problems during childhood and youth. Some 70 %
had experienced learning and behavioural problems in
school, 38 % had been the victim of bullying and 21 % had
received psychiatric treatment during childhood and
adolescence (Lauritzen et al., 1997). Female drug users
with psychiatric co-morbidity have often been the victims of
traumatic sexual abuse (e.g. Beutel, 1999).
Diagnosis
Routine assessment for psychiatric and personality disorders
does not always form part of the standard diagnostic
procedures performed at the commencement of treatment in
drug services. Except in some particularly aware and/or
specialised services, mental symptoms and disorders are
rarely explored in drug treatment services.
In any case, co-morbidity is notoriously difficult to
diagnose. Drug addiction and the disruptive behaviour it
causes often dominates the clinical picture and disguises
psychiatric symptoms. In addition, substance abuse can
cause psychiatric symptoms that are barely distinguishable
from those of psychiatric disorders (Berthel, 2003), while
substance withdrawal or acute intoxication can also mimic
almost any such disorder (Liappas, 2001). Furthermore,
depression and anxiety can be viewed as inherent
symptoms of the intoxication–withdrawal cycle; symptoms
that used to be alleviated by drugs become manifest in the
course of abstinence or substitution treatment.
Methodological advances have also improved the diagnosis
of both psychiatric and substance use disorders. A wide
range of standardised and validated instruments are now
available to measure psychiatric symptoms and personality
disorder, as are various instruments that assess the level of
drug use patterns and addiction. The addiction severity index
(ASI) is a multifunctional instrument that can be used in
diagnosis, treatment planning and follow-up, and research.
The ASI has the advantage of being multidimensional,
measuring past and current problems in seven areas: health
status, employment and self-support, alcohol use, drug use,
legal status, family and social relationships and psychiatric
symptoms (Krausz, 1999a; Öjehagen and Schaar, 2003). It
is standardised and has been translated from English into
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The Spanish national report notes that the observed
increase in co-morbidity might partly be due to an increase
in dependence on psychostimulants.
Prevalence of co-morbidity in treatment settings
Table 7 gives details of some studies of co-morbidity in
different drug treatment and psychiatric settings in Member
States as presented in the national reports. Data on
substance disorders in psychiatric settings are not as readily
available as data on psychiatric disorders in drug treatment
settings. Although the studies presented in this review are
not comparable, they do give an indication of the situation
in EU countries. There is considerable divergence in the
populations studied, the diagnostic criteria selected, the
instruments used and the time of diagnosis. For reasons
discussed above, under-diagnosis is likely in many cases.
A comparative study in Greece and France found that,
although the overall rates of psychopathology in opiate
users under treatment were quite similar in the two
countries, the psychopathological patterns varied: the
prevalence of affective disorders was higher in French than
in Greek drug users (19 % vs. 7 %), whereas antisocial
personality patterns were more prevalent in the Greek
sample (20 % vs. 7 %). The authors attributed these
differences to the lower prevalence of drug use in Greece:
‘the more limited the extent of socially unacceptable
behaviour, the more likely it is that socially deviant
individuals are involved in it’ (Kokkevi and Facy, 1995).
A Norwegian study examined gender differences between
poly-substance abusers (of whom 85 % were heroin users)
and pure alcoholics. The sample included a very high
proportion of subjects with psychiatric and personality
disorders (93 %). Overall, women had significantly higher
levels of major depression, simple phobia and borderline
personality disorder than men. The co-occurrence of an
antisocial personality disorder was highest in male poly-
substance abusers (Landheim et al., 2003).
Prevalence — prisons and compulsory treatment
The prison population deserves particular attention. The
prevalence of psychiatric disturbances, like the prevalence
of drug use, is much higher in the prison population than
among the population overall. Irish data suggest that 48 %
of male and 75 % of female prisoners are mentally
disturbed, while 72 % of men and 83 % of women in prison
report lifetime experience of drug use (Hannon et al.,
2000). In 1999, 23 % of problem drug users held at the
Vienna Police Detention Centre had psychiatric problems
(Dialog, 2000). The relapse rate among drug users who
most other European languages (EuroASI) (172). The Trimbos
Institute has developed and tested protocols for the diagnosis
and treatment of addicted clients with attention
deficit/hyperactivity disorder (ADHD) (Eland and Van de
Glint, 2001).
Prevalence
Numerous studies have been carried out to measure the
prevalence of psychiatric and personality disorders as well
as drug use patterns in the general population as well as
among psychiatric patients and drug users in and outside
treatment services. The results, in terms of both numbers
and diagnoses, vary greatly, depending on population
availability and selection, sampling methods, diagnostic
skills and competence, the validity and reliability of the
diagnostic instruments used and the period of the study.
In a review of different studies, Uchtenhagen and
Zeiglgänsberger (2000) concluded that the most common
psychiatric diagnosis among drug users is personality
disorder, affecting 50–90 %, followed by affective disorder
(20–60 %) and psychotic disorders (20 %). Between 10 and
50 % of patients exhibit more than one psychiatric or
personality co-morbidity disorder.
In a review of international studies on psychopathology in
drug-dependent subjects, Fridell (1991, 1996) outlined a
clinical picture of co-morbidity in drug addiction that has
been confirmed by his own studies in Lund, Sweden. Three
main groups of disorders could be identified: personality
disorders (65–85 %), depression and anxiety states
(30–50 %), and psychoses (15 %). Verheul (2001), in his
overview of six studies of treated addicts, found that
antisocial (23 %), borderline (18 %) and paranoid (10 %)
personality disorders were particularly prevalent.
Many drug professionals believe that the prevalence of
drug dependence in combination with mental disorders is
increasing, although some argue that this is due to a
greater awareness of this issue and/or changes in the
diagnosis and the classification of psychiatric diseases
and/or restructuring of healthcare systems. In Finland,
according to the hospital discharge register, the number of
treatment periods associated with simultaneous drug-related
and other mental health problems increased from 441 in
1987 to 2 130 to 2001. Treatment periods for opiate use
combined with psychiatric disorders have tripled since
1996. This is consistent with the increase in drug use,
although no direct causality is suggested. In Ireland, the
rate of first admissions of drug users to inpatient psychiatric
services increased almost fourfold between 1990 and
2001.
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Table 7: Prevalence of co-morbidity in treatment settings in various countries of the EU
NB: Data in this table refer to different timeframes (e.g. lifetime or last year’s diagnoses).
n.a.: data not available.
(1) More details on this study can be found in the online version of the annual report in Table 12 OL: Co-morbidity country tables.
Country Setting Population Sample size Prevalence of Diagnoses Source
co-morbidity (%)
Belgium Psychiatric hospitals and Admissions for drug 18 920 86 Schizoid, paranoid, Minimum psychiatric 
psychiatric services in problems (1996–99) schizotypal: 86 % database (1)
general hospitals Depression: 50 %
Personality disorders: 
43 % 
Czech Republic Therapeutic communities Residential clients 200 35 Personality disorders: Czech national 
(2001–02) 14 % report (1)
Depression: 7 %
Neurotic disorders: 6 %
Eating disorders: 5 %
Germany Treatment centres Opiate addicts 272 55 Stress and somatoform Krausz (1999b) (1)
disorders: 43 %
Affective disorders: 32 %
Phobias: 32 %
Depressive episodes: 16 %
Greece Prison and treatment Opioid-dependent men 176 86 Anxiety: 32 % Kokkevi and Stefanis 
services Affective disorders: 25 % (1995) (1)
Schizophrenia: 6 %
Spain Methadone service Opiate-dependent 150 n.a. Borderline: 7 % Spanish national 
persons Antisocial disorders: 6 % report (1)
Social phobia: 6 %
Depression: 5 %
France Methadone service Opiate-dependent 3 936 n.a. Anxiety: 4 % Facy (1999) (1)
persons Depression: 3 %
Behavioural disorders: 3 %
Eating disorders: 2 %
Ireland Inpatient acute First admissions with a 1 874 26 Depression: 21 % National psychiatric 
psychiatric services diagnosis of drug Schizophrenia and other inpatient reporting 
dependency (1996–2001) psychoses: 11 % system (1)
Personality disorders: 19 %
Italy Mental health services Lifelong drug users 58 > 22 Mood disorders: 22 % Siliquini et al. (2002) (1)
Anxiety: 21 %
Schizophrenia: 16 %
Luxembourg Specialised drug Patients previously in 380 32 n.a. AST/RELIS 
treatment services contact with psychiatric (2002) (1)
services excluding detoxi-
fication (1996–2002)
Netherlands Dutch population Drug-dependent persons n.a. n.a. Depression: 29 % Ravelli et al. 
aged 18–64 (1996) Social phobia: 29 % (1998) (1)
Bipolar disorders: 24 %
Dysthymia: 22 %
Austria Different treatment Drug clients n.a. 41–96 Personality disorders, Austrian national 
services (review) antisocial disorders, report (1)
borderline, narcissism
Portugal Xabregas CAT Drug clients 596 > 73 Obsessive–compulsive Portuguese national 
Treatment Centre disorders: 73 % report (1)
Depression: 72 %
Somatisation: 60 %
Paranoid ideation: 58 %
Finland Hospitals Drug-related hospital 2 180 29 Paranoid ideation: 58 % Hospital patient 
treatment periods Psychotic disorders: 32 % discharge register
(2002) Mood disorders: 28 %
Neurotic disorders: 10 %
Personality disorders: 29 %
Sweden University Hospital, Lund Patients on detoxication 1 052 83 Antisocial disorders: 23 % Fridell (1996) (1)
ward (1977–95) Any psychosis: 14 %
Depressive disorders: 11 %
United Community and Drug-dependent patients, 1 075 > 33 Psychoticism Marsden et al. 
Kingdom residential addiction 90 % opiate-addicted Anxiety (2000) (1)
treatment services Depression
Paranoia
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from drug treatment because of their mental problems. In
Spain, for example, most psychiatric services exclude clients
with substance disorders and their staff members have no
appropriate training. A survey among Austrian
psychotherapists revealed that only some are willing to
admit drug-addicted patients as clients (Springer, 2003).
From Italy it is reported that there are no clear rules for the
referral of clients from drug treatment services to mental
health services and that there is resistance in mental health
services because of lack of expertise. In Norway, referral
from low-threshold drug services to psychiatric treatment is
reported to be difficult.
In Greece, 54 % of drug-treatment programmes do not
admit drug users with psychiatric disorders. In drug-free
residential treatment in Slovenia, and also in other
countries, treatment programmes require patients to be
drug-free as a condition for admission. In the case of dual
diagnosis patients, this presents a serious obstacle, as
complete abstinence would require the termination of other
treatments, which is not always possible.
Treatment structures
The international literature describes three service delivery
models for the treatment of co-morbidity:
1. Sequential or serial treatment. Psychiatric and substance
disorders are treated consecutively and there is little
communication between the services. Patients usually
receive treatment for the most serious problems first,
and, once this treatment is completed, they are treated
for their other problems. However, this model may also
lead to patients being passed between services, with no
service being able to meet their needs.
2. Parallel treatment. Treatment of the two different
disorders is undertaken at the same time, with drug and
mental health services liaising to provide services
concurrently. The two treatment needs are often met with
different therapeutic approaches and the medical model
of psychiatry may conflict with the psychosocial
orientation of drug services.
3. Integrated treatment. Treatment is provided within a
psychiatric or a drug treatment service or a special co-
morbidity programme or service. Cross-referral to other
agencies is avoided. Treatments include motivational
and behavioural interventions, relapse prevention,
pharmacotherapy and social approaches (Abdulrahim,
2001).
The actuality of co-morbidity treatment in the EU, as
described in the national reports, is not easily categorised
have served prison sentences is high, and there is
increasing recognition that incarceration can contribute to a
worsening of mental health problems. The situation is even
more dramatic in long-term and high-security prisons.
In Sweden, between 72 % and 84 % of adults in
compulsory drug treatment were found to suffer from
psychiatric problems in addition to being substance abusers
(Gerdner, 2004). Of 46 substance-dependent girls in
compulsory care for children and young people, two thirds
had psychiatric diagnoses or personality disorders (Jansson
and Fridell, 2003).
Obstacles to the treatment of co-morbidity
One of the main obstacles to the diagnosis and treatment of
co-morbidity is the fact that psychiatric staff generally have
little knowledge of drug treatment and drug-treatment staff
generally know little about psychiatry. The paradigms of the
two specialties are quite different: one is based on the
disciplines of medicine and science, the other on
psychosocial methods and theories. Additionally, the
philosophy of mental health services is usually concerned
principally with preserving the safety of individuals and the
public, whereas addiction services expect clients to be
motivated, to some degree, to attend treatment. These
different points of departure often prevent a global,
integrated perception.
As discussed above, both psychiatric teams and substance
services regularly fail to identify significant numbers of
patients with co-morbidity. When patients with dual
diagnosis seek treatment, their acute psychiatric syndromes
are often mistaken for substance-induced symptoms or,
conversely, withdrawal or intoxication phenomena are
misinterpreted as psychiatric illness. Too often, mental-
health workers are inclined to send people with co-
morbidity to addiction care and workers in addiction care
promptly send them back — or vice versa. Continuity of
care is impossible under such circumstances. Even when co-
morbidity is diagnosed, it is often considered no further in
the subsequent treatment interventions (Krausz et al.,
1999). The same is true of patients diagnosed with
substance use problems in psychiatric care, who normally
do not receive any substance-related interventions (Weaver
et al., 2003). These generalisations do not, of course,
exclude the fact that some psychiatric and drug services
achieve very good results with patients with co-morbidity.
In addition, when identified, drug users are often met with
suspicion in psychiatric services, and may be refused
admission, as may happen to users who are stable on
substitution treatment. Similarly, clients may be excluded
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into these three groups. Integrated treatment is seen as the
model of excellence, but it is a standard that is difficult to
achieve. Relevant research usually comes from outside
Europe. The Australian national co-morbidity project
(Commonwealth Department for Health and Ageing, 2003)
has concluded from a literature review that approaches to
the management and care of co-morbidity clients have not
been studied systematically or evaluated rigorously, partly
because of the difficulty of studying people with coexisting
mental illness and substance abuse disorder, among other
reasons because of their irregular lifestyle. Another review
concluded that there is evidence that integrated treatment
for people with dual diagnosis is beneficial to both mental
health and substance use outcomes (Drake et al., 1998).
Only one study compared integrated with parallel
approaches, but did not find any significant difference, and
no study compared integrated and sequential approaches.
Sequential treatment
Some experts, for example in Denmark (Andreason, 2002),
the United Kingdom (Department of Health, 2002a) and
Norway (Sosial- og helsedepartementet, 1999), believe that
the treatment services, at least for the seriously mentally ill
with substance use problems, should be based in
psychiatry, possibly involving external drug therapists. In
Denmark, formalised bridges have been set up between
psychiatric hospitals and local drug services. In Luxembourg
and in Norway, specific measures have been initiated by
psychiatric services to reach individuals in the early stages
of schizophrenia, many of whom have serious substance
abuse problems, as research indicates that early treatment
improves the prognosis.
The Czech national report suggests that addiction problems
should usually be considered more urgent than mental
problems, as it is more difficult to treat psychiatric disorders
when addiction distorts the clinical picture. However,
currently, 10–20 % of Czech drug-treatment clients take
medication prescribed by a psychiatrist, something that
would have been unimaginable some years ago. In Greece,
too, medication for psychiatric symptoms is extremely rare in
drug-treatment clients. However, in the Greek criminal justice
system, mental disorders are considered to prevail over
addiction and co-morbid offenders are admitted to a
psychiatric hospital either in a prison or in the community 
(K. Matsa, personal communication, 2004). In Spain, drug
users are normally cared for within the drug treatment system
and referrals to psychiatric services are made only when
disorders are so severe that hospitalisation is necessary.
It has long been the view of some professionals that all
pharmacotherapy should be avoided in drug-addicted
persons because of the risk of combined addiction, e.g. to
heroin and benzodiazepines, but this view is beginning to
be reconsidered (e.g. Popov, 2003). In some cases, there is
a tendency to prescribe psychopharmacological medication
indiscriminately to drug users, partly because of a lack of
time to conduct the necessary investigations. The Austrian
national report points out that low compliance among drug
users makes pharmacological treatment of psychiatric
conditions difficult and, in addition, the combined used of
narcotic substances and medicines may, if not properly
supervised, lead to interactions between illicit and
prescribed medicines or to neutralisation of the prescribed
medicine.
Parallel treatment
Shared responsibility for one client between a mental health
and a drug service in a parallel treatment model appears to
be rare in practice. However, local working groups involving
representatives of both drug services and mental health
services are often an important medium of exchange,
cooperation and networking. In France, Italy and the
Netherlands official regulations or protocols oblige drug
services to maintain close liaison and preferably establish
formal regional agreements with the psychiatric services
concerning procedures for referrals and clinical information
exchange (Olin and Plaisait, 2003). However, more than half
of Dutch dual diagnosis patients believe that such agreements
do not result in improved care (Van Rooijen, 2001).
In Luxembourg and Austria, drug treatment staff may follow
up their clients who have been referred to psychiatric
hospitals. United Kingdom guidelines stress that
professionals from both addiction and mental care services
should be involved in planning the care of a dual diagnosis
client in order to prioritise care pathways (Department of
Health, 2002a).
Integrated treatment
Under this model, one team handles the treatment of both
disorders. This has the advantage that the client is not
confronted with two contradictory messages. In some
countries, separate administrative systems (e.g. Spain) or
different finance systems (e.g. Germany) complicate such
integration.
In most countries there are only a few specialised integrated
programmes or units for co-morbidity patients and the
availability is far from meeting the demand, as Table 8,
which shows available information, demonstrates.
The most common implementation of an integrated
treatment model is the employment of psychiatrists in drug
99
Annual report 2004: the state of the drugs problem in the European Union and Norway
Treatment methods and best practice
The treatment of clients with co-morbidity is characterised
by many problems and is extremely demanding on staff
and often unrewarding. Clients are often difficult to manage
because of their disruptive and aggressive social behaviour,
especially those with the more ‘dramatic’ type of personality
disorders, and their emotional instability. Resistance to or
failure to comply with treatment rules and requirements, for
example keeping appointments or taking medication, is
common and the disillusion this causes is made worse by
unrewarding personal relationships. Success is generally
low and drop-out rates high, which makes treatment time-
consuming and costly, as well as frustrating for staff, who,
not surprisingly, often experience impatience, suppressed
aggression and symptoms of burn-out. A lack of follow-up
procedures and aftercare leads to high relapse rates, and
both mental and substance disorders frequently become
chronic. On the other hand, clients have often had many
negative encounters with the support services and may
therefore be reluctant or unwilling to undergo treatment.
In spite of this difficult situation, professionals are constantly
searching for and developing more effective approaches.
Regular, interdisciplinary case discussions and intensive
cooperation could remedy the mutual lack of understanding
among staff. Such endeavours provide everyone involved
with more detailed information about clients and facilitate
the development of best practice or strategies for care. The
quality of treatment is the most important factor in
achieving positive results.
As in so many drug-related areas, documentation,
evaluation and research in the area of co-morbidity
treatment services and/or drug workers in mental health
services. This might be the most practical solution in smaller
regions where specialised, integrated clinics are not a
viable solution. In Spain, since 2002, general practitioners
working in drug treatment have been able to obtain the title
‘specialist in psychiatry’ if they pass an exam and have
documented experience of working with patients with
mental disorders. In Portugal, it is mandatory for
accreditation and certification for a treatment centre to
have at least one psychiatrist on the staff. However, not all
psychiatrists working in drug treatment services have the
specialist knowledge and training necessary to treat drug
users and further specific training may be necessary.
Case management
Case management as a method of coordinating clients’
treatment to ensure individualised sequential or
simultaneous care as well as helping clients find their way
through the treatment system appears to be infrequent in
the EU. From France it is reported that cooperation between
drug treatment and psychiatric services is being established
with a view to organising joint admissions and case
management for patients with psychiatric disturbances and
addictions; however, such collaboration is often limited to a
particular case. In Luxembourg as well as in the
Netherlands, professionals have come to recognise that
case management is the most effective method of dealing
with dual diagnosis patients, but it is costly and time-
consuming and requires specific professional skills.
However, in some countries, a type of case management
known as ‘assertive community treatment’ is being
implemented (see below).
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Table 8: Integrated treatment services in various European countries
Country Integrated treatment services
Belgium Development of integrated services in the feasibility phase
Germany First initiatives 20 years ago. The availability of integrated treatment is still inadequate
Greece One integrated programme started in 1995 and provides two different treatment options, according to the severity of the psychiatric disorder. Results have
been positive
Spain 185 centres cared for 4 803 co-morbidity clients in 2002. One specialised integrated unit in Catalonia and one therapeutic community in Cantabria 
for co-morbidity patients needing residential treatment
Netherlands Two specialised integrated inpatient treatment wards. Process evaluation to develop best practice is ongoing
Austria Cooperation between drug service and a nearby psychiatric hospital; some of the hospital psychologists work in the drug treatment facility. Clients stay in 
drug treatment and are referred to the hospital only if psychiatric symptoms become too severe
United Kingdom Several integrated services in different community settings. Several dual diagnosis practitioners appointed, based in addiction services or in mental health
teams
Norway One integrated project attached to a psychiatric centre in Oslo. Follow-up and evaluation for up to two years, focusing on basic needs such as housing, 
work, social benefits and social relations 
(173) Dialectical behaviour therapy (DBT) is the application of a broad array of cognitive and behavioural therapeutic strategies to the problems of borderline
personality disorder (BPD), including suicidal behaviour.
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treatment is deplorable. The evidence base is far from clear
regarding which type of treatment is most successful. The
Cochrane collaboration reviewed psychosocial treatment
programmes (Ley et al., 2003). The review material was
limited: six studies, four of which were small, and all of
which were generally of low quality in terms of design and
reporting. The main finding was that ‘there is no clear
evidence supporting an advantage of any type of substance
misuse programme for those with serious mental illness over
the value of standard care’. The conclusion was that
‘implementation of new specialist substance misuse services
for those with serious mental illnesses should be within the
context of simple, well-designed controlled clinical trials.’
A large overview of international alcohol and drug
treatment research found only eight randomised studies on
the treatment of drug addicts with severe psychiatric
disorders (Jansson and Fridell, 2003). The drop-out rate
was extremely high even before the start of treatment.
Short-term follow-up revealed that residential treatment,
specifically in therapeutic communities, produced better
results in terms of living conditions and substance use, but
not psychiatric symptoms.
Some features are relevant to all treatment situations. The
recommendations presented below are taken from reviews
and meta-analyses of internationally published randomised
controlled studies of drug treatment (Berglund et al., 2003):
1. There should be a constant focus on changing the drug
habit(s).
2. Interventions should have a high level of structure.
3. Interventions should continue long enough to have an
impact.
4. Intervention should continue for at least three months,
preferably longer.
In the United Kingdom, Department of Health guidelines
(Department of Health, 2002b) and research projects and
literature reviews (e.g. Crawford, 2001) have moved dual
diagnosis up the agenda. However, the evidence base is
mainly North American, with less than 10 % of Crawford’s
abstracts coming from studies in the United Kingdom.
According to a Dutch review of international studies, a
potentially effective case management model is assertive
community treatment, which includes structural (caseload,
teamwork, cooperation with other health professionals),
organisational (explicit inclusion criteria, limited admittance
of new clients, 24-hour crisis intervention) and content
(support and care provided in daily situations, an active
approach, frequent contacts) aspects (Wolf et al., 2002). In
Birmingham, United Kingdom, assertive community
treatment teams receive training using a manual-based
approach, cognitive behavioural integrated treatment.
Teams are offered ongoing support to deliver the
intervention and are evaluated regarding both process and
outcome (Joint Meeting of the Faculty of Substance Misuse
of the Royal College of Psychiatrists and the World
Psychiatric Association, 2003). In Norway, a few integrated
teams based on assertive community treatment are being
tested.
The following overview contains evidence of best practice
reported by the Reitox national focal points:
• A follow-up study of 219 opiate addicts in treatment in
the Hamburg drug services showed a decrease in the
use of heroin and cocaine over two years. Some 47 %
showed a positive change in psychiatric disorders
(Krausz et al., 1999).
• An Italian study found that the results of methadone
maintenance treatment were not substantially different in
patients with severe or mild psychiatric symptoms, in
terms of either retention or heroin use. However, it
seems that clients with more severe psychiatric disorders
needed higher mean methadone dosages (Pani et al.,
2003).
• Dialectical behaviour therapy (173) is a treatment option
that seems to be particularly suitable for women
substance users with severe borderline personality
disorders and/or suicidal tendencies. However, evidence
is limited to few studies. A Dutch controlled trial of
dialectical behavioural therapy found that both the
experimental and the ‘treatment-as-usual’ group
benefited in terms of exhibiting reductions in self-
destructive behaviour. The experimental group showed
significantly larger reductions in alcohol use but no
differences in drug use were found (Van den Bosch et
al., 2001).
• In a Swedish study, repeated administration of the ASI
questionnaire throughout the treatment period within a
sustainable quality management model revealed that in
a two-year follow-up from discharge 46 % of patients
had been abstinent. Patients with a dual diagnosis
exhibited a more severe problem profile on ASI than
patients without a psychosis. In general, there were
small changes in personality profiles and symptoms, but
for many patients quality of life was higher and life
situation more stable at follow-up (Jonsson, 2001).
• In the United Kingdom, Barrowclough et al. (2001)
found that the combination of motivational interviewing,
101
(174) See http://www.entermentalhealth.net/papers/kbm02.pdf.
Annual report 2004: the state of the drugs problem in the European Union and Norway
studied will comprise severity of addiction, psychiatric
symptoms, treatment compliance, psychosocial functioning,
social network, relapse and mortality. The results are
expected in 2005 (174).
Training
In most countries, doctors and nurses in training receive
very little instruction about drug addiction and even less
about the issue of co-morbidity. In Italy, joint training of
mental health and drug treatment staff has increased. In the
Netherlands, the Trimbos Institute organises training courses
for both addiction and mental healthcare professionals
involved in the treatment of dual diagnosis patients. Other
countries report in-service training and courses, but
implementation is random and patchy.
In the United Kingdom, the Royal College of Psychiatry
undertook a training needs analysis (Mears et al., 2001)
with a variety of professional groups, from both mental
health and drug services. Some 55 % of the sample reported
that they felt inadequately prepared to work with clients with
co-morbidity and expressed a need for further training.
cognitive behavioural therapy and family interventions
produced improvements in patients with schizophrenia
and substance misuse disorders.
• An overview of Norwegian treatment studies on clients
with co-morbidity concluded that aggressive, impulsive
behaviour was best treated with confrontational,
structured group therapy combined with family therapy.
Depressed or anxious patients benefited more from
individual psychotherapy and supportive group therapy
(Vaglum, 1996).
Research
A research project on dual diagnosis within the fifth
framework research and development programme of the
European Commission has recently begun. This prospective
multicentre study, including Denmark, France, Poland,
Scotland, England and Finland, is designed to describe
service provision for patients with dual diagnosis in seven
European psychiatric settings and to compare, over a
period of 12 months, morbidity and service use between
dual-diagnosis and single-diagnosis patients. The outcomes
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
is one of the European Union’s decentralised agencies. Established in 1993
and based in Lisbon, it is the central source of comprehensive information
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates objective, reliable and
comparable information on drugs and drug addiction. In doing so, it
provides its audiences with an evidence-based picture of the drug
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide
range of audiences including policy-makers and their advisors;
professionals and researchers working in the drugs field; and, more
broadly, the media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug
phenomenon in the EU Member States and Norway and is an essential
reference book for those seeking the latest findings on drugs in Europe.
